G PROTEIN-COUPLED GLUTAMATE RECEPTORS

Abstract: Mammalian G protein-coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereto can be used to identify agonists and antagonists of G protein-coupled glutamate receptor mediated neuronal excitation and in methods of diagnosis.

Description: G PROTEIN-COUPLED GLUTAMATE RECEPTORS ♦ 5 10 Background of the Invention The majority of nerve cell connections are chemical synapses. A neurotransmitter is released from the presynaptic terminal, typically in response to the 15 arrival of an action potential in the neuron, and diffuses across the synaptic space to bind to membrane receptor proteins of the postsynaptic terminal. The binding of neurotransmitters to membrane receptors is coupled either to the generation of a permeability change 20 in the postsynaptic cell or to metabolic changes. Neurotransmitters produce different effects according to the type of receptor to which they bind. In general, those which produce effects that are rapid in onset and brief in duration bind to receptors that act as 25 ligand-gated ion channels, where binding almost instantly causes an ion flow across the membrane of the postsynaptic cell. Those neurotransmitters which act more like local chemical mediators bind to receptors that are coupled to intracellular enzymes, thereby producing 30 effects that are slower in onset and more prolonged. These neurotransmitters alter the concentration of intracellular second messengers in the postsynaptic cell. Four second messenger systems have been linked • to neurotransmitter or hormone receptors and have been 35 studied for their roles in the control of neuronal excitability. They are the adenylate cyclase/cyclic AMP- dependent protein kinase system, guanylate cyclase and cGMP-dependent protein kinase, the inositol trisphosphate/diacyl glycerol-protein kinase C system. and systems which are activated by calcium ions, such as the calcium/calmodulin-dependent protein kinase system. Thus, binding of a transmitter to a receptor may activate, for example, adenylate cyclase, thereby increasing the intracellular concentration of cAMP. The cAMP activates protein kinases that phosphorylate proteins in the cells, which form ion channels, thereby altering the cells' electrical behavior. As with the ligand-gated ion channel transmitters, the effects can be either excitatory or inhibitory, and may affect the cell at many levels, including the pattern of gene expression. It is also believed that these chemical synapses, associated with second-messenger systems, may be involved in long-term changes that comprise the cellular basis of learning and memory. The ligand-activated membrane receptors do not activate the second messenger systems directly, however, but via a membrane-bound protein, the GTP-binding protein (G protein) , which binds GTP on the cytoplasmic surface of the cell membrane and thereby acts to couple adenylate cyclase to the membrane receptor. Neurotransmitter binding to the membrane receptor is believed to alter the conformation of the receptor protein to enable it to activate the G protein in the lipid bilayer, which then binds GTP at the cytoplasmic surface and produces a further change in the G protein to allow it to activate, e.g., an adenylate cyclase molecule to synthesize cAMP. When a ligand binds a receptor, an enzymatic cascade results as each receptor activates several molecules of G protein, which in turn activate more molecules of adenylate cyclase which convert an even larger number of ATPs to cAMP molecules, producing a substantial amplification from the initial event. Glutamate, aspartate and their endogenous derivatives are believed to be the predominant excitatory neurotransmitters in the vertebrate central nervous system. (Krinjrvic, Phγs. Rev. 54:418-540, 1974). Recently, glutamate has been described as playing a major, widespread role in the control of neuroendocrine neurons, possibly controlling not only the neuroendocrine system but other hypothalamic regions as well. Four major subclasses of glutamate receptors have been described but their characterization has until recently been limited to pharmacological and electrophysiological functional analyses. See generally. Hollman et al.. Nature 342:643-648 (1989) and Sommer et al., Science 249:1580-1585 (1990). Three of the receptors, the quisqualate (QA/AMPA) , kainate (KA) , and N-methyl-D- aspartate (NMDA) receptors, are believed to be directly coupled to cation-specific ion channels and thus are classified as ligand-gated ionotropic receptors. The fourth glutamate receptor binds some of the agonists of the ionotropic receptors (quisqualate and glutamate, but not AMPA) but has no shared antagonists, and is coupled to G protein. Thus, this receptor, referred to as the G protein-coupled glutamate receptor, or Glu G R, is pharmacologically and functionally distinct from the other major glutamate receptors. This receptor has also been termed the metabotropic receptor. Agonist binding to Glu G R has been shown to result in the activation of a number of second messenger systems, depending on the system studied. One of the best characterized is the quisqualate activation of phospholipase C through a G protein-coupled interaction that leads to the stimulation of inositol phospholipid metabolism. This activity has been studied in systems that measure the accumulation of radiolabeled inositol monophosphate in response to stimulation by glutamate. The systems typically use brain slices from regions such as the hippocampus, striatum, cerebral cortex and hypothalamus (Nicoletti, et al., Proc. Natl. Acad. Sci. USA 83:1931-1935 (1986), and Nicoletti, et al., £__ Neurochem. 46:40-46 (1986)), neuronal cultures derived from embryonic mouse and rat cerebellum, corpus striatum and cerebral cortex (Nicoletti et al., J. Neurosci. 6:1905-1911 (1986), Sladeczek et al.. Nature 317:717-719 (1985), Dumuis, et al.. Nature 347:182-184 (1990), and Drejer et al., J. Neurosci. 7:2910-2916 (1987)) and rat brain synaptosomes (Recasens et al., Eur. J. Phar . 141: 87-93 (1987), and Recasens et al., Neurochem. In . 13:463-467 (1988)). A major disadvantage of each of these model systems is the difficulty in analyzing the pharmacological and functional activities of Glu G R in an environment where other glutamate receptors and G protein-coupled receptors such as muscarinic and serotonin receptors are also present. The Xenopus oocyte system has been used to identify Glu G R as a member of the family of G protein- coupled receptors. An endogenous inositol triphosphate second messenger-mediated pathway in the oocyte allows the detection of Glu G R after injection of total rat brain mRNA, in that the oocyte responds to ligand via the oocyte G protein-coupled PLC-mediated activation of a chloride channel that can be detected as a delayed, oscillatory current by voltage-clamp recording (Houa ed et al., Nature 310:318-321 (1984), Gunderson et al. , Proc. Royal Soc. B221:127-143 (1984), Dascal et al. , Mol. Brain Res. 1:301-309 (1986), Verdoorn et al., Science 238:1114-1116 (1987), Sugiyama et al., Nature 325:531-533 (1987), Hirono et al., Neuros. Res. 6:106-114 (1988), Verdoorn and Dingledine, Mol. Pharmacol. 34:298-307 (1988), and Sugiyama et al. , Neuron 3:129-132 (1989)). Injection of region-specific brain mRNA and of size fractionated mRNA have suggested that Glu G R may be a large mRNA (6-7 kb) and that it is enriched in the cerebellum (Fong et al., Synapse 2:657-665 (1988) and Horikoshi et al., Neurosci. Lett. 105:340-343 (1989)). There remains considerable need in the art for isolated and purified Glu G R, as well as systems capable of expressing Glu G R separate from other neurotransmitter receptors. Further, it would be desirable to specifically identify the presence of Glu G R in cells and tissues, thereby avoiding the time-consuming, complex and nonspecific functional electrophysiological and pharmacological assays. It would also be desirable to screen and develop new agonists and/or antagonists specific for Glu G R, but to date this has not been practical. Quite surprisingly, the present invention fulfills these and other related needs. Summary of the Invention The present invention provides isolated and substantially pure preparations of mammalian G protein- coupled glutamate receptors and fragments thereof. In preferred embodiments the receptors are coupled to a G protein in vertebrate cells, bind glutamate and quisqualate and thereby activate phospholipase C, and are capable of stimulating inositol phospholipid metabolism. Having provided such receptors in isolated and purified form, the invention also provides antibodies to the receptors, in the form of antisera and/or monoclonal antibodies. In another aspect the invention provides the ability to produce the mammalian G protein-coupled glutamate receptors and polypeptides or fragments thereof by recombinant means, preferably in cultured eukaryotic cells. The expressed receptors or fragments may or may not have the biological activity of corresponding native receptors, and may or may not be coupled to a G protein in the cell used for expression. Accordingly, isolated and purified polynucleotides are described which code for the receptors and fragments thereof, where the polynucleotides may be in the form of DNA, such as cDNA, or RNA. Based on these sequences probes may be used to hybridize and identify these and related genes which encode mammalian G protein-coupled glutamate receptors. The probes may be full length cDNA or as small as from 14 to 25 nucleotide, more often though from about 40 to about 50 or more nucleotides. In related embodiments the invention concerns DNA constructs which comprise a transcriptional promoter, a DNA sequence which encodes the receptor or fragment. and a transcriptional terminator, each operably linked for expression of the receptor. For expression the construct may also contain at least one signal sequence. The constructs are preferably used to transform or transfect eukaryotic cells, more preferably mammalian cells which do not express endogenous G protein-coupled glutamate receptors. When bound by an appropriate ligand such as glutamate or quisqualate, the receptor may activate phospholipase C in the host cell via coupling to G protein. Further, for large scale production the expressed receptor may also be isolated from the cells by, for example, immunoaffinity purification. Cells which express the G protein-coupled glutamate receptors may also be used to identify compounds which can alter the receptor-mediated metabolism of a eukaryotic cell. Compounds may be screened for binding to the receptor, and/or for effecting a change in receptor-mediated metabolism in the host cell. Agonists and/or antagonists of the G protein- coupled glutamate receptors may also be screened in cell- free systems using purified receptors or binding fragments thereof for the effect on ligand-receptor interaction, or using reconstituted systems such as micelles which also provide the ability to assess metabolic changes. In yet other embodiments the invention relates to methods for diagnosis, where the presence of a mammalian G protein-coupled glutamate receptor in a biological sample may be determined. For example, a monospecific antibody which specifically binds a G protein-coupled glutamate receptor is incubated with the sample under conditions conducive to immune complex formation, which complexes are then detected, typically by means of a label such as an enzyme, fluorophore, radionuclide, chemiluminescer, particle, or a second labeled antibody. Thus, means are provided for immunohistochemical staining of tissues, including brain tissues, for the subject receptors. Brief Description of the Figures Figure 1 illustrates the construction of plasmid pVEGT, where Fig. IA shows the construction of pVEG, Fig. IB shows the construction of pVEG" and Fig. IC shows pVEGT'. Symbols used are T7 pro, the T7 promoter; Tl and T2, synthetic and native T7 terminators, respectively; M13, M13 intergenic region; the parentheses indicate a restriction site destroyed in vector construction; and pA is the Asperαillus niger polyadenylate sequence. Figure 2 illustrates representative responses from voltage-clamp assays of oocytes injected with RNA from positive pools. Figure 3 illustrates a partial restriction map of clone 45-A. Figure 4 illustrates the cloning of the receptor cDNA present in clone 45-A into Zem228R. Figure 5 illustrates the DNA sequence and deduced amino acid sequence of clone 45-A (corresponding to Sequence ID Nos. 1 and 2) . Numbers below the line refer to amino acid sequence, numbers above the line refer to nucleotide number. Putative transmembrane domains have been overlined, and putative N-linked glycosylation sites are indicated by closed circles. Figure 6 illustrates a representative dose response curve for varying concentrations of L-glutamic acid. Error bars, where larger than the symbols, represent SEM. Figure 7 illustrates the DNA sequence and deduced amino acid sequence of a subtype lb glutamate receptor clone (Sequence ID Nos. 16 and 17) . Numbers below the line refer to amino acid sequence. Numbers above the line refer to nucleotide sequence. Figure 8 illustrates the DNA sequence and deduced amino acid sequence of a subtype 2a glutamate SUBSTITUTE SHEET receptor clone (Sequence ID Nos. 18 and 19). Numbers below the line refer to amino acid sequence. Numbers above the line refer to nucleotide sequence. Figure 9 illustrates the DNA sequence of a partial subtype 2b glutamate receptor clone (Sequence ID No. 20) . Numbers refer to the nucleotide sequence. Description of the Specific Embodiments Glu G R is a family of G protein-coupled membrane receptors for the neurotransmitter glutamate. As glutamate has been described as having a major role in the control of neurons, particularly neuroendocrine neurons, Glu G R may play a critical role in effectuating such control. Consequently, the development of agonists and antagonists of the Glu G R-ligand interaction and Glu G R-mediated metabolism is of great interest. The present invention presents the means to identify agonists and antagonists of the Glu G R-ligand interaction by providing isolated Glu G R. The term "Glu G R" refers to any protein either derived from a naturally occurring Glu G R, or which shares significant structural and functional characteristics peculiar to a naturally occurring Glu G R. Such a receptor may result when regions of a naturally occurring receptor are deleted or replaced in such a manner as to yield a protein having a similar function. Homologous sequences, allelic variations, and natural mutants; induced point, deletion, and insertion mutants; alternatively expressed variants; proteins encoded by DNA which hybridize under high or low stringency conditions to nucleic acids which encode naturally occurring Glu G R-encoding nucleic acids; proteins retrieved from naturally occurring materials; and closely related proteins retrieved by antisera directed against Glu G R proteins are also included. SUBSTITUTE SHEET analog, or chimeric Glu G R as generally described in U.S. Pat. No. 4,859,609, incorporated by reference herein. The molecule may be chemically synthesized or may occur in nature. Ligands may be grouped into agonists and antagonists. Agonists are those molecules whose binding to a receptor induces the response pathway within a cell. Antagonists are those molecules whose binding to a receptor blocks the response pathway within a cell. By "isolated" Glu G R is meant to refer to a GlU g R which is in other than its native environment such as a neuron, including, for example, substantially pure Glu G R as defined hereinbelow. More generally, isolated is meant to include a Glu G R as a heterologous component of a cell or other system. For example, a Glu G R may be expressed by a cell transfected with a DNA construct which encodes the Glu G R, separated from the cell and added to micelles which contain other selected receptors. In another example described below, a Glu G R is expressed by a cell which has been co-transfected with a gene encoding muscarinic receptor. Thus, in this context, the 4 environment of the isolated Glu G R is not as it occurs in its native state, particularly when it is present in a system as an exogenous component. The invention provides cloned Glu G R coding sequences which are capable of expressing Glu G R proteins. Complementary DNA encoding Glu G R may be obtained by constructing a cDNA library from mRNA from, for example, brain tissue. The library may be screened by transcribing the library and injecting the resulting mRNA into oocytes and detecting, by functional assays, those oocytes which express the Glu G R. Alternatively, the clones may be screened with a complementary labeled oligonucleotide probe. The present invention relates to successfully isolating a cDNA encoding a Glu G R. Functional cloning of Glu G R was accomplished by substantial modifications and improvements to a number of cDNA cloning and molecular biology techniques. Initially, an enriched source of Glu G R mRNA prepared by sucrose gradient centrifugation of >4kb length rat cerebellum poly(A)+ mRNA was used as template for cDNA synthesis. Further, a cDNA cloning vector that was employed included a poly(A) tail, thereby increasing by 40-fold the translational efficiency of the transcription product of the cDNA insert and a polylinker site to allow the directional cloning of the cDNA into the vector between the promoter and the poly(A) tail. Vector construction for directional cloning is described in co-pending U.S.S.N. 07/320,191, incorporated herein by reference. The cDNA cloning vector also was used with two transcriptional terminators, in tandem, following the poly(A) sequences, efficiently generating a unit length transcript product without non-coding plasmid or viral sequences, and without requiring a restriction endonuclease to linearize the DNA template (a standard practice that will often prevent functional cloning strategies from working due to the presence of the endonuclease site within the coding region of the cDNA) . The cDNA synthesis strategy maximized insert size and recreation of the 5' ends of the cDNA's, without introduction of homopolymer tails. cDNA inserts were size-selected to be greater than 4 kb in length before insertion into the vector. A library of 10 cDNA inserts in pools of 100,000 was replica plated to reduce the number of amplification steps in the fractionation of sequentially smaller pools. Moreover, ml uscarinic cDNA (another G protein-coupled receptor coupled to phosphoinositol metabolism) template was included in transcription reactions of the subfractionated pools so that before injection the in vitro transcripts from each pool could be assayed by Northern analysis to assess relative quantity and quality of the mRNA, and by voltage-clamp of oocytes as an internal positive control for each oocyte not responding to quisqualate or glutamate. The inclusion of a dilution of SEAP-VEGT 1 (a secreted form of alkaline phosphatase) template in transcriptions was also employed so that oocytes selected for voltage-clamp analysis were those synthesizing higher levels of the co-injected Glu G R mRNA. And further, low noise electrical recording techniques were used to monitor the small signals initially generated from rare transcripts. The above-described methods were used to isolate a cDNA clone encoding a Glu G R designated "subtype la." Oligonucleotide probes based on the sequence of the subtype la clone were used to probe additional brain and cerebellum cDNA libraries. These libraries yielded clones encoding additional subtypes, which were designated lb, 2a and 2b. With the Glu G R and cDNA clones thereof provided herein, nucleotide and amino acid sequences may be determined by conventional means, such as by dideoxy sequencing. See generally, Sambrook et al.. Molecular Cloning. A Laboratory Manual. 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, incorporated by reference herein. Genomic or cDNA sequences encoding Glu G R and homologous receptors of this family may be obtained from libraries prepared from other mammalian species according to well known procedures. For instance, using oligonucleotide probes from rodent Glu G R, such as whole length cDNA or shorter probes of at least about fourteen nucleotides to twenty-five or more nucleotides in length; often as many as 40 to 50 nucleotides, DNA sequences encoding Glu G R of other mammalian species, such as lagomorph, avian, bovine, porcine, murine, etc. may be obtained. If partial clones are obtained, it is necessary to join them in proper reading frame to produce a full length clone, using such techniques as endonuclease cleavage, ligation and loopout mutagenesis. A DNA sequence encoding Glu G R is inserted into a suitable expression vector, which in turn is used to transfect eukaryotic cells. Expression vectors for use in carrying out the present invention will comprise a promoter capable of directing the transcription of a cloned DNA and a transcriptional terminator. To direct proteins of the present invention for transport to the plasma membrane, at least one signal sequence is operably linked to the DNA sequence of interest. The signal sequence may be derived from the GlU g coding sequence, from other signal sequences described in the art, or synthesized de novo. Host cells for use in practicing the present invention include mammalian, avian, plant, insect and fungal cells, but preferably mammalian cells. Fungal cells, including species of yeast (e.g., Saccharomvces S PP- 1 particularly £_. cerevisiae. Schizosaccharomyces spp.) or filamentous fungi (e.g., Aspergillus spp., Neurospora spp.) may be used as host cells within the present invention. Suitable yeast vectors for use in the present invention include YRp7 (Struhl et al., Proc. Natl. Acad. Sci. USA 76: 1035-1039, 1978), YEpl3 (Broach et al.. Gene 8: 121-133, 1979), POT vectors (Kawasaki et al, U.S. Patent No. 4,931,373, which is incorporated by reference herein) , pJDB249 and pJDB219 (Beggs, Nature 275:104-108, 1978) and derivatives thereof. Such vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include LEU2 (Broach et al., ibid.), URA3 (Botstein et al.. Gene 8: 17, 1979), HIS3 (Struhl et al., ibid.) or PQT1 (Kawasaki et al., ibid.). Another suitable selectable marker is the CAT gene, which confers chloramphenicol resistance on yeast cells. Additional vectors, promoters and terminators for use in expressing the receptor of the invention in yeast are well known in the art and are reviewed by, for example, Emr, Meth. Enzy ol. 185:231-279, (1990), incorporated herein by reference. The receptors of the invention may be expressed in Aspergillus spp. (McKnight and Upshall, described in U.S. Patent 4,935,349, which is incorporated herein by reference) . Useful promoters include those derived from Aspergillus nidulans glycolytic genes, such as the ADH3 promoter (McKnight et al., EMBO J. 4:2093-2099, 1985) and the tpiA promoter. An example of a suitable terminator is the ADH3 terminator (McKnight et al., ibid.). Techniques for transforming fungi are well known in the literature, and have been described, for instance by Beggs (ibid.), Hinnen et al. (Proc. Natl. Acad. Sci. USA 75:1929-1933, 1978), Yelton et al. (Proc. Natl. Acad. Sci. USA 81:1740- 1747, 1984), and Russell (Nature 301:167-169, 1983) each of which are incorporated herein by reference. A variety of higher eukaryotic cells may serve as host cells for expression of the Glu G R, although not all cell lines will be capable of functional coupling of the receptor to the cell's second messenger systems. Cultured mammalian cells, such as BHK, CHO, Yl (Shapiro et al., TIPS SUPPl. 43-46 (1989)), NG108-15 (Dawson et al., Neuroscience Approached Through Cell Culture. Vol. 2, pages 89-114 (1989)), N1E-115 (Liles et al., J. Biol. Chem. 261:5307-5313 (1986)), PC 12 and COS-1 (ATCC CRL 1650) are preferred. Preferred BHK cell lines are the tk ~ tsl3 BHK cell line (Waechter and Baserga, Proc. Natl. Acad. Sci. USA 79:1106-1110 (1982)) and the BHK 570 cell line (deposited with the American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD. under accession number CRL 10314) . A tk " BHK cell line is available from the ATCC under accession number CRL 1632. Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Viral promoters include the immediate early cytomegalovirus promoter (Boshart et al.. Cell 41: 521-530, 1985) and the SV40 promoter (Subramani et al., Mol. Cell. Biol. 1: 854-864, 1981) . Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse V promoter (Bergman et al., Proc. Natl. Acad. Sci. USA 81: 7041-7045, 1983; Grant et al., Nuc. Acids Res. 15: 5496, 1987) and a mouse V H promoter (Loh et al., Cell 33: 85-93, 1983). A particularly preferred promoter is the major late promoter from Adenovirus 2 (Kaufman and Sharp, Mol. Cell. Biol. 2: 1304-13199, 1982). Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, ibid.), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9: 3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer and the mouse μ enhancer (Gillies, Cell 33: 717-728, 1983). Expression vectors may also include sequences encoding the adenovirus VA RNAs. Cloned DNA sequences may be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al.. Cell 14: 725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7: 603, 1981; Graham and Van der Eb, Virology 52: 456, 1973.) Other techniques for introducing cloned DNA sequences into mammalian cells, such as electroporation (Neumann et al., EMBO J. 1: 841-845, 1982), may also be used. In order to identify cells that have integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may .be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DltFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (Mammalian Cell Technology. Butterworth Publishers, Stoneham, MA, which is incorporated herein by reference) . The choice of selectable markers is well within the level of ordinary skill in the art. Selectable markers may be introduced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid. If on the same plasmid, the selectable marker and the gene of interest may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Patent No. 4,713,339). It may also be advantageous to add additional DNA, known as "carrier DNA" to the mixture which is introduced into the cells. Transfected mammalian cells are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. Transfected cells may also be selected in the presence of antagonist to inhibit the activity of the receptor. Suitable antagonists in this context include D, L, 2-amino-3-phosphonopropionate. For cells that have been transfected with an amplifiable selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Promoters, terminators and methods suitable for introducing expression vectors encoding recombinant Glu G R into plant, avian and insect cells are known in the art. The use of baculoviruses, for example, as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. fPestic. Sci. 28: 215-224,1990) . The use of Agrobacterium rhizogenes as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (J. Biosci. (Banglaore) 11: 47-58, 1987). Host cells containing DNA constructs of the present invention are then cultured to produce recombinant Glu G R. The cells are cultured according to accepted methods in a culture medium containing nutrients required for growth of mammalian or other host cells. A variety of suitable media are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins, minerals and growth factors. The growth medium will generally select for cells containing the DNA construct by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker on the DNA construct or co-transfected with the DNA construct. Transfected cells expressing a cloned Glu G R can be detected by several methods. By transfecting cells with an expression vector containing expression units for both the Glu G R and a reporter gene (e.g. luciferase) , the activity of the reporter gene provides an indicator of expression of the cotransfected Glu G R clone. By including one or more cyclic AMP response elements (CRE) in the reporter gene expression unit, clones encoding receptors coupled to either the stimulation or inhibition of the second messenger adenylate cyclase can be identified by a change in reporter gene expression in response to added ligand. DNA constructs comprising a linked CRE and reporter gene are known in the art. See, for example, Mellon et al., Proc. Natl. Acad. Sci. USA 86: 4887-4891 (1989) , incorporated herein by reference. Cell lines expressing functional receptors can also be detected by electrophysiological measurements of agonist-induced channel activity. Receptor activity can also be assayed by measuring cytosolic free calcium concentrations in transfected cells. See, for example, Thastrup et al., Proc. Natl. Acad. Sci. USA 87: 2466-2470 (1990) and Picard et al.. Science 247: 327-329 (1990), which are incorporated herein by reference. A preferred method for measuring cytosolic free calcium is by scanning cells with a fluorescent microscope coupled to a video camera. The cells are injected with a fluorescent Ca 2+ indicator (e.g. Fluo-3 or Fura-2, Molecular Probes, Inc., Eugene, OR) and exposed to ligand. The Glu G R produced according to the present invention may be purified from the recombinant expression systems or other sources using purification protocols that employ techniques generally available to those skilled in the art. The most convenient sources for obtaining large quantities of Glu G R are cells which express the recombinant receptor. However, other sources, such as tissues, particularly brain tissues of the cerebellum which contain Glu G R, may also be employed. Purification may be achieved by conventional chemical purification means, such as liquid chromatography, lectin affinity chromatography, gradient centrifugation, and gel electrophαresis, among others. Methods of protein purification are known in the art (see generally. Scopes, R. , Protein Purification. Springer-Verlag, NY (1982) , which is incorporated herein by reference) and may be applied to the purification of the Glu G R and particularly the recombinantly produced Glu G R described herein. In a preferred embodiment immunoaffinity chromatography is employed using antibodies directed against Glu G R as herein described. In another method of purification, a recombinant gene encoding Glu G R or portions thereof can be modified at the amino terminus, just behind a signal peptide, with a sequence coding for a small hydrophilic peptide, such as described in U.S. Patent Nos. 4,703,004 and 4,782,137, incorporated herein by reference. Specific antibodies for the peptide facilitate rapid purification of Glu G R, and the short peptide can then be removed with enterokinase. Thus, as discussed above, the present invention provides Glu G R isolated from its natural cellular environment, substantially free of other G protein- coupled glutamate receptors. Purified Glu G R is also provided. Substantially pure Glu G R of at least about 50% is preferred, at least about 70-80% more preferred, and 95-99% or more homogeneity most preferred, particularly for pharmaceutical uses. Once purified, partially or to homogeneity, as desired, the recombinant Glu G R or native Glu G R may then be used to generate antibodies, in assay procedures, etc. In another aspect, the invention concerns polypeptides and fragments of Glu G R. Polypeptides and fragments of Glu G R may be isolated from recombinant expression systems or may be synthesized by the solid phase method of Merrifield, Fed. Proc. 21:412 (1962), Merrifield, J. Am. Chem. Soc. 85:2149 (1963), or Barany and Merrifield, in The Peptides, vol. 2, pp. 1-284 (1979) Academic Press, NY, each of which are incorporated herein by reference, or by use of an automated peptide synthesizer. By "polypeptides" is meant a sequence of at least about 3 amino acids, typically 6 or more, up to 100-200 amino acids or more, including entire proteins. For example, the portion(s) of Glu G R proteins which bind ligand may be identified by a variety of methods, such as by treating purified receptor with a protease or a chemical agent to fragment it and determine which fragment is able to bind to labeled glutamate in a ligand blot. Polypeptides may then be synthesized and used as antigen, to inhibit ligand-Glu G R interaction, etc. It should be understood that as used herein, reference to Glu G R is meant to include the proteins, polypeptides, and fragments thereof unless the context indicates otherwise. In another aspect, the invention provides means for regulating the Glu G R-ligand interaction, and thus treating, therapeutically and/or prophylactically, a disorder which can be linked directly or indirectly to a Glu G R or to its ligands, such as glutamate and other endogenous excitatory amino acids. By virtue of having the receptors of the invention, agonists or antagonists may be identified which stimulate or inhibit the interaction of ligand with a Glu G R. With either agonists or antagonists the metabolism and reactivity of cells which express the receptor are controlled, thereby providing a means to abate or in some instances prevent the disease of interest. Thus, the invention provides screening procedures for identifying agonists or antagonists of events mediated by the ligand-Glu G R interaction. Such screening assays may employ a wide variety of formats, depending to some extent on which aspect of the ligand/receptor/G protein interaction is targeted. For example, such assays may be designed to identify compounds which bind to the receptor and thereby block or inhibit interaction of the receptor with the ligand. Other assays can be designed to identify compounds which can substitute for ligand and therefore stimulate Glu G R- mediated intracellular pathways. Yet other assays can be used to identify compounds which inhibit or facilitate the association of Glu G R to G protein and thereby mediate the cellular response to Glu G R ligand. In one functional screening assay, the initiation of fertilization activation events are monitored in eggs which have been injected with, e.g., mRNA which codes for Glu G R and subsequently exposed to selected compounds which are being screened, in conjunction with or apart from an appropriate ligand. See generally, Kline et al., Science 241:464-467 (1988), incorporated herein by reference. Oocytes injected with mRNA coding for Glu G R can also be assayed by measurement of free cytosolic Ca + as described above. Another screening assay is based on the use of mammalian cell lines which express Glu G R functionally coupled to a mammalian G protein. In this assay, compounds are screened for their relative affinity as receptor agonists or antagonists by comparing the relative receptor occupancy to the extent of ligand induced stimulation or inhibition of second messenger metabolism. For example, activation of phospholipase C leads to increased inositol monophosphate metabolism. Means for measuring inositol monophosphate metabolism are generally described in Subers and Nathanson, . Mol. Cell. Cardiol. 20:131-140 (1988), incorporated herein by reference. As noted previously, receptor subtypes that are coupled to the stimulation or inhibition of the second messenger adenylate cyclase can be used in assay systems wherein reporter gene (e.g. luciferase) activity is linked to receptor-ligand interactions. The screening procedure can be used to identify reagents such as antibodies which specifically bind to the receptors and substantially affect their interaction with ligand, for example. The antibodies may be monoclonal or polyclonal, in the form of antiserum or monospecific antibodies, such as purified antiserum or monoclonal antibodies or mixtures thereof. For administration to humans, e.g., as a component of a composition for in vivo diagnosis or imaging, the antibodies are preferably substantially human to minimize immunogenicity and are in substantially pure form. By substantially human is meant generally containing at least about 70% human antibody sequence, preferably at least about 80% human, and most preferably at least about 90-95% or more of a human antibody sequence to minimize immunogenicity in humans. Antibodies which bind Glu G R may be produced by a variety of means. The production of non-human antisera or monoclonal antibodies, e.g., murine, lagomorpha, equine, etc. is well known and may be accomplished by, for example, immunizing the animal with the receptor molecule or a preparation containing a desired portion of the receptor molecule, such as that domain or domains which contributes to ligand binding. Receptor subtype- specific antibodies can be generated by immunizing with specific peptides. Small peptides (e.g., about 14-20 amino acids) can be coupled to keyhole limpet hemocyanin, for example, to enhance immunogenicity. For the production of monoclonal antibodies, antibody producing cells obtained from immunized animals are immortalized and screened, or screened first for the production of antibody which binds to the receptor protein and then immortalized. As the generation of human monoclonal antibodies to human Glu G R antigen may be difficult with conventional techniques, it may be desirable to transfer antigen binding regions of the non-human antibodies, e.g. the F(ab') 2 or hypervariable regions, to human constant regions (Fc) or framework regions by recombinant DNA techniques to produce substantially human molecules. Such methods are generally known in the art and are described in, for example, U.S. Patent No. 4,816,397 and EP publications 173,494 and 239,400, which are incorporated herein by reference. Alternatively, one may isolate DNA sequences which code for a human monoclonal antibody or portions thereof that specifically bind to the human receptor protein by screening a DNA library from human B cells according to the general protocol outlined by Huse et al.. Science 246:1275-1281 (1989), incorporated herein by reference, and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity. In other embodiments, the invention provides screening assays conducted in vitro with cells which express the receptor. For example, the DNA which encodes the receptor or selected portions thereof may be transfected into an established cell line, e.g., a mammalian cell line such as BHK or CHO, using procedures known in the art (see, e.g.. Sambrook et al.. Molecular Cloning. A Laboratory Manual. 2d ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, which is incorporated herein by reference) . The receptor is then expressed by the cultured cells, and selected agents are screened for the desired effect on the cell, separately or in conjunction with an appropriate ligand such as glutamate or quisqualate. Means for amplifying nucleic acid sequences which may be employed to amplify sequences encoding the receptor or portions thereof are described in U.S. Pat. Nos. 4,683,195 and 4,683,202, incorporated herein by reference. In yet another aspect, the screening assays provided by the invention relate to transgenic mammals whose germ cells and somatic cells contain a nucleotide sequence encoding Glu G R protein or a selected portion of the receptor which, e.g., binds ligand, GTP binding protein, or the like. There are several means by which a sequence encoding, for example, the human Glu G R may be introduced into a non-human mammalian embryo, some of which are described in, e.g., U.S. Patent No. 4,736,866, Jaenisch, Science 240-1468-1474 (1988) and Westphal et al., Annu. Rev. Cell Biol. 5:181-196 (1989), which are incorporated herein by reference. The animal's cells then express the receptor and thus may be used as a convenient model for testing or screening selected agonists or antagonists. In another aspect the invention concerns diagnostic methods and compositions. By means of having the Glu G R molecule and antibodies thereto, a variety of diagnostic assays are provided. For example, with antibodies, including monoclonal antibodies, to Glu G R, the presence and/or concentration of receptor in selected cells or tissues in an individual or culture of interest may be determined. These assays can be used in the diagnosis and/or treatment of diseases such as, for example, cerebral ischemia, Parkinsons, senile dementia and other cognitive disorders, Huntington's chorea, amyotrophic lateral sclerosis, emesis, migraine, and others. Numerous types of immunoassays are available and are known to those skilled in the art, e.g., competitive assays, sandwich assays, and the like, as generally described in, e.g., U.S. Pat. Nos. 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, Antibodies. A Laboratory Manual. Cold Spring Harbor Publications, N.Y. (1988) , each incorporated by reference herein. In one assay format Glu G R is identified and/or quantified by using labeled antibodies, preferably monoclonal antibodies which are reacted with brain tissues, e.g., cortex, striatum, hippocampus, cerebellum, and determining the specific binding thereto, the assay typically being performed under conditions conducive to immune complex formation. Unlabeled primary antibody can be used in combination with labels that are reactive with primary antibody to detect the receptor. For example, the primary antibody may be detected indirectly by a labeled secondary antibody made to specifically detect the primary antibody. Alternatively, the anti-GlU g R antibody can be directly labeled. A wide variety of labels may be employed, such as radionuclides, particles (e.g., gold, ferritin, magnetic particles, red blood cells) , fluorophores, chemiluminescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens) , etc. The Glu G R DNA may be directly detected in cells with a labeled Glu G R DNA or synthetic oligonucleotide probe in a hybridization procedure similar to the Southern or dot blot. Also, the polymerase chain reaction (Saiki et al., Science 239:487 (1988), and U.S. Pat. No. 4,683,195) may be used to amplify DNA sequences, which are subsequently detected by their characteristic size on agarose gels, Southern blots of these gels using Glu G R DNA or a oligonucleotide probe, or a dot blot using similar probes. The probes may comprise from about 14 nucleotides to about 25 or more nucleotides, preferably, 40 to 60 nucleotides, and in some instances a substantial portion or even the entire cDNA of Glu G R may be used. The probes are labeled with a detectable signal, such as an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, paramagnetic particle, etc. Kits can also be supplied for use with the receptor of the subject invention in the detection of the presence of the receptor or antibodies thereto, as might be desired in the case of autoimmune disease. Thus, antibodies to GlU g R, preferably monospecific antibodies such as monoclonal antibodies, or compositions of the receptor may be provided, usually in lyophilized form in a container, either segregated or in conjunction with additional reagents, such as anti-antibodies, labels, gene probes, polymerase chain reaction primers and polymerase, and the like. The following examples are offered by way of illustration, not by limitation. EXAMPLE I Preparation of Glu c R enriched mRNA Total RNA was prepared from the cerebellum of rats using guanidine isothiocyanate (Chirgwin et al. Biochemistry 18:52-94 (1979)) and CsCl centrifugation. Poly(A)+ RNA was isolated using oligo d(T) cellulose chromatography. After 2 rounds of chromatography on oligo d(T) cellulose the RNA (800 μg) was divided into two aliquots and layered over 10-40% linear sucrose gradients in tubes for an SW 28 rotor. The gradients were centrifuged for 28 hours at 25,000 rpm to pellet RNA greater than 4 kb in size. The enriched RNA was injected into frog oocytes and assayed for the presence of the GlU g R. Injection of oocytes and voltage-clamp assay of Glu c R activity Oocytes were prepared from ovarian lobes that were surgically removed from anesthetized Xenopus females. The ovarian lobes were washed, pulled apart into small clumps and dissociated by treatment with collagenase for 2-3 hours at 20°C with constant, gentle agitation. The dissociation and defolicularization of the oocytes is completed manually after removal of the collagenase. Oocytes that were judged healthy and greater than 1 mm in diameter were transferred to a 50 mm sterile tissue culture dish and incubated in sterile, antibiotic-supplemented Barth's medium (88 mM NaCl, lmM KC1, 0.82 mM MgS0 4 , 0.33 mM Ca(N0 3 ) 2 , 0.41 mM CaCl 2 , 2.4 mM NaHC0 3 , 10 mM HEPES, pH 7.4, 0.1 mg/ml gentamicin, 0.01 mg/ml penicillin, 0.01 mg/ml streptomycin, 0.5 mM theophylline, and 2.5 mM Na pyruvate) at 19 β C. Injection pipettes were pulled from hard glass tubing (Drummond) on a modified 700C Kopf vertical puller. The tip was broken and bevelled using a List Medical microforge. Tip diameters of the pipettes ranged from 20-30 mM. Injection pipettes were made RNase free by heating to 285°C overnight. Following overnight incubation, healthy oocytes were selected for injection. RNA, which was stored at -70 β C in DEPC-treated water, was thawed and centrifuged at 15,000 g for five minutes. Injection was performed using a modified pipetting device (Drummond) . After injection, the oocytes were incubated in fresh, sterile Barth's medium which was changed daily, and unhealthy oocytes were removed. Voltage-clamp assays were carried out on injected oocytes which were each placed in a small chamber of approximately 500 μl in volume and which was continuously perfused with standard frog Ringer's (115 mM NaCl, 2.5 mM KC1, 1.8 mM CaCl 2 , 10 mM HEPES, pH 7.2) at 1-6 ml/min. The oocyte was impaled with two glass microelectrodes for recording which, when filled with 3 M KCl, had a tip resistance of 0.5 to 7.0 megaohms. One of the two electrodes was connected to a differential amplifier via a silver/silver chloride half cell. The bath potential was measured by connecting the other side of the differential amplifier to the bath via a silver/silver chloride pellet and a Ringer/Agar bridge. A low noise, high compliance, voltage-clamp system (NPI) was used to control the membrane potential and to measure membrane current. The oocyte membrane potential was maintained at -60 mV (inside cell negative) . One millimolar glutamate (Sigma) , 100 μM quisqualate (Sigma) , 1 mM carbamylcholine (Sigma) , and the other drugs used in this assay were applied by switching the perfusing medium to a medium containing a drug for approximately three minutes, and the membrane current was recorded on a chart recorder (Linear Instruments) . After impaling the oocyte with the two microelectrodes, and imposing the voltage-clamp, the membrane current (the holding current) gradually declines to a steady state over a period of several minutes. When the holding current stabilizes, so that the chart record is horizontal, the drug is applied for one to three minutes. An oocyte is judged to have a positive response if a rapid inward current spike (downward deflection on the chart) , followed by slow current oscillations of decreasing magnitude, is observed. Our lower limit of detection depended on the steadiness of the holding current prior to drug application, but was in the range of 5-10 nA. Construction of pVEGT' To permit transcription of cloned cDNA without prior endonuclease digestion, bacteriophage T7 transcriptional terminators were added to a cloning vector. Plasmid pVEGT* is described in copending U.S.S.N. 07/581,342, which is incorporated by reference herein. The sequence of the putative T7 RNA transcription terminator, which lies between gene 10 and gene 11 of bacteriophage T7, is disclosed by Dunn and Studier (J. Mol. Biol. 166: 477-536 (1983)). As shown in Figure 5, four synthetic oligonucleotides were designed from this sequence and ligated into the vector pGEM-1 (obtained from Promega Biotec, Madison, WI) , a plasmid containing a bacterial origin of replication, ampicillin resistance gene, and the T7 promoter adjacent to a multiple cloning site. Terminal phosphates were added to the 5' ends of oligonucleotides ZC776 and ZC777 (Sequence ID Nos. 4 and 5) with T4 polynucleotide kinase and ATP, under standard conditions (Maniatis et al. ibid). (The sequences of these and other oligonucleotides referred to herein are shown in Table 1.) After the incubation, the kinase was heat killed at 65 β C for 10 min. Twenty-five nanograms of oligonucleotide ZC775 (Sequence ID Number 3) and 25 ng of oligonucleotide ZC776 (Sequence ID Number 4) were annealed by incubation at 65 β C for 15 minutes, then allowed to cool to room temperature in 500 ml of water. Oligonucleotides ZC777 and ZC778 (Sequence ID Nos. 5 and 6) were similarly annealed. The annealed oligonucleotides were stored at -20*C until use. The vector pGEM-1 was digested with Pst I and Hind III, and the linearized vector DNA was purified by agarose gel electrophoresis. The synthetic T7 terminator (annealed oligonucleotides ZC775, ZC776, ZC777 and ZC778; Sequence ID Nos. 3, 4, 5 and 6) was then cloned into pGEM-1. Twenty-five nanograms of vector plus an equal molar amount of each of the annealed oligonucleotides ZC775/ZC776 (Sequence ID Nos. 3 and 4) and ZC777/ZC778 (Sequence ID Nos. 5 and 6) were combined in a 10 μl reaction mix. After an overnight ligation at 14 β C, the DNA was transformed into competent E. coli JM83 cells, and the transformed cells were selected for ampicillin resistance. Plasmid DNA was prepared from selected transformants by the alkaline lysis procedure (Birnboim and Doly, Nuc. Acids Res. 7:1513-1523 (1979)). A portion of the DNA from these samples was cut with Pst I and Hind III and analyzed on a 4% polyacrylamide gel to identify clones that released an 80 bp Pst I-Hind III fragment. Other diagnostic cuts, such as Eco RI and Not I, were also made. One of the isolates, designated pGEMT, was shown by restriction analysis to contain the T7 terminator fragment. Table 1 Oligonucleotide Sequences (5* - 3') ZC775 (Sequence ID Number 3) : GCT AGC ATA ACC CCT TGG GGC CTC TAA ACG GGT CT ZC776 (Sequence ID Number 4) : CTC AAG ACC CGT TTA GAG GCC CCA AGG GGT TAT GCT AGC TGC A ZC777 (Sequence ID Number 5) : TGA GGG GTT TTT TGC TGA AAG GAG GAA CTA TGC GGC CGC A ZC778 (Sequence ID Number 6) : AGC TTG CGG CCG CAT AGT TCC TCC TTT CAG CAA AAA ACC C ZC1751 (Sequence ID Number 7) : AAT TCT GTG CTC TGT CAA G ZC1752 (Sequence ID Number 8) GAT CCT TGA CAG AGC ACA G ZC2063 (Sequence ID Number 9) : GAT CCA AAC TAG TAA AAG AGC T ZC2064 (Sequence ID Number 10) : CTT TTA CTA GTT TG (Table 1, continued) ZC2938 (Sequence ID Number 11) : GAC AGA GCA CAG ATT CAC TAG TGA GCT CTT TTT TTT TTT TTT T ZC3015 (Sequence ID Number 12) : TTC CAT GGC ACC GTC AAG GCT ZC3016 (Sequence ID Number 13) AGT GAT GGC ATG GAC TGT GGT ZC3652 (Sequence ID Number 14) ACA TGC ACC ATG CTC TGT GT ZC3654 (Sequence ID Number 15) AGT GAT GGC ATG GAC TGT GGT The native T7 terminator from plasmid pAR2529 (Rosenberg et al., Gene 56:125-135 (1987)) was added to plasmid pGEMT. Plasmid pGEMT was digested with Bam HI and plasmid pAR2529 was digested with Bam HI and Bgl II (Figure 1) . The Bam HI-Bgl II terminator fragment from pAR2529 was purified by agarose gel electrophoresis. The terminator fragment was ligated to Bam HI digested pGEMT, and the DNA was transformed into competent E. coli LM1035 cells. Colonies that were ampicillin resistant were inoculated into 5 ml cultures for overnight growth. Plasmid DNA prepared by the alkaline lysis procedure was screened for proper terminator orientation by Bam Hi-Sal I digestion and electrophoresis on an 8% polyacrylamide gel. A clone that contained the terminator in the correct orientation, as evidenced by the presence of a 130 bp Bam HI-Sal I fragment, was chosen and named pGEMTT (Figure 1) . To allow pGEMTT to be packaged as single-stranded DNA in the presence of M13 phage proteins, the M13 intergenic region from pUC382 (similar to pUCllδ and 119 as disclosed by Vieira and Messing, Methods Enzymol. 153: 3-11 (1987) was added to pGEMTT (Figure 1). Plasmid pGEMTT was digested with Fsp I and Nar I, and the fragment containing the T7 promoter and transcription terminator was purified. Plasmid pUC382 was digested with Fsp I and Nar I, and the fragment encoding the ampicillin resistance gene and the M13 intergenic region was gel purified. These fragments were then ligated together in the presence of T4 DNA ligase. The ligated DNA was transformed into competent Ej_ coli LM1035 cells. Plasmid DNA from twelve ampicillin-resistant colonies was prepared by the alkaline lysis method, and the DNA was screened by digestion with Ava I. The appropriate construction gave two bands, one of 2430 bp and another of 709 bp. One such isolate was chosen and named pVEG. Synthetic oligonucleotides encoding the prime sequence were added to pVEG between the Bam HI and Eco RI sites (Figure 1) . Plasmid pVEG was digested with Bam HI and Eco RI and the vector fragment was gel purified. Ninety-six nanograms each of oligonucleotides ZC1751 and ZC1752 (Sequence ID Nos. 7 and 8) were annealed in 4.5 μl of 10 mM Tris pH 7.5, 20 mM MgCl 2 and 10 mM NaCl at 65 β C for 20 minutes, then the mixture was cooled to room temperature over a period of 30 minutes. The annealed oligonucleotides were ligated to the pVEG vector fragment with T4 DNA ligase and then transformed into competent E. coli LM1035 cells. After growing overnight to develop the colonies, a filter lift was taken of the colonies on the agar plate. The filter was probed with 32P-labeled oligonucleotide ZC1751 (Sequence ID Number 7) . All of the colonies were positive. Plasmid DNA was prepared from cultures grown from 12 of the colonies. The plasmid DNA was screened by digestion with Sst I to verify the absence of the Sst I site between the Eco RI and Bam HI sites of pVEG. All 12 of the plasmid DNAs were negative for Sst I digestion. One of these 12 isolates was chosen and named pVEG' . A polyadenylate sequence derived from an Aspergillus alcohol dehydrogenase cDNA was added to pVEG. As shown in Figure 1, plasmid pM098 (disclosed in published European patent application EP 272,277 and deposited with American Type Culture Collection under accession number 53428) was digested with Dra I and Bam HI, and the approximately 150 bp poly(A) fragment was purified by agarose gel electrophoresis. This fragment contained mostly poly(A) sequence with very little flanking cDNA. To clone the poly(A) cDNA fragment into pVEG, pVEG was digested with Bam HI and Sma I, and the 3.4 kb vector fragment was gel purified. The vector and poly(A) fragments were ligated together with T4 DNA ligase to produce vector pVEGT (Figure 1) . Synthetic oligonucleotides encoding the prime sequence were added to pVEGT. To accomplish this, pVEGT was digested with Not I and Sst I, and the 370 bp fragment containing the poly(A) sequence and the two T7 transcriptional terminators was purified by agarose gel electrophoresis. Plasmid pVEG' was digested with Not I and Bam HI, and the 3.2 kb vector fragment was gel-purified. Two oligonucleotides (ZC2063 and ZC2064; Sequence ID Nos. 9 and 10) that formed, when annealed, a Bam Hl-Sst I adapter were synthesized. The two oligonucleotides were individually kinased and annealed, and ligated with the linearized vector and the poly(A)-terminator fragment. The resultant vector, designated pVEGT' (Figure 1), contained a T7 RNA transcription promoter, an Eco RI cloning site flanked by the prime sequence, a poly(A) tract, and two T7 RNA polymerase terminators. Construction of cDNA library from rat cerebellum polvCA.4- RNA Because there was evidence suggesting that the GlU g R was encoded a very large mRNA of 7 kb (Fong, Davidson, and Lester, Synapse 2:657 (1988)) and because full length cDNA encompassing the coding sequence is required for functional cloning of cDNA, measures were taken to optimize for synthesis of large cDNA. A novel method of cDNA synthesis was developed which yielded large full length cDNA. This was evident by demonstration that full length 7.5 kb cDNA could be synthesized from a model 7.5 kb mRNA and that large full length cDNA were present in a library constructed from poly(A)+ RNA as demonstrated by Southern blot analysis. In addition, all enzymes which were important in this method were pretested and selected from a large number of lots of enzymes available from commercial suppliers. Once a satisfactory lot was identified, a large amount of the enzyme was purchased and the enzyme was stored at -70 β C until used. Once used, the enzyme was stored at -20 β C for a few months and then discarded. Different "lots" of enzymes from commercial suppliers, including lots of Superscript reverse transcriptase (BRL) , E. coli DNA polymerase I (Amersham) and Mung bean nuclease (NEB) , which were used in the cDNA synthesis, were screened for quality in test synthesis assays. Superscript reverse transcriptase lots were assayed for the ability to synthesize unit length (7.5 kb) first strand cDNA from 7.5 kb RNA (BRL) control. Conditions for first strand synthesis with Superscript reverse transcriptase lots were prepared as described below. Radiolabeled first strand cDNA was analyzed by alkaline agarose gel electrophoresis. Superscript lots capable of producing unit length, 7.5 kb cDNA were selected for use. E. coli DNA polymerase I lots were assayed for the ability to produce, by hairpin DNA formation, full-length second strand cDNA from the 7.5 kb unit-length first strand cDNA. The second strand cDNA syntheses were carried out as described below. The quality of the second strand syntheses were assessed by alkaline agarose electrophoresis of the radiolabeled product. DNA polymerase I lots capable of producing 15 kb second strand DNA from the 7.5 kb unit length first strand cDNA were selected for use. Mung bean nuclease lots were tested for the ability to clip the hairpin DNA formed during second strand synthesis without degrading the cDNA. In addition, varying concentrations of enzyme were added to determine the optimum enzyme concentration for the conditions set forth below. The reactions were assessed by alkaline agarose electrophoresis. Lots and concentrations resulting in the production of 7.5 kb unit length cDNA were selected for use. Total RNA was prepared from rat cerebella using guanidine isothiocyanate (Chirgwin et al. Biochemistry 18:52-94 1979) and CsCl centrifugation (Gilsin et al. Biochemistry 13:2633-2637 1974). Poly(A)+ RNA was selected from the total RNA using oligo d(T) cellulose chromatography (Aviv and Leder, Proc. Natl. Acad. Sci. USA 69:1408 (1972)) . First strand cDNA was synthesized from one time poly d(T)-selected cerebellum poly(A)+ RNA in two separate reactions. One reaction, containing radiolabeled dATP, was used to assess the quality of first strand synthesis. The second reaction was carried out in the absence of radiolabeled dATP and was used, in part, to assess the quality of second strand synthesis. Superscript reverse transcriptase (BRL) was used specifically as described below. A 2.5x reaction mix was prepared at room temperature by mixing, in order, 10 μl of 5x reverse transcriptase buffer (BRL; 250 mM Tris-HCl pH 8.3, 375 mM KCl, and 15 mM MgCl 2 ) , 2.5 μl 200 mM dithiothreitol (made fresh or stored in aliquots at -70 β C) and 2.5 μl of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and 5-methyl dCTP (Pharmacia) . The reaction mix was aliquoted into two tubes of 7.5 μl each. To the first tube, 1.3 μl of 10 μCi/μl α 32 P-dATP (Amersham) was added and 1.3 μl of water was added to the second reaction tube. Seven microliters from each tube was transferred to reaction tubes. Fourteen microliters of a solution containing 10 μg of cerebellum poly(A)+ RNA diluted in 14 μl of 5 mM Tris-HCl pH 7.4, 50 μM EDTA was mixed with 2 μl of 1 μg/μl first strand primer, ZC2938 (Table 1; Sequence ID No. 11) , and the primer was annealed to the RNA by heating the mixture to 65"C for 4 minutes, followed by chilling in ice water. Eight microliters of the RNA-primer mixture was added to each of the two reaction tubes followed by 5 μl of 200 U/μl Superscript reverse transcriptase (BRL) . The reactions were mixed gently, and the tubes were incubated at 45 β C for 30 minutes. After incubation, 80 μl of 10 mM Tris-HCl pH 7.4, 1 mM EDTA was added to each tube, the samples were vortexed and centrifuged briefly. Three microliters of each reaction was removed to determine total counts and TCA precipitable counts (incorporated counts) . Two microliters of each sample was analyzed by alkaline gel electrophoresis to assess the quality of first strand synthesis. The remainder of each sample was ethanol precipitated. The nucleic acids were pelleted by centrifugation, washed with 80% ethanol and air dried for ten minutes. The first strand synthesis yielded 1.4 μg of cerebellum cDNA or a 28% conversion of RNA into DNA. Second strand cDNA synthesis was performed on the RNA-DNA hybrid from the first strand reactions under conditions which encouraged first strand priming of second strand synthesis resulting in DNA hairpin formation. The nucleic acid pellets containing the first strand cDNA were resuspended in 71 μl of water. To assess the quality of second strand synthesis, α 32 P-dATP was added to the unlabeled first strand cDNA. To encourage formation of the hairpin structure, all reagents except the enzymes were brought to room temperature, and the reaction mixtures were set up at room temperature. (Alternatively, the reagents can be on ice and the reaction mixture set up at room temperature and allowed to equilibrate at room temperature for a short time prior to incubation at 16*C.) Two reaction tubes were set up for each synthesis. One reaction tube contained the unlabeled first strand cDNA and the other reaction tube contained the radiolabeled first strand cDNA. To each reaction tube, 20 μl of 5x second strand buffer (100 mM Tris, pH 7.4, 450 mM KCl, 23 mM MgCl 2 , 50 mM (NH 4 ) 2 S0 4 ), 3 μl of beta-NAD and 1 μl of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and dCTP (Pharmacia) , 1 μl α 32 P-dATP or 1 μl of water (the radiolabeled dATP was added to the tube containing the unlabeled first strand cDNA), 0.6 μl of 7 U/μl E. coli DNA ligase (Boehringer-Mannheim) , 3.1 μl of 8 U/μl E. coli DNA polymerase I (Amersham) , and 1 μl of 2 U/μl of RNase H (BRL). The reactions were incubated at 16 β C for 2 hours. After incubation, 3 μl was taken from each reaction tube to determine total and TCA precipitable counts. Two microliters of each sample was analyzed by alkaline gel electrophoresis to assess the quality of second strand synthesis by the presence of a band of approximately twice unit length. To the remainder of each sample, 2 μl of 2.5 μg/μl oyster glycogen, 5 μl of 0.5 M EDTA and 200 μl of 10 mM Tris-HCl pH 7.4, 1 mM EDTA were added, the samples were phenol-chloroform extracted, and isopropanol precipitated. The nucleic acids were pelleted by centrifugation, washed with 80% ethanol and air dried. The yield of double stranded cDNA in each of the reactions was approximately 2 μg. The single-stranded DNA in the hairpin structure was clipped using mung bean nuclease. Each second strand DNA sample was resuspended in 12 μl of water. Two microliters of lOx mung bean buffer (0.3 M NaOAC, pH 4.6, 3 M NaCl, 10 mM ZnS0 4 ) , 2 μl of 10 mM dithiothreitol, 2 μl of 50% glycerol, and 2 μl of 10 U/μl mung bean nuclease (NEB, lot 7) were added to each tube, and the reactions were incubated at 30 β C for 30 minutes. After incubation, 80 μl of 10 mM Tris-HCl pH 7.4, 1 mM EDTA was added to each tube, and 2 μl of each sample was subjected to alkaline gel electrophoresis to assess the cleavage of the second strand product into unit length cDNA. One hundred microliters of 1 M Tris-HCl pH 7.4 was added to each sample, and the samples were twice extracted with phenol-chloroform. Following the final phenol-chloroform extraction, the DNA was isopropanol precipitated. The DNA was pelleted by centrifugation, washed with 80% ethanol and air dried. Approximately 2 μg of DNA was obtained from each reaction. The cDNA was blunt-ended with T4 DNA polymerase after the cDNA pellets were resuspended in 12 μl of water. Two microliters of lOx T4 DNA polymerase buffer (330 mM Tris-acetate, pH 7.9, 670 mM KAc, 100 mM MgAc, 1 mg/ml gelatin) , 2 μl of 1 mM dNTP, 2 μl 50 mM dithiothreitol, and 2 μl of 1 U/μl T4 DNA polymerase (Boehringer-Mannheim) were added to each tube. After an incubation at 15°C for 1 hour, 180 μl of 10 mM Tris-HCl pH 7.4, 1 mM EDTA was added to each sample, and the samples were phenol-chloroform extracted followed by isopropanol precipitation. The cDNA was pelleted by centrifugation, washed with 80% ethanol and air dried. Eco RI adapters (Invitrogen, Cat. # N409-20) were ligated to the blunted cDNA after the DNA from each reaction was resuspended in 6.5 μl water. The first strand primer encoded an Sst I cloning site to allow the cDNA to be directionally cloned into an expression vector. The cDNA was digested with Sst I followed by phenol-chloroform extraction and isopropanol precipitation. After digestion, the cDNA was electrophoresed in a 0.8% low melt agarose gel, and the cDNA over 4.2 kb was electroeluted using an Elutrap (Schleicher and Schuell, Keene, NH) . The electroeluted cDNA in 500 μl of buffer was isopropanol precipitated and the cDNA was pelleted by centrifugation. The cDNA pellet was washed with 80% ethanol. A cerebellum cDNA library was established by ligating the cDNA to the Eco Rl-Sst I digested, agarose gel purified pVEGT' . Ten sublibraries of one million clones each were constructed representing a library of ten million independent clones. To prepare each sublibrary, 80 ng of linearized vector were ligated to 40 ng of cDNA. After incubation at room temperature for 11 hours, 2.5 μg of oyster glycogen and 80 μl of 10 mM Tris-HCl, 1 mM EDTA was added and the sample was phenol-chloroform extracted followed by ethanol precipitation. The DNA was pelleted by centrifugation, and the DNA pellet washed with 80% ethanol. After air drying, the DNA was resuspended in 3 μl of water. Thirty-seven microliters of electroporation-competent DH10B cells (BRL) was added to the DNA and electroporation was completed using a BioRad electroporation unit. After electroporation, 4 ml of SOC (Maniatis et al.) was added to the cells, and 400 μl was spread on each of 10-150 mm LB ampicillin plates. Each plate represented a sublibrary of 100,000 clones. After an overnight incubation, the cells were harvested by adding 10 ml of LB ampicillin media to each plate and scraping the cells into the media. Glycerol stocks and plasmid DNA were prepared from each plate. The library background (vector without insert) was established at about 15%. Detection of Glu c R activity from the cDNA library The Xenopus oocyte efficiently translates exogenously added mRNA. Preliminary experiments were done using the mouse ml muscarinic receptor cDNA (a G protein-coupled receptor that can be detected by voltage- clamp) cloned into pVEGT'. Injection of RNA transcribed in vitro from increasing dilutions of the ml template DNA indicated that ml agonist induced activity could be detected for one clone in a pool size of 100,000. A cerebellum sublibrary was plated into ten pools of 100,000 unique clones. The pools could also be replica plated onto a nitrocellulose filter and the original and replica allowed to grow for a few hours. The original plate is scraped to harvest all the colonies. Plasmid DNA is prepared and purified by cesium chloride gradient ultracentrifugation. The DNA from each pool is transcribed .in vitro with T7 RNA polymerase in the presence of 7-methyl-G, the capped nucleotide, to increase translation efficiency. Template DNA transcription reactions are spiked with a dilution of two control genes cloned into pVEGT' : the mouse ml gene and a secreted version of the human placental alkaline phosphatase gene (SEAP; Tate et al., Fed. Am. Soc. Exp. Biol. 8: 227-231 (1990), incorporated by reference herein) . Transcription from the control genes would allow selection of oocytes that more efficiently translate the injected RNA, and a determination whether oocytes that are negative for the Glu G R are true negatives, that is, still having a detectable ml agonist- induced response. Plasmid DNA prepared from each of the 10 pools of 100,000 clones, which in total represented one sublibrary of one million clones of the cerebellum cDNA library, was purified by cesium chloride gradient ultracentrifugation. The DNA was transcribed in vitro with T7 RNA polymerase (Pharmacia) in the presence of capped nucleotide (GpppG, Pharamcia) . The presence of a poly(A) sequence and two T7 RNA polymerase terminators in pVEGT' resulted in RNA with a capped 5' end, the sequence of the cDNA insert, and 3* poly(A) tails. Capped RNA is believed necessary for efficient translation in oocytes (Noma et al. Nature 319:640 (1986)) and the poly(A) sequence has been shown to increase the synthesis of a protein in oocytes by more then 40 fold. The transcription reaction tubes were set up by adding 12 μl of 5x transcription buffer (Stratagene Cloning Systems, La Jolla, CA) , 3 μl each of 10 mM ATP, CTP, GTP, and UTP, 6 μl of 10 mM GpppG (Pharmacia) , 6 μl of 1 mg/ml BSA, 3 μl of 200 mM DTT, 1.5 μl of 40 ϋ/μl RNasin (ProMega Biotech, Madison, WI) , 8.5 μl of water, 10 μl of cDNA containing 5 to 10 μg DNA, and 1 μl of 70 U/μl T7 RNA polymerase. After mixing, 10 μl of the reaction was transferred to a tube containing 0.5 μCi of α 32P-UTP to determine the total counts and counts incorporated into RNA. The samples were incubated at 37*C for one hour. The cDNA in the unlabeled samples was degraded with the addition of 1 μl of 200 mM DTT, 2 μl of 30 U/μl DNase I, and 0.5 μl of 40 U/μl RNasin and the incubation was continued at 37 β C for 15 minutes. Forty microliters of water was added to the radiolabeled reactions, and 1 μl was removed from each sample and counted to determine total counts. The remainder of the labeled samples were ethanol precipitated. The samples were centrifuged to collect the RNA and the RNA pellets were counted to determine the counts incorporated into RNA. After the DNA degradation reaction in the unlabeled samples, 70 μl of 10 mM Tris-HCl, 1 mM EDTA was added to each sample, and the samples were twice-extracted with phenol-chloroform followed by one chloroform extraction. The RNA was ethanol precipitated. After centrifugation to collect the RNA, the pellets were washed with 80% ethanol, followed by air drying for 10 minutes. A typical yield of the unlabeled RNA was 20 to 30 μg. The unlabeled RNA was resuspended at 2 μg/μl in diethylpyrocarbonate (DEPC, Sigma) treated water and stored at -70 β C. Prior to microinjection into oocytes, the RNA samples were thawed and centrifuged in a microfuge for 5 minutes to remove any particles that might clog a microinjection pipet. After centrifugation, 80% of each sample was removed and split into two tubes. The RNA from each of the 10 sublibraries were injected into oocytes as described above and translation was allowed for four days. Expression of Glu G R activity was assessed by voltage-clamp assay as described above. One of the 10 sublibraries, Z93-1.9, produced a signal with administration of quisqualate to the oocyte. Subdivision of the cDNA library pool to obtain pure Glu c R clone The DNA pool (Z93-1.9) was subdivided by plating clones from the glycerol stock onto LB ampicillin plates. To determine the number of clones that should be plated for the subdivision of the 100,000 clone pool to identify a positive clone, the probability equation N = ln (1- P) / ln (1 - f) (Maniatis et al., ibid.) was used, where P is the desired probability of including the clone of interest, f is the fraction of positive clones in the pool, and N is the number of clones to be plated to provide the given probability. For a probability of 99.8% for a pool size of 100,000 to contain one positive clone, 621,461 clones should be plated. Forty-eight 150 mm LB ampicillin plates were plated with the glycerol stock representing the 100,000 positive pool, Z93-1.9, at a density of approximately 14,000 clones per plate to give a total of 670,000 clones. After an overnight incubation 37 β C, the bacteria on each plate were harvested into 10 ml of Solution I (as described by Birnboim and Doly, Nuc. Acids Res. 7:1513 (1979)), incorporated by reference herein). A glycerol stock was prepared from a portion of the cells, and plasmid DNA was prepared from the remainder of the cells. Six pools of DNA representing eight of the LB ampicillin plates each were prepared by combining one tenth of the plasmid DNA from groups of eight plates into each pool. The plasmid DNA from these six pools was purified by cesium chloride gradient centrifugation. The DNA was transcribed into RNA as outlined above. Transcription of the parent pool Z95-1.9 was included as the positive control. Oocytes were injected with the RNA and voltage-clamp assays on the oocytes identified pool Z99-25-32 as positive for Glu G R. Pool Z99-25-32 contained DNA prepared from plates 25 through 32. Plasmid DNA from plates 25 to 32 were cesium chloride banded and transcribed into RNA as described above along with the positive parent pool Z99-25-32. Oocytes were injected with the RNA and voltage clamp assays, carried out as described above, identified pools Z104-25 and Zlll-32 as being weakly positive, Z106-27 and Z109-30 as intermediately positive, and Z108-29 and Z110-31 as the most positive. The pool resulting in Z110-31 was chosen for further subdivision. Identification of positive pools from the subdivision of the positive pool of 14,000 (Z110-31) from the glycerol stock was unsuccessful. Therefore, plasmid DNA prepared from the pool resulting in Z110-31 was electroporated into bacteria and plated on 60 plates at a density of 1,000 clones/plate. Plasmid DNA was prepared from the bacteria harvested from each plate. Aliquots of the plasmid DNA from each plate were mixed to make six pools representing ten plates each. The plasmid DNA was cesium chloride banded, and the RNA was transcribed as described above. RNA was transcribed from pools Z108-29, Z110-31, and a muscarinic receptor cDNA, ml, for use as positive controls. The RNA was injected into oocytes and voltage-clamp assays were carried out as described, above. The assays identified pool Z133-21 to 30 as positive. Plasmid DNA from plates 21 to 30 were cesium chloride banded and transcribed as described above. The transcribed RNA and the RNA from the parent pool Z133-21 to 30 were injected into oocytes and assayed as described above. The voltage-clamp assay identified pool Z142-22 as positive. Identification of positive pools by the subdivision of the positive pool Z142-22 from a glycerol stock proved unsuccessful. Restriction analysis of plasmid DNA prepared from randomly selected clones from pools Z110-31 (the pool of 14,000) and Z142-22 (the pool of 1,000) indicated that 50% of pool Z110 - 31 and 68% of pool Z142 - 22 were clones without inserts. To assess physical methods for enriching for the Glu G R clone and to establish how many clones from pool Z142-22 needed to be assayed to include a Glu G R clone, undigested plasmid DNA from pool Z142-22 was electrophoresed on an agarose gel. The super-coil band representing vector without insert was cut out and the remainder of the DNA was eluted from the gel. The DNA was then electroporated into bacteria cells, and plated at densities of 3,400, 6,900, and 13,800 clones per plate. The plates were replica plated and grown overnight. Plasmid DNA was prepared from the cells harvested from the replica of each plate. The plasmid DNA was transcribed, and the RNA was assayed in oocytes as described above. As a control, each pool contained the equivalent of one colony of ml as an internal positive control. In addition, ml was used as an external positive control. The voltage-clamp assays identified the DNA from the 6,900 clone pool (Z167-7) as positive. The clones represented on the 6,900 clone plate that resulted in the positive pool Z167-7 were subdivided by replica plating the master plate onto a Biodyne-A nylon membrane on an LB ampicillin plate. The replica plate was incubated four hours at 37 β C. After incubation, sub-pools were prepared by removing the membrane from the plate, taping the membrane to a sterile glass plate on a light box, and overlaying the membrane with a grid which divided the membrane into 100 sections. The sections of the grid and underlying membrane were then cut out with a razor blade that had been dipped in alcohol and flamed between each cut. Alcohol-treated, flamed forceps were used to transfer each membrane section to a test tube containing 12.5 ml of LB ampicillin media. The cultures containing the membrane sections were incubated overnight at 37 β C. After incubation, 0.5 ml of each culture was mixed with 0.5 ml of 50% glycerol and stored at -70°C to establish glycerol stocks of each sub-pool. Aliquots of the 100 cultures were pooled in a 10 X 10 matrix with samples (1) through (10) on the abscissa and samples (a) through (j) on the ordinate. For example, 1 ml of cultures (1) through (10) were added to tube 1 and 1 ml of cultures (1) , (11) , (21), (31), (41), (51), (61), (71), (81), and (91) were added to tube (a) and so on until 10 rows of 10 and 10 columns containing pools of 10 cultures each were completed. Ten microliters of an overnight culture containing ml-transformed bacteria was added to each pool as an internal control. Plasmid DNA was prepared from the 20 sub-pools, and the DNA was purified by cesium chloride gradient centrifugation. RNA was transcribed from the plasmid DNA and was assayed in oocytes as described above. Positive controls were the parent pool Z167-7 and pure ml RNA. The voltage-clamp assays indicated that only pools Z175-1 and Z191-g were positive. Consulting the matrix, this indicated that the membrane section number (7) contained the Glu G R clone. To subdivide the clones contained in section (7) , a piece of Biodyne A membrane was applied to the master plate containing section (7) , the membrane extending beyond section (7) on each side by half the width of section (7) . The membrane was removed from the plate, applied to a fresh LB ampicillin plate colony side v up, and incubated overnight at 37*C. The membrane was subdivided as described above with the central region of the membrane, the actual section (7) area, divided into 9 small, equivalent-sized squares and the membrane on each side of section (7) was taken as four additional areas. Each membrane section was used to inoculate a 10 ml liquid culture. Bacteria transformed with the ml clone were used as an internal control in each culture as described above. After overnight incubation at 37*C, plasmid DNA was prepared, and the DNA was purified by cesium chloride gradient centrifugation. RNA was transcribed and assayed in oocytes as described above using RNA from ml and the parent pool number (7) as positive controls. Glu G R activity was found in only pool Z203-7 corresponding to membrane section number (7) . Pool Z203-7 was subdivided by electroporating the plasmid DNA prepared from the membrane section number (7) into DH10B electroporation-competent cells. The transformants were plated at a density enabling individual colonies to be picked. Individuals clones were picked to a master plate and into 2 ml of LB ampicillin media. The cultures were incubated overnight, and plasmid DNA was prepared by the method essentially described by Holms and Quigley (Anal. Bioc. 114: 193, (1981)). Restriction analysis suggested that the clones were grouped into 7 different classes of clones. Plasmid DNA, prepared from each class, representing fifty total clones were prepared, transcribed*, and assayed in oocytes as described above. However, none of the clones were positive. To screen for positive clones, electroporation- competent E. coli DH10B cells were electroporated with the DNA prepared from membrane section number (7) (Z203-7) and were plated at 180, 360, 900, and 1800 colonies per plate. The plates were incubated overnight, and replica plates were prepared as described above. Plasmid DNA prepared from each replica plate was combined with 1 to 1000 parts of ml as an internal control. The DNA pools, the ml clone and the parent pool Z203-7 were transcribed, and the RNA was assayed by oocyte injection. The first transcription and injection showed no positives, however, upon retranscription and reanalysis the 1800 clone pool (Z264-1800) was positive for Glu G R activity. To subdivide the positive pool of 1800 (Z264-1800) , all of the colonies from the plate of 1800, 1528 in total, were each picked to two 100 mm LB ampicillin agar plates on a 100 colony grid. After overnight growth, one set of the duplicate plates was designated as a master set and was placed at 4°C. The other set was replica plated to a third set of plates. After overnight incubation of these plates, the cells on the replica plates were harvested into media and plasmid DNA was prepared from the pooled cells. As described above, an internal ml control was included in each DNA preparation, ml DNA and the parent Z264-1800 DNA were used as external positive controls. Plasmid DNA prepared from the 16 plates was transcribed, and the RNA was assayed in oocytes as described above. One of the pools of 100 clones, Z256-I produced Glu G R activity. To identify which clone of the 100 clones from Z256-I produced the Glu G R activity, a 10 x 10 matrix of the clones was constructed. A liquid culture of each clone was grown. One milliliter of each culture was added to each of two tubes representing the appropriate row and column of the 10 x 10 matrix. As described previously, plasmid DNA encoding ml was used as an internal positive control. Plasmid DNA prepared from each tube, ml DNA and DNA from the parent pool Z264-1800 were transcribed and assayed in oocytes as described above. Glu G R activity was identified only in row (5) and column (e) . Thus, the positive clone number 45 was identified as containing the Glu G R activity. To confirm the result, plasmid DNA from clone #45 was prepared, transcribed and assayed in oocytes as described above. The results of the assay indicated that clone #45 was capable of producing Glu G R activity. Figure 2 illustrates the data taken from voltage-clamp recordings at several stages in the subfractionation of the cerebellum library. Panel (a) is a recorded response to quisqualate of an oocyte previously injected with in vitro transcribed RNA from a rat cerebellum sublibrary of 100,000 independent colonies; panel (b) shows the response to quisqualate in a cell previously injected with RNA transcribed from a subfractionated pool of 14,000 colonies. The peak current was truncated by the chart recorder, but the actual peak current (estimated from a digital panel meter) was approximately 1300 nA. Panel (c) shows the response to quisqualate in a cell injected with pure Glu G R RNA from clone 45-A. The amount of RNA injected per oocyte was approximately 100 ng, except in panel (c) where the amount of RNA was 50 pg. The following describes an alternative means for subdividing and screening a positive pool. Working with cDNA inserts in a plasmid based rather than a lambda- based vector influences the subfractionation protocol. Once a positive pool is identified, the replica filter is overlayed with another sterile nitrocellulose filter. The filter is cut into 88 pieces by using evenly spaced cuts of 10 rows and 10 columns to form a grid. Each of the 88 pieces is transferred to 10 ml of sterile LB +Amp and grown for several hours. Twenty pools are formed; C 1-10 (corresponding to column number) and R 1-10 (corresponding to row number) . An aliquot of each of the 88 subfractions is pipetted into 2 tubes, corresponding to its position in a row and a column. DNA is isolated from the 20 pools, purified on CsCl gradients and transcribed in an in vitro reaction that includes the control ml and SEAP plasmids. After injection into oocytes and voltage-clamp recording there are 2 positive pools, pinpointing the location of 1 of the 88 original subfractions. Because the positive clone is still part of a pool it must be further subdivided. The probability equation described above is used to determine the number of clones to be plated for the next subdivision of the pool. The glycerol stock from the positive pool is plated out at, e.g., 3000, 6000 and 18,000 clones per plate. After replica plating the DNA is harvested, transcribed, injected and assayed. The pool which is positive is subdivided into a grid of 88 as described above. The assay is repeated, and a single square of the grid is positive. At the next step of subdivision of the pool, 100 individual colonies to a plate are picked, replica plated, and 20 pools are made for transcription and assay. Positive clones are streaked out, several colonies picked and restriction mapped and template and transcript prepared for injection and assay. Characterization of Glu c R To establish that the Glu G R encoded by clone 45-A couples to G-protein, clone 45-A Glu G R RNA was transcribed and injected into oocytes as described above. Two days after injection the oocytes were divided into control and toxin-treated groups. The oocytes in the toxin-treated group were treated with a final concentration of 4 μg/ml of B. pertussis toxin (List Biological Laboratories Inc. , Campbell, CA) , and both groups were incubated for 24 hours at 19*C as described by Sugiyama et al., Nature 325:531 (1987) and Moriarity et al., J. Biol. Chem. 264:13521 (1989), both of which are incorporated by reference herein. The oocytes from both the control and toxin-treated groups were subjected to voltage-clamp assays as described previously. In one example, oocytes perfused as described previously with 100 μM L-glutamic acid showed a mean L-glutamic acid-induced current of 264.2 nA +/" 73 nA in control oocytes (SEM, n=6) and 57.7 nA +/- 19 nA (n=9) in toxin-treated oocytes. The mean membrane current in the toxin-treated group was significantly smaller (p < 0.01) than in the control group suggesting that oocytes injected with 45-A RNA coupled to a pertussis toxin-sensitive G protein. L-glutamic acid and some of its structural derivatives that are known to activate Glu G R currents in a dose-dependent manner were applied to oocytes that had been injected with RNA transcribed from the 45-A clone. RNA was transcribed and oocytes were prepared and injected as previously described. Dose dependent responses were measured using voltage clamp assays were carried out in the presence of increasing concentrations of L-glutamic acid (Sigma) , quisqualic acid (Sigma) , ibotenic acid (Sigma), or trans l-amino-cyclopentyl-1,3 dicarboxylic acid (tACPD; Tocris Neuramin, Essex, England) . Four or five separate oocytes were perfused with increasing concentrations of a particular drug with 30 minutes between consecutive applications of the drug to minimize any interference from desensitization. The responses were normalized to a subsequent response to 100 μM L-glutamic acid. The data were analyzed using the following equation: (Fractional current) = (Dose n )/(Dose n ) + (EC 50 ) n , where: Dose = a dose of drug normalized to that evoked by a subsequent application of 100 μM L-glutamic acid; Fractional current = the peak current evoked by a dose, as defined above; EC 50 = effective concentration that evokes a 50% response (a measure of the potency of an agonist) ; and n =_ the Hill coefficient, a measure of the cooperativity of the reaction. Using this equation, the effective concentration at 50% stimulation relative to 100 μM L-glutamic acid was determined for each dose response experiment. Figure 6 shows a representative dose response curve for varying concentrations of L-glutamic acid. The potency series of glutamate analogs and their associated EC 50 's are listed in Table 2. Table 2 Glutamate Analog Potencies CEC Z0 ) Quisqualic acid 0.681 μM L-glutamic acid 12.32 μM Ibotenic acid 32.37 μM tACPD 376 μM In addition, oocytes were exposed to the following L-glutamic acid analogs: aspartic acid (Tocris Neuramin) , kainic acid, N-methyl-D-aspartic acid (NMDA; Sigma) , 2-amino-4-phosphonobytyric acid (APB; Sigma) , α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA; Research Biochemicals Inc., Wayland, MA) at saturating concentrations and the responses were each normalized to a subsequent response to 100 μM L-glutamate. The L-glutamic acid analogs that were found to be ineffective were 1 mM aspartic acid, 1 mM kainic acid, 100 μM NMDA + 10 μM glycine, 100 μM APB and 100 μM AMPA. Voltage clamp assays were also carried out on injected oocytes to measure the inhibition by the putative glutamate G protein-coupled receptor antagonist, 2-amino-3-phosphonopropionic acid (AP3) . Voltage clamp assays showed that at 1 mM, DL-AP3 (Sigma) reduced the current evoked by 10 μM glutamic acid to 59.3 +/- 7.3% of the control. Clone 45 cells were streaked out on LB Amp plates and several colonies were picked, grown up and the DNA isolated. Pure 45-A DNA was prepared and restriction mapped by standard procedures. Clone 45-A has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, 20852, under ATCC Accession No. 68497. DNA was digested with single or multiple enzymes. The fragments were separated on both 1% agarose and 4% Nusieve gels by electrophoresis. After electrophoresis the DNA was transferred to nitrocellulose filters using standard protocols for Southern transfer. Restriction sites were mapped based on size and based on hybridization to Pst I subclones of 45-A DNA. Additionally, the entire 45-A cDNA insert can be isolated by digestion with Not I restriction endonuclease. The Not I insert was kinased with 7- 32 P ATP, and after digestion of half of the sample with Bam HI to remove the 3' label, both samples were subjected to digestion with a number of enzymes known to be present once in the insert. In this way the unique sites could be localized. A restriction map of Glu G R clone 45-A is shown in Figure 3. The entire 45-A clone was sequenced in both directions using the dideoxynucleotide chain termination method (Sanger and Coulson, J. Mol. Biol. 94:441 (1975), incorporated herein by reference) . Figure 5 (Sequence ID Nos. 1 and 2) shows the DNA sequence and deduced amino acid sequence of clone 45-A. Figure 5 also shows the location of putative N-linked glycosylation sites, which have been predicted to occur at the amino acid sequence Asn-X-Thr. As shown in Figure 5, seven putative transmembrane domains have been predicted from the deduced amino acid sequence of clone 45-A using the method described by Eisenberg et al. J. Mol. Biol. 179:125-142, (1984), incorporated herein by reference. Only those predicted to be transmembrane multimeric domains were included. An additional transmembrane domain (the third) was predicted using the method of Hopp and Woods, Proc. Natl. Acad. Sci. USA 78:3824-3838 (1981). Based on these predictions, the protein encoded by clone 45-A appears to have two unusually large domains on the amino- and carboxy-termini that are not found in any of the other reported G protein-coupled receptors which have the common structural feature of seven predicted membrane spanning regions. Analysis of the deduced amino acid sequence of clone 45-A predicts three other hydrophobic stretches including one at the amino-terminus of the sequence. This amino-terminal hydrophobic stretch may be a signal sequence, although no signal cleavage site is predicted downstream of the sequence. Poly(A)+ RNA was isolated from total rat brain and rat cerebellum using oligo d(T) cellulose chromatography as described by Aviv and Leder (ibid.). Poly(A)+ RNA from rat retina, rat heart, rat lung, rat liver, rat kidney, rat spleen, rat testis, rat ovary and rat pancreas were purchased from Clonetech. The poly(A)+ RNA samples were analyzed by northern analysis (Thomas, Proc. Natl. Acad. Sci. USA 77:5201-5205 (1980), which is incorporated by reference herein) . The RNA was denatured in glyoxal, electrophoresed in agarose and transferred to a nitrocellulose membrane essentially as described by Thomas (ibid.). The northern blot was hybridized with a radiolabeled 3473 bp Eco Rl-Xba I fragment from the 45-A clone. Autoradiography of the blot showed hybridization to a major band of approximately 7 kb and a smaller band of approximately 3.8 kb in the total rat brain and rat cerebellum RNA. Single-stranded cDNA was synthesized using 1 μg of the poly(A)+ RNA using Superscript reverse transcriptase (BRL) under conditions described by the manufacturer. One fourth of the cDNA was used as a template for PCR amplification using 40 pmoles each of the GluGR-specific primers ZC3652 (Table 1; Sequence ID Number 14) and ZC3654 (Table 1; Sequence ID Number 15) and 2.5 U Taq I polymerase (Perkin Elmer Cetus, Norwalk, VA) and conditions specified by the manufacturer. As an internal control, the PCR reaction also contained 2 pmoles each of the glucose-6-phosphate dehydrogenase-specifiσ primers ZC3015 (Table 1; Sequence ID Number 12) and ZC3016 (Table 1; Sequence ID Number 13) . After thirty cycles (one minute at 94°C, one minute at 60 β C, ninety seconds at 72 β C), the samples were phenol-chloroform extracted and 20% of each reaction was electrophoresed in agarose. The DNA was bidirectionally transferred to nitrocellulose membranes, and the filters were hybridized with either radiolabeled ZC3652, ZC3654, ZC3015 and ZC3016 (Sequence ID Nos. 14, 15, 12 and 13, respectively) or with the radiolabeled Eco Rl-Xba I fragment of clone 45-A described above. Autoradiography of the hybridized blot showed that Glu G R transcript was mainly confined to total rat brain and rat cerebellum; however, longer exposures showed a Glu G R-specific transcript in both retina and testis. Total RNA was prepared, as described above, from specific rat brain regions including frontal cortex, cerebellum, hippocampus, cortex, striatum, pons medulla, and the remainder of the brain. Single-stranded cDNA was synthesized as described previously using 20 μg of total RNA in 50 μl using Superscript reverse transcriptase (BRL) under conditions described by the manufacturer. After a one hour incubation at 42 β C, the samples were treated with RNAse (Boehringer Mannheim Biochemicals, Indianapolis, IN) , phenol-chloroform extracted, and ethanol precipitated. The samples were resuspended in water and half of each sample was subjected to PCR amplification. Each PCR amplification contained 40 pmoles of each of the Glu G R-specific primers ZC3652 and ZC3654 described above (Sequence ID Numbers 14 and 15) , 2 pmoles of each of the glucose-6-phosphate dehydrogenase-specific primers ZC3015 and ZC3016 (Sequence ID Nos. 12 and 13) and 2.5 U Taq I polymerase (Perkin Elmer Cetus) and conditions described by the manufacturer. After 35 cycles (one minute at 94 β C, one minute at 60*C, ninety seconds at 72 β C), the samples were phenol-chloroform extracted, and 20% of each reaction was electrophoresed in agarose. The DNA was transferred to a nitrocellulose membrane, and the filter was hybridized with the radiolabeled Eco Rl-Xba I fragment of clone 45-A described above. Autoradiography of the hybridized blots showed a broad distribution of the Glu G R transcript throughout the brain, although the frontal cortex and cerebellum appear to be somewhat enriched. Southern analysis of rat and human genomic DNA was carried out using the method essentially described by Blin et al. (Nuc. Acids Res. 3:2303 (1976), which is incorporated by reference herein) . Briefly, rat and human genomic DNA was prepared from the rat cell line UMR 106 (ATCC CRL 1661) and a human hepatoma cell line (ATCC HTB 52) , respectively. The genomic DNA was digested with either Eco RI or Pst I, and electrophoresed through agarose. The DNA was transferred to a nitrocellulose membrane, and the membrane was hybridized with a radiolabeled 1.6 kb Pst I fragment from clone 45-A. Autoradiography of the hybridized blot suggest that the human gene has a similar sequence to the rat Glu G R sequence, the Glu G R gene contains at least one intron, and that there are a small number of closely related genes. Expression in Mammalian Cells T Thhee eennttiirree GGlluu GG RR ccDDNNAA :insert was removed from the pVEGT' cloning vector by digestion with Not I and Xba I. The ends were blunted with DNA polymerase I (Klenow fragment) and dNTPs, and were then ligated with Eco RI (Smart) linkers. After linker ligation, the insert with Eco RI ends in kinased and ligated to Eco Rl-cut and capped Zem228 expression vector. Bacteria were transformed with the ligation reaction and clones were characterized by restriction analysis and partial sequencing (see Fig. 4) . Cultured mammalian cells, such as BHK 570 and BHK tsl3 served as host cells for expression. Twenty five μg of CsCl-purified DNA was precipitated with calcium phosphate and added to tissue culture cells in a 150 mm plate. After 4 hours the cells were subjected to a glycerol shock and were then put into non-selective medium. In some cases it may be necessary to include an antagonist to the Glu G R in the medium to prevent expression of a cytotoxic response in those cells where the Glu G R is expressed at levels high enough to cause a certain amount of autoactivation. Transiently expressed Glu G R ligand binding activity or PLC activation, cells are harvested after 48 hours. Stable expression was detected after 2 weeks of selection. The Zem228 expression vector includes a promoter capable of directing the transcription of the Glu G R gene, and a selectable marker for the bacterial neomycin resistance gene. Resistance to the drug G-418, an inhibitor of protein synthesis, was used to identify stably transfected clones. Presence of the SV40 ori region on the vector allows the expression construction to also be used for transient expression. In some instances it was preferable to include DNA for another selectable marker, the DHFR gene, in the transfection protocol. Selection with both G-418 and methotrexate allowed isolation of clones whose expression of Glu G R can be subsequently amplified by the addition of increasingly higher concentrations of methotrexate to the culture medium. Transfected cell lines expressing Glu G R were identified by the binding of 3 H-glutamate to membrane preparations from transfected cells. Cell lines expressing low to moderate levels of Glu G R are used to set up functional screening assays. Clones of BHK 570 and BHK TK " tsl3 cells expressing the rat G protein-coupled glutamate receptor cDNA were plated in two or three 150 mm maxi-plates culture dishes and were grown to confluency. The cells from each plate were scraped in 5 ml of PBS (phosphate buffered saline, Sigma Chemical Co., St. Louis, MO), which was was pre-chilled to 4 β C. The cells were removed to a chilled centrifuged tube, and the plates were each rinsed with 5 ml of chilled PBS and pooled with the cells. The chilled tubes were spun at 1,000 rpm for two minutes, and the supernatant was discarded. The cells were frozen at either -70 β C or on dry ice. In some cases, the cells were left overnight at -70 β C. The cells were thawed on ice and were resuspended in 10 ml of a buffer containing 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 , 1 mM PMSF, which was pre-chilled to 4 β C, by homogenizing the cells for about 15 seconds. The suspension was poured into chilled centrifuge tubes. The homogenizer was rinsed with 10 ml of the same chilled solution, and the rinse was combined with the suspension. The centrifuge tubes were spun for fifteen minutes at 40,000 x g at 4 C C, and the supernatant was discarded. The pellet was homogenized with a buffer containing 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 , which was pre-chilled to 4 β C. The homogenizer was rinsed with the chilled buffer, and the rinse was combined with the homogenate. The homogenate was spun as described above. The second homogenization was repeated on the resulting pellet. The final pellet was resuspended in between two and five milliliters of 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 , which was pre-chilled to 4 C C. Triplicate samples were prepared for each plus and minus quisqualate assay point such that 250 μl aliquots of each homogenate sample were added to the wells of a 96-well microtiter plate. To a buffer containing 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 , which was pre-chilled to 4°C, a final concentration of 10 nM tritiated glutamic acid was added, and the solution was split in half. To one half, quisqualate was added to a final concentration of 1 mM. Two hundred and fifty microliter aliquots of either 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 , 5 nM tritiated glutamic acid and 500 mM quisqualate, or 30 mM Tris, pH 7.0, 2.5 mM CaC12, 5 nM tritiated glutamic acid were added to the triplicate samples. The samples were incubated for thirty minutes at room temperature. The samples were harvested onto glass filters and were immediately washed with ice-cold 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 under vacuum using an LKB 1295-001 automated cell harvester (Pharmacia LKB, Piscataway, NJ) . The filters were dried in a microwave oven and counted in a gamma counter. Protein determinations were carried out using a Coomassie Blue-based assay from Pierce Chemical Company (Rockford, IL) under conditions set forth by the manufacturer. One hundred microliters of undiluted cell homogenate or BSA standard was added to 2 ml of reagent and the optical density was measured at 595 nm. Protein concentrations of the samples were taken from a standard curve generated using the BSA standards diluted in 30 mM Tris, pH 7.0, 2.5 mM CaCl 2 . The results of these assays showed that quisqualate was able to competitively bind the glutamate receptor expressed by the transfected BHK cells. Functional screening of agonists and antagonists BHK 570 cells expressing GluGR or mock-transfected BHK 570 cells are plated into 24-well tissue culture dishes at about 100,000 cells per well. After 24 hours, the cells are labeled with 0.2 μCi of myo-(2-H) inositol (specific activity - 20 Ci/mmol; New England Nuclear,) per well. At the end of a 24 to 48 hour incubation, the cells are washed with prewarmed DMEM (Dulbecco's Modified Eagles Medium; Product No. 51-432, JRH Biosciences, Lenexa, KS) which has been buffered to pH 7.4 with Hepes buffer (Sigma Chemical Co.) containing 10 mM LiCl, and are incubated for five minutes at 37. The selected drugs are then added and the cells are incubated for an additional thirty minutes at 37'C. The reaction is stopped by placing the cells on ice, and the cells are lysed by aspirating off the media and adding 0.5 ml of cold DMEM and 0.5 ml of ice-cold 10% perchloric acid. After ten minutes the cell lysate is transferred to a tube on ice containing 250 μl 10 mM EDTA, pH 7.0. The samples are neutralized with 325 μl of 1.5 M KOH in 60 mM Hepes Buffer. After the precipitates settles, 1.0 ml of the supernatant is applied to an Amprep minicolumn (Amersham, Arlington Heights, IL, RPN1908) . Inositol phosphates are eluted off the column and samples are counted in a scintillation counter. A positive response is indicated by an increase in labeled inositol phosphate levels. EXAMPLE II Screening for additional glutamate receptor subtypes Additional glutamate receptor subtypes were isolated using probes derived from clone 45-A. Glutamate receptor subtypes were isolated from a total rat brain cDNA library in Lambda Zap II, which was size selected for inserts of 3 kb before ligation (prepared for Terry Snutch, Ph.D., University of British Columbia, Vancouver, British Columbia, Canada by Stratagene Cloning Systems, La Jolla, CA) and a rat cerebellum cDNA library in Lambda Zap II, which was size selected for inserts of 3 kb before ligation (Stratagene Cloning Systems, La Jolla, CA) . The total rat brain library and the rat cerebellum library were plated out with E. coli XL-1 cells onto NZY agar plates (Table 3) to obtain approximately 2.1 x 10 plaques. Clone 45-A, encoding subtype la, was digested with Pst I to isolate the 1.3 and 1.6 kb fragments. The 45-A Pst I fragments were labeled by random priming using the Amersham random-priming kit (Amersham, Arlington Hts, IL) . Duplicate lifts were prepared from the plates, and the filters were hybridized with the probes in 50% formamide at 37*C. After an overnight hybridization, the filters were washed in 2x SSC + 0.1% SDS at 50'C. Positive plaques were isolated by several rounds of dilution plating and repeated screening with the random-primed probes. Table 3 NZY Aoar To 950 ml of deionized water, add: 10 g NZ amine: Casein hydrolysate enzymatic (ICN Biochemicals) 5 g NaCl 5 g bacto-yeast extract 1 g casamino acids 2 g MgS0 4 ' 7H 2 0 Shake until the solutes have dissolved. Adjust to pH 7.0 with 5 N NaOH (approximately 0.2 ml). Adjust the volume of the solution to 1 liter with deionized H 2 0. Sterilize by autoclaving for 20 minutes. 20x SSC Dissolve 175.3 g NaCl and 88.2 g sodium citrate in 800 ml H 2 0. Adjust the pH to 7.0 with a few drops of 10 N NaOH. Adjust the volume to 1 liter with H 2 0. Sterilize by autoclaving. Plasmid DNA was prepared from positive plaques using the Bluescript system (Stratagene Cloning Systems) . The plasmid DNA was subjected to restriction analysis and Southern blot analysis (Sambrook et al., ibid., which is incorporated herein by reference). Two clones, SN23, derived from the total rat brain library, and SR2, derived from the rat cerebellum library, were identified as being different than the 45-A clone and were sequenced. Sequence analysis showed that they represented two additional subtypes. SN23 encodes subtype lb, which contains an additional 85 bp exon that encodes a new stretch of 20 amino acids and a stop codon in the intracellular domain, is 292 amino acids shorter than the 45-A clone. The nucleotide sequence and deduced amino acid sequence of clone SN23 are shown in Fig. 7. SR2 was found to contain a partial cDNA sequence encoding subtype 2a, which is a novel sequence that shares a 42% homology to the transmembrane domains and extracellular domain of the 45-A clone. A complete subtype 2a clone was obtained by rescreening both libraries as described above with the radiolabeled 1.3 kb Pst I fragment from clone 45-A and a radiolabeled 1.4 kb Eco RI-Pvu II fragment from SR2. Two additional clones were obtained. SN30, derived from the total rat brain library, contained the entire subtype 2a coding sequence. The nucleotide sequence and deduced amino acid sequence of clone SN30 are shown in Fig. 8. SR13, derived from the rat cerebellum library, contained an incomplete sequence of a new receptor subtype, 2b. Sequence analysis of SR13 showed that the coding sequence was incomplete at the 3' end and was virtually identical to the SN30 sequence except that it contained a 610 base pair deletion within the 3' terminus of SN30. The DNA sequence of the cDNA insert in clone SR13 is shown in Figure 9. The complete 3' end of the subtype 2a clone was generated using PCR amplification and an oligonucleotide containing a sequence unique to SR13 (ZC4520, Table 4) and an oligonucleotide corresponding to a sequence near the 3' end of the 3' non-translated region of SN30 (ZC4519, Table 4). DNA was prepared from plate lysates of the original plating of each library. Each plate produced a pool of clones. For the PCR reactions, ten nanograms from each library and 100 pmol of each oligonucleotide were combined in a reaction volume of 50 μl containing 50 mM KCl, 10 mM Tris-HCl pH 9.0, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.01% gelatin, 0.2 mM each deoxynucleotide triphosphate and 2.5 units of Thermus aαuaticus (Taq) DNA polymerase (Promega Corporation, Madison, WI) . The reaction mixture was overlaid with mineral oil. After five cycles (30 seconds at 94 β C, 30 seconds at 45*C, 1 minute at 50*C) and twenty-five cycles (30 seconds at 94 β C, 30 seconds at 45 β C, 1 minute at 72 β C) the amplified DNA was removed for analysis. Table 4 Degenerate Oligonucleotide Primer Sequences (5* - 3'. ZC4519 TTT ATT AGA AAT GTT CTC GGT ZC4520 CCT CTT CCA TAT TTT TCC ATT ZC4559 ATA AGA ATT CAT NKR YTT NGC YTC RTT RAA ZC4560 ATA AGA ATT CTT YRA YGA RAA NGG NGA YGC ZC4561 ATA AGA ATT CGC NGG NAT HTT YYT NKG NTA ZC4562 ATA AGA ATT CTA NCM NAR RAA DAT NCC NGC ZC4563 ATA AGA AAT CAN GTN GTR TAC ATN GTR AA An aliquot from each reaction was electrophoresed on agarose and transferred to nitrocellulose for Southern analysis. Southern analysis of the PCR products showed that a 460 bp fragment corresponding to the 3 ' end of the 2b sequence was present in several pools. One of the pools that produced the correct size PCR product encoding the 3' sequence of the 2b subtype was diluted and screened with radiolabeled ZC4519 and ZC4520 (Table 4) . Phage that hybridize to both radiolabeled ZC4519 and ZC4520 are picked, eluted, diluted, plated and rescreened with the oligonucleotide probes. The screening is repeated until a pure clone is obtained. The pure clone is sequenced, and a full-length clone is constructed using the most convenient restriction enzyme(s) . Based on an alignment of the deduced amino acid sequences of subtypes la and 2a, strategies were designed for cloning additional subtypes using PCR amplification. Degenerate oligonucleotide families were prepared to encode conserved amino acid sequences in the sixth transmembrane domain, a region surrounding the conserved amino acid sequence Phe-Asp-Glu-Lys, the third cytoplasmic loop, and the second transmembrane domain (Table 4) . Glutamate receptor cDNA sequences were amplified with pairs of degenerate primers from Table 4 using the PCR method on cDNA from the total rat brain library, the cDNA from the rat cerebellum library, a rat cortex cDNA library or a rat hippocampus cDNA library (both obtained from Michael Brownstein, National Institutes of Health, Bethesda, MD) . The primers also each contained a 5' tail of 10 nucleotides, which provided convenient restriction enzyme sites. For each PCR reaction, ten nanograms from the library and 100 pmol of the oligonucleotide pools ZC4563 and ZC4560 (Table 4) were combined in a reaction volume of 50 μl containing 50 mM KCl, 10 mM Tris-HCl pH 9.0, 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.01% gelatin, 0.2 mM each deoxynucleotide triphosphate and 2.5 units of Taq DNA polymerase. The reaction mixture was overlaid with mineral oil. After five cycles (30 seconds at 94'C, 30 seconds at 45 β C, 1 minute at 50'C) and twenty-five cycles (30 seconds at 94 β C, 30 seconds at 45"C, 1 minute at 72 β C) the amplified DNA was removed for analysis. An aliquot from each reaction was electrophoresed on an agarose gel. Southern analysis of the gel was performed using essentially the method described by Sambrook et al. (ibid.) and random-primed fragments covering the entire coding regions from both the subtype la and 2a clones. The autoradiographs showed that the PCR reaction generated fragments of novel size that were different from either the la or 2a subtype. The PCR-generated fragments were electrophoresed on an agarose gel. Regions corresponding to the unique-sized receptor-related products were excised and electrophoresed onto NA45 paper (Schleicher and Schuell, Keene, NH) . The purified fragments were recovered using essentially the method described by the manufacturer, digested with Eco RI and ligated to plasmid pVEGT' that had been linearized by digestion with Eco RI and treated with phosphatase to prevent recircularization. The ligation mixtures were transformed into E. coli strain DHlOb cells. Transformants were picked and replica plated onto nitrocellulose filters and screened using random-primed probes from the la and the 2a clones. Forty-eight colonies were picked for restriction analysis and sequencing. DNA sequences from the cDNA from the total rat brain library and the cDNA from the rat cerebellum library were each amplified and analyzed using the methods described above and oligonucleotide ZC4559. in combination with either ZC4561 or ZC4559 (Table 4) . A rat cortex cDNA library and a rat hippocampus cDNA library (both obtained from Michael Brownstein, NIH) are subdivided into 30 pools of 10,000 colonies. Plasmid DNA is prepared from each pool, and the DNA is subjected to Southern analysis after restriction digestion of the pools with Bam HI and Xho I or by PCR amplification of each pool using the degenerate oligonucleotides of Table 4. The library pools containing DNA that hybridize to the probes and appear to contain a full-length cDNA are subdivided. The plasmid DNA is prepared and screened as described above. Positive pools are again divided and the procedure is continued until the pool is reduced to pure clones. The clones are subjected to restriction analysis and partial sequence analysis. Clones that represent distinct glutamate receptor homologs are completely sequenced. Full length clones are generated by subjecting the original pools to PCR amplification using an oligonucleotide primer specific to the SP6 promoter at the 5' end of the cDNA insert and an antisense oligonucleotide primer corresponding to the 5' end of the most complete cDNA to identify pools that contain the longest glutamate receptor homolog cDNA. The pool is then diluted and rehybridized with the probes as described above to isolate a full length cDNA clone. Expression of Glutamate Receptor Subtypes Complementary DNA sequences encoding subtypes lb and 2a were subcloned first into the mammalian expression vector Zem228R to obtain convenient terminal restriction sites. The cDNAs were then subcloned into pVEGT 1 . The cDNA sequence encoding subtype lb was constructed by replacing the 3' terminal portion of subtype la described in Example I with the analogous portion of subtype lb from SN23. Plasmid SN23 was digested with Kpn I and Xba I to isolate the fragment containing the 3* terminus of the lb subtype. The plasmid containing the subtype la coding sequence (45-A) in Zem228R was digested with Kpn I and Xba I to isolate the vector containing fragment. The vector containing fragment is ligated to the Kpn I-Xba I fragment from SN23. The resulting plasmid comprises the MT-1 promoter, the subtype lb cDNA and the hGH terminator. This plasmid was transfected into the BHK 570 cell line essentially as described in Example I to obtain stably transfected cell lines expressing the subtype lb receptor. The subtype lb cDNA fragment was isolated as a Bam HI fragment, which was ligated with pVEGT' that had been linearized with Bam HI. A plasmid containing the cDNA sequence in the correct orientation was used to synthesize RNA in an in vitro system. The RNA was injected into oocytes as described above. Plasmid SN30, which comprises the subtype 2a cDNA, was digested with Eco RI to isolate the subtype 2a cDNA. The Eco RI fragment was ligated with Eco Rl-linearized Zem228R. A plasmid containing the insert in the correct orientation was digested with Bam HI to isolate the cDNA sequence. The Bam HI fragment comprising the subtype 2a cDNA was ligated with Eco Rl-linearized pVEGT 1 . A plasmid containing the cDNA in the correct orientation was used to synthesize RNA in an in vitro translation. The RNA was injected into frog oocytes as described above. EXAMPLE III Generation of antibodies to glutamate receptor subtypes Receptor subtype-specific polyclonal antisera were generated in rabbits using standard immunization techniques. Synthetic peptides (Table 5) were designed from the cloned receptor sequences. The peptides were conjugated to keyhole limpet hemocyanin, and each antigen was used to immunize two animals. For each peptide, the animals were injected with 100-200 μg of conjugated peptide divided among three subcutaneous sites. The animals were immunized at three-week intervals and bled via an ear vein 10 days after the third and subsequent immunizations. Table 5 Anti-peptide antibodies were purified by affinity purification using the Proton™ Kit (Multiple Peptide Systems (San Diego, CA) . Purified antibodies were stored in column elution buffer and neutralizing buffer (supplied by Multiple Peptide Systems) . Bovine serum albumin was added to a concentration of 1 mg/ml, and sodium azide was added to a concentration of 0.05%. The antibodies were stored at 4 β C or in small aliquots at -20 β C. Antibodies generated from the peptides listed in Table 6 were used to detect G protein-coupled glutamate receptors by Western blot analysis of membranes prepared from transfected cell lines that were stably expressing the subtype la or subtype lb receptors. Control cell lines were transfected with vector alone. Table 6 Transfectants that were stably expressing either the la or lb subtype were each grown to confluency in five to ten 150 mm plates. Each plate was first washed twice with 15 ml of cold PBS and then 20 ml of ice cold 10 mM NaHC03 was added to each plate. The cells from each plate were scraped off the plates with a rubber spatula and transferred to a glass dounce homogenizer on ice. The cells were disrupted with ten strokes of the B pestle. The ho ogenates from each plate were combined and centrifuged for thirty minutes at 3000 rpm at 4 β C. The pellets were resuspended in 4-8 ml of 10 mM NaHC0 3 using a 22 g needle and syringe, and 69% sucrose was added (6-12 ml) to each sample until an index of refraction of 1.410 was reached. The samples were transferred to a high speed centrifugation tube, and each sample was overlayed with 42% sucrose. The samples were centrifuged for two hours at 25,000 rpm at 4 β C. The samples were collected by gently floating the membranes off the 42% sucrose layer by adding 1 ml of 10 mM NaHC0 3 and resuspending the membranes by carefully stirring the upper layer. The upper layer was transferred to a fresh tube on ice. The purified membranes were centrifuged at 10,000 rpm at 4 β C and the pellets resuspended in 10 mM NaHC0 3 . The purified membranes were then adjusted to a final protein concentration of 1-2 μg/ml. Ten to twenty micrograms of each purified membrane preparations were diluted with 2x SDS-mercaptoethanol buffer (100 mM Tris HCl (pH 6.8), 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol). The, samples were incubated for 15 minutes at 37 β C followed by boiling for 5 minutes. The samples were subjected to SDS-PAGE on 4-15% gradient gel. The samples were electrotransferred to nitrocellulose using the method essentially described by Towbin (Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979; which is incorporated herein by reference in its entirety) . After transfer, the nitrocellulose was cut into strips such that each strip contained a control and receptor samples. The nitrocellulose was preincubated in blocking buffer and then incubated with a dilution of either the preimmune serum or the serum collected after antigenic stimulation (serum from later bleeds (i.e. those after four antigen stimulations) were diluted 1:1500). After washing, a horse radish peroxidase-conjugated goat anti-rabbit antibody (Bio-Rad Laboratories, Richmond, CA) diluted 1:2,500 was added and after incubation and washing, the horse radish peroxidase substrate (Bio-Rad Laboratories) was added and the color reaction was initiated. The reaction was stopped by rinsing the filters in distilled water. Table 6 shows the results of the Western blot analysis. _ __- PCr/υS9./094_2 67 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Mulvihill, Eileen R. Hagen, Frederick S. Houamed, Khaled M. Aimers, Wolf ard (ii) TITLE OF INVENTION: G PROTEIN-COUPLED GLUTAMATE RECEPTORS (iii) NUMBER OF SEQUENCES: 33 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Townsend and Townsend (B) STREET: One Market Plaza, Steuart Street Tower - (C) CITY: San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94105-1492 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/672,007 (B) FILING DATE: 18-MAR-1991 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/648,481 (B) FILING DATE: 30-JAN-1991 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 07/626,806 (B) FILING DATE: 12-DEC-1990 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Parmelee, Steven W. (B) REGISTRATION NUMBER: 31,990 (C) REFERENCE/DOCKET NUMBER: 13952-6PC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (206) 467-9600 (B) TELEFAX: (415) 543-5043 (2) INFORMATION FOR SEQ ID NO:l: SUBSTIT 68 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: 45-A (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 377..3973 --, '<i) SEQUENCE DESCRIPTION: SEQ ID NO:l: CCGAGAACGG CTGCAGTCCT CTGACCTGAG ACCAATAGCT GTGTCTACCC GGACTCAGCG 60 TCCAGCTCAC CGCCACTAAC GCGCCGCGCA TTGGACACCT GATCCACACA CA 120 CCAGTGAAAA ACCGCGACTT GATTTTCTGG AAGAACGCCC CCAGGGTGTG GGAGCGGTCG 180 TGGAGGACCA GCAGGAGGAA GCGGAGGGGA GAGGGGCAGT AGTGGAGGCA GAGAAAGCGT 240 TGAACCAGCT GTGTTGGCCG AAGGCACGAA ACGGCAAAAG GCAGCGGTGA GCATCTGTGT 300 GGTTCCCGCT GGGAACCTGC AGGCAGGACC GGCGTGGGAA CGTGGCTGGC CCGCGGTGGA 360 CCGCGTCTTC GCCACA ATG GTC CGG CTC CTC TTG ATT TTC TTC CCA ATG 409 Met Val Arg Leu Leu Leu lie Phe Phe Pro Met 1 5 10 ATC TTT TTG GAG ATG TCC ATT TTG CCC AGG ATG CCT GAC AGA AAA GTA 457 lie Phe Leu Glu Met Ser lie Leu Pro Arg Met Pro Asp Arg Lys Val 15 20 25 TTG CTG GCA GGT GCC TCG TCC CAG CGC TCC GTG GCG AGA ATG GAC GGA 505 Leu Leu Ala Gly-Ala Ser Ser Gin Arg Ser Val Ala Arg Met Asp Gly 30 35 40 GAT GTC ATC ATC GGA GCC CTC TTC TCA GTC CAT CAC CAG CCT CCA GCC 553 Asp Val He He Gly Ala Leu Phe Ser Val His His Gin Pro Pro Ala 45 50 55 GAG AAG GTA CCC GAA AGG AAG TGT GGG GAG ATC AGG GAA CAG TAT GGT 6Q1 Glu Lys Val Pro Glu Arg Lys Cys Gly Glu He Arg Glu Gin Tyr Gly 60 65 70 75 ATC CAG AGG GTG GAG GCC ATG TTC CAC ACG TTG GAT AAG ATT AAC GCG 649 He Gin Arg Val Glu Ala Met Phe His Thr Leu Asp Lys He Asn Ala 80 85 90 GAC CCG GTG CTC CTG CCC AAC ATC ACT CTG GGC AGT GAG ATC CGG GAC 697 69 95 100 105 TCC TGC TGG CAC TCT TCA GTG GCT CTC GAA CAG AGC ATC GAA TTC ATC 745 Ser Cys Trp His Ser Ser Val Ala Leu Glu Gin Ser He Glu Phe He 110 115 120 AGA GAC TCC CTG ATT TCC ATC CGA GAT GAG AAG GAT GGG CTG AAC CGA 793 Arg Asp S* Leu He Ser He Arg Asp Glu Lys Asp Gly Leu Asn Arg 125 130 135 TGC CTG CCT GAT GGC CAG ACC CTG CCC CCT GGC AGG ACT AAG AAG CCT 841 Cys Leu Pro Asp Gly Gin Thr Leu Pro Pro Gly Arg Thr Lys Lys Pro 140 145 150 155 ATT GCT GGA GTG ATC GGC CCT GGC TCC AGC TCT GTG GCC ATT CAA GTC 889 He Ala Gly Val He Gly Pro Gly Ser Ser Ser Val Ala He Gin Val 160 165 170 -v CAG AAT CTT CTC CAG CTG TTC GAC ATC CCA CAG ATC GCC TAT TCT GCC 937 Gin Asn Leu Leu Gin Leu Phe Asp He Pro Gin He Ala Tyr Ser Ala 175 180 185 ACA AGC ATA GAC CTG AGT GAC AAA ACT TTG TAC AAA TAC TTC CTG AGG 985 Thr Ser He Asp Leu Ser Asp Lys Thr Leu Tyr Lys Tyr Phe Leu Arg 190 195 200 GTG GTC CCT TCT GAC ACT TTG CAG GCA AGG GCG ATG CTC GAC ATA GTC 1033 Val Val Pro Ser Asp Thr Leu Gin Ala Arg Ala Met Leu Asp He Val 205 210 215 AAG CGT TAC AAC TGG ACC TAT GTC TCA GCA GTC CAC ACA GAA GGG AAT 1081 Lys Arg Tyr Asn Trp Thr Tyr Val Ser Ala Val His Thr Glu Gly Asn 220 225 230 235 TAC GGC GAG AGT GGA ATG GAT GCT TTC AAA GAA CTG GCT GCC CAG GAA 1129 Tyr Gly Glu Ser Gly Met Asp Ala Phe Lys Glu Leu Ala Ala Gin Glu 240 245 250 GGC CTC TGC ATC GCA CAC TCG GAC AAA ATC TAC AGC AAT GCT GGC GAG 1177 Gly Leu Cys He Ala His Ser Asp Lys He Tyr Ser Asn Ala Gly Glu 255.- 260 265 AAG AGC TTT GAC CGG CTC CTG CGT AAA CTC CGG GAG CGG CTT CCC AAG 1225 Lys Ser Phe Asp Arg Leu Leu Arg Lys Leu Arg Glu Arg Leu Pro Lys 270 275 280 GCC AGG GTT GTG GTC TGC TTC TGC GAG GGC ATG ACA GTG CGG GGC TTA 1273 Ala Arg Val val Val cys Phe Cys Glu Gly Met Thr Val Arg Gly Leu 285 290 295 CTG AGT GCC ATG CGC CGC CTG GGC GTC GTG GGC GAG TTC TCA CTC ATT 1321 Leu Ser Ala Met Arg Arg Leu Gly Val Val Gly Glu Phe Ser Leu He 300 305 310 315 GGA AGT GAT GGA TGG GCA GAC AGA GAT GAA GTC ATC GAA GGC TAT GAG 1369 Gly Ser Asp Gly Trp Ala Asp Arg Asp Glu Val He Glu Gly Tyr Glu 320 325 330 70 GTC- GAA GCC AAC GGA GGG ATC ACA ATA AAG CTT CAG TCT CCA GAG GTC 1417 Val Glu Ala Asn Gly Gly He Thr He Lys Leu Gin Ser Pro Glu Val 335 340 345 AGG TCA TTT GAT GAC TAC TTC CTG AAG CTG AGG CTG GAC ACC AAC ACA 1465 Arg Ser Phe Asp Asp Tyr Phe Leu Lys Leu Arg Leu Asp Thr Asn Thr 350 355 360 AGG AAT CCT TGG TTC CCT GAG TTC TGG CAA CAT CGC TTC CAG TGT CGC 1513 Arg Asn Pro Trp Phe Pro Glu Phe Trp Gin His Arg Phe Gin Cys Arg 365 370 375 CTA CCT GGA CAC CTC TTG GAA AAC CCC AAC TTT AAG AAA GTG TGC ACA 1561 Leu Pro Gly His Leu Leu Glu Asn Pro Asn Phe Lys Lys Val Cys Thr 380 385 390 395 GGA AAT GAA AGC TTG GAA GAA AAC TAT GTC CAG GAC AGC AAA ATG GGA 1609 Η f n Glu Ser Leu Glu Glu Asn Tyr Val Gin Asp Ser Lys Met Gly 400 405 410 TTT GTC ATC AAT GCC ATC TAT GCC ATG GCA CAT GGG CTG CAG AAC ATG 1657 Phe Val He Asn Ala He Tyr Ala Met Ala His Gly Leu Gin Asn Met 415 420 425 CAC CAT GCT CTG TGT CCC GGC CAT GTG GGC CTG TGT GAT GCT ATG AAA 1705 His His Ala Leu Cys Pro Gly His Val Gly Leu Cys Asp Ala Met Lys 430 435 440 CCC ATT GAT GGC AGG AAG CTC CTG GAT TTC CTC ATC AAA TCC TCT TTT 1753 Pro He Asp Gly Arg Lys Leu Leu Asp Phe Leu He Lys Ser Ser Phe 445 450 455 GTC GGA GTG TCT GGA GAG GAG GTG TGG TTC GAT GAG AAG GGG GAT GCT 1801 Val Gly Val Ser Gly Glu Glu Val Trp Phe Asp Glu Lys Gly Asp Ala 460 465 470 475 CCC GGA AGG TAT GAC ATT ATG AAT CTG CAG TAC ACA GAA GCT AAT CGC 1849 Pro Gly Arg Tyr Asp He Met Asn Leu Gin Tyr Thr Glu Ala Asn Arg 480 485 490 TAT GAC TAT GTC'-CAC GTG GGG ACC TGG CAT GAA GGA GTG CTG AAT ATT 1897 Tyr Asp Tyr Val His Val Gly Thr Trp His Glu Gly Val Leu Asn He 495 500 505 GAT GAT TAC AAA ATC CAG ATG AAC AAA AGC GGA ATG GTA CGA TCT GTG 1945 Asp Asp Tyr Lys He Gin Met Asn Lys Ser Gly Met Val Arg Ser Val 510 515 520 TGC AGT GAG CCT TGC TTA AAG GGT CAG ATT AAG GTC ATA CGG AAA GGA 1993 Cys Ser Glu Pro Cys Leu Lys Gly Gin He Lys Val He Arg Lys Gly 525 530 535 GAA GTG AGC TGC TGC TGG ATC TGC ACG GCC TGC AAA GAG AAT GAG TTT 2041 Glu Val Ser Cys Cys Trp He Cys Thr Ala Cys Lys Glu Asn Glu Phe 540 545 550 555 Val- Gin Asp Glu Phe Thr Cys Arg Ala Cys Asp Leu Gly Trp Trp Pro 560 565 570 AAC GCA GAG CTC ACA GGC TGT GAG CCC ATT CCT GTC CGT TAT CTT GAG 2137 Asn Ala Glu Leu Thr Gly cys Glu Pro He Pro Val Arg Tyr Leu Glu 575 580 585 TGG AGT GAC ATA GAA TCT ATC ATA GCC ATC GCC TTT TCT TGC CTG GGC 2185 Trp Ser Asp He Glu Ser He He Ala He Ala Phe Ser Cys Leu Gly 590 595 600 ATC CTC GTG ACG CTG TTT GTC ACC CTC ATC TTC GTT CTG TAC CGG GAC 2233 He Leu Val Thr Leu Phe Val Thr Leu He Phe Val Leu Tyr Arg Asp 605 610 615 ACA CCC GTG GTC AAA TCC TCC AGT AGG GAG CTC TGC TAT ATC ATT CTG 2281 Thr Pro Val Val Lys Ser Ser Ser Arg Glu Leu Cys Tyr He He Leu ',20 625 630 635 GCT GGT ATT TTC CTC GGC TAT GTG TGC CCT TTC ACC CTC ATC GCC AAA 2329 Ala Gly He Phe Leu Gly Tyr Val Cys Pro Phe Thr Leu He Ala Lys 640 645 650 CCT ACT ACC ACA TCC TGC TAC CTC CAG CGC CTC CTA GTT GGC CTC TCT 2377 Pro Thr Thr Thr Ser Cys Tyr Leu Gin Arg Leu Leu Val Gly Leu Ser 655 660 665 TCT GCC ATG TGC TAC TCT GCT TTA GTG ACC AAA ACC AAT CGT ATT GCA 2425 Ser Ala Met Cys Tyr Ser Ala Leu Val Thr Lys Thr Asn Arg He Ala 670 675 680 CGC ATC CTG GCT GGC AGC AAG AAG AAG ATC TGC ACC CGG AAG CCC AGA 2473 Arg He Leu Ala Gly Ser Lys Lys Lys He Cys Thr Arg Lys Pro Arg 685 690 695 TTC ATG AGC GCT TGG GCC CAA GTG ATC ATA GCC TCC ATT CTG ATT AGT 2521 Phe Met ser Ala Trp Ala Gin Val He He Ala Ser He Leu He Ser 700 705 710 715 GTA CAG CTA ACA CTA GTG GTG ACC TTG ATC ATC ATG GAG CCT CCC ATG 2569 Val Gin Leu Thr' eu Val Val Thr Leu He He Met Glu Pro Pro Met 720 725 730 CCC ATT TTG TCC TAC CCG AGT ATC AAG GAA GTC TAC CTT ATC TGC AAT 2617 Pro He Leu Ser Tyr Pro Ser He Lys Glu Val Tyr Leu He Cys Asn 735 740 745 ACC AGC AAC CTG GGT GTA GTG GCC CCT GTG GGT TAC AAT GGA CTC CTC 2665 Thr Ser Asn Leu Gly Val Val Ala Pro Val Gly Tyr Asn Gly Leu Leu 750 755 760 ATC ATG AGC TGT ACC TAC TAT GCC TTC AAG ACC CGC AAC GTG CCG GCC 2713 He Met Ser Cys Thr Tyr Tyr Ala Phe Lys Thr Arg Asn Val Pro Ala 765 770 775 AAC TTC.AAT GAG GCT AAA TAC ATC GCC TTC ACC ATG TAC ACT ACC TGC 2761 e Thr et T r Thr Thr C s 78C- "85 790 795 ATC ATC TGG CTG GCT TTC GTT CCC ATT TAC TTT GGG AGC AAC TAC AAG 2809 He He Trp Leu Ala Phe Val Pro He Tyr Phe Gly Ser Asn Tyr Lys 800 805 810 ATC ATC ACT ACC TGC TTC GCG GTG AGC CTC AGT GTG ACG GTG GCC CTG 2857 He He Thr Thr Cys Phe Ala Val Ser Leu Ser Val Thr Val Ala Leu 815 820 825 GGG TGC ATG TTT ACT CCG AAG ATG TAC ATC ATC ATT GCC AAA CCT GAG 2905 Gly Cys Met Phe Thr Pro Lys Met Tyr He He He Ala Lys Pro Glu 830 835 840 AGG AAC GTC CGC AGT GCC TTC ACG ACC TCT GAT GTT GTC CGC ATG CAC 2953 Arg Asn Val Arg Ser Ala Phe Thr Thr Ser Asp Val Val Arg Met His 845 850 855 GTC GGT GAT GGC AAA CTG CCG TGC CGC TCC AAC ACC TTC CTC AAC ATT 3001 Val Gly Asp Gly Lys Leu Pro Cys Arg Ser Asn Thr Phe Leu Asn He 860 865 870 875 TTC CGG AGA AAG AAG CCC GGG GCA GGG AAT GCC AAT TCT AAC GGC AAG 3049 Phe Arg Arg Lys Lys Pro Gly Ala Gly Asn Ala Asn Ser Asn Gly Lys 880 885 890 TCT GTG TCA TGG TCT GAA CCA GGT GGA AGA CAG GCG CCC AAG GGA CAG 3097 Ser Val Ser Trp Ser Glu Pro Gly Gly Arg Gin Ala Pro Lys Gly Gin 895 900 905 CAC GTG TGG CAG CGC CTC TCT GTG CAC GTG AAG ACC AAC GAG ACG GCC 3145 His Val Trp Gin Arg Leu Ser Val His Val Lys Thr Asn Glu Thr Ala 910 915 920 TGT AAC CAA ACA GCC GTA ATC AAA CCC CTC ACT AAA AGT TAC CAA GGC 3193 Cys Asn Gin Thr Ala Val He Lys Pro Leu Thr Lys Ser Tyr Gin Gly 925 930 935 TCT GGC AAG AGC CTG ACC TTT TCA GAT GCC AGC ACC AAG ACC CTT TAC 3241 Ser Gly Lys Ser Leu Thr Phe Ser Asp Ala Ser Thr Lys Thr Leu Tyr 940 -** ■ 945 950 955 AAT GTG GAA GAA GAG GAC AAT ACC CCT TCT GCT CAC TTC AGC CCT CCC 3289 Asn Val Glu Glu Glu Asp Asn Thr Pro Ser Ala His Phe Ser Pro Pro 960 965 970 AGC AGC CCT TCT ATG GTG GTG CAC CGA CGC GGG CCA CCC GTG GCC ACC 3337 Ser Ser Pro Ser Met Val Val His Arg Arg Gly Pro Pro Val Ala Thr 975 980 985 ACA CCA CCT CTG CCA CCC CAT CTG ACC GCA GAA GAG ACC CCC CTG TTC 3385 Thr Pro Pro Leu Pro Pro His Leu Thr Ala Glu Glu Thr Pro Leu Phe 990 995 1000 CTG GCT GAT TCC GTC ATC CCC AAG GGC TTG CCT CCT CCT CTC CCG CAG 3433 Leu Ala Asp Ser Val He Pro Lys Gly Leu Pro Pro Pro Leu Pro Gin 1005 1010 1015 73 CAG-CAG CCA CAG CAG CCG CCC CCT CAG CAG CCC CCG CAG CAG CCC AAG 3481 Gin Gin Pro Gin Gin Pro Pro Pro Gin Gin Pro Pro Gin Gin Pro Lys 1020 1025 1030 1035 TCC CTG ATG GAC CAG CTG CAA GGC GTA GTC ACC AAC TTC GGT TCG GGG 3529 Ser Leu Met Asp Gin Leu Gin Gly Val Val Thr Asn Phe Gly Ser Gly 1040 1045 1050 ATT CCA GAT TTC CAT GCG GTG CTG GCA GGC CCG GGG ACA CCA GGA AAC 3577 He Pro Asp Phe His Ala Val Leu Ala Gly Pro Gly Thr Pro Gly Asn 1055 1060 1065 AGC CTG CGC TCT CTG TAC CCG CCC CCG CCT CCG CCG CAA CAC CTG CAG 3625 Ser Leu Arg Ser Leu Tyr Pro Pro Pro Pro Pro Pro Gin His Leu Gin 1070 1075 1080 ATG CTG CCC CTG CAC CTG AGC ACC TTC CAG GAG GAG TCC ATC TCC CCT 3673 §t J.au Pro Leu His Leu Ser Thr Phe Gin Glu Glu Ser He Ser Pro 1085 1090 1095 CCT GGG GAG GAC ATC GAT GAT GAC AGT GAG AGA TTC AAG CTC CTG CAG 3721 Pro Gly Glu Asp He Asp Asp Asp Ser Glu Arg Phe Lys Leu Leu Gin 1100 1105 1110 1115 GAG TTC GTG TAC GAG CGC GAA GGG AAC ACC GAA GAA GAT GAA TTG GAA 3769 Glu Phe Val Tyr Glu Arg Glu Gly Asn Thr Glu Glu Asp Glu Leu Glu 1120 1125 1130 GAG GAG GAG GAC CTG CCC ACA GCC AGC AAG CTG ACC CCT GAG GAT TCT 3817 Glu Glu Glu Asp Leu Pro Thr Ala Ser Lys Leu Thr Pro Glu Asp Ser 1135 1140 1145 CCT GCC CTG ACG CCT CCT TCT CCT TTC CGA GAT TCC GTG GCC TCT GGC 3865 Pro Ala Leu Thr Pro Pro Ser Pro Phe Arg Asp Ser Val Ala Ser Gly 1150 1155 1160 AGC TCA GTG CCC AGT TCC CCC GTA TCT GAG TCG GTC CTC TGC ACC CCT 3913 Ser Ser Val Pro Ser Ser Pro Val Ser Glu Ser Val Leu Cys Thr Pro 1165 1170 1175 CCA AAT GTA ACC-TAC GCC TCT GTC ATT CTG AGG GAC TAC AAG CAA AGC 3961 Pro Asn Val Thr Tyr Ala Ser Val He Leu Arg Asp Tyr Lys Gin Ser 1180 1185 1190 1195 TCT TCC ACC CTG TAGTGTGTGT GTGTGTGTGG GGGCGGGGGG AGTGCGCATG 4013 Ser Ser Thr Leu GAGAAGCCAG AGATGCCAAG GAGTGTCAAC CCTTCCAGAA ATGTGTAGAA AGCAGGGTGA 4073 GGGATGGGGA TGGAGGACCA CGGTCTGCAG GGAAGAAAAA AAAAATGCTG CGGCTGCCTT 4133 AAAGAAGGAG AGGGACGATG CCAACTGAAC AGTGGTCCTG GCCAGGATTG TGACTCTTGA 193 ATTATTCAAA AACCTTCTCT AGAAAGAAAG GGAATTATGA CAAAGCACAA TTCCATATGG 4253 TATGTAACTT TTATCGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAA 4300 74 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1199 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Val Arg Leu Leu Leu He Phe Phe Pro Met He Phe Leu Glu Met 1 5 10 15 Ser He Leu Pro Arg Met Pro Asp Arg Lys Val Leu Leu Ala Gly Ala 20 25 30 Ser Ser Gin Arg Ser Val Ala Arg Met Asp Gly Asp Val He He Gly 35 40 45 Ala Leu Phe Ser Val His His Gin Pro Pro Ala Glu Lys Val Pro Glu 50 55 60 Arg Lys Cys Gly Glu He Arg Glu Gin Tyr Gly He Gin Arg Val Glu 65 70 75 80 Ala Met Phe His Thr Leu Asp Lys He Asn Ala Asp Pro Val Leu Leu 85 90 95 Pro Asn He Thr Leu Gly Ser Glu He Arg Asp Ser cys Trp His Ser 100 105 110 Ser Val Ala Leu Glu Gin Ser He Glu Phe He Arg Asp Ser Leu He 115 120 125 Ser He Arg Asp Glu Lys Asp Gly Leu Asn Arg Cys Leu Pro Asp Gly 130 135 140 Gin Thr Leu Pro Pro Gly Arg Thr Lys Lys Pro He Ala Gly Val He 145 ~- 150 155 160 Gly Pro Gly Ser Ser Ser Val Ala He Gin Val Gin Asn Leu Leu Gin 165 170 175 Leu Phe Asp He Pro Gin He Ala Tyr Ser Ala Thr Ser He Asp Leu 180 185 190 Ser Asp Lys Thr Leu Tyr Lys Tyr Phe Leu Arg Val Val Pro Ser Asp 195 200 205 Thr Leu Gin Ala Arg Ala Met Leu Asp He Val Lys Arg Tyr Asn Trp 210 215 220 Thr Tyr Val Ser Ala Val His Thr Glu Gly Asn Tyr Gly Glu Ser Gly 225 230 235 240 K /US 1/09.22 75 e£ Asp Ala Phe Lys Glu Leu Ala Ala Gin Glu Gly Leu Cys He Ala 245 250 255 His Ser Asp Lys He Tyr Ser Asn Ala Gly Glu Lys Ser Phe Asp Arg 260 265 270 Leu Leu Arg Lys Leu Arg Glu Arg Leu Pro Lys Ala Arg Val Val Val 275 280 285 Cys Phe Cys Glu Gly Met Thr Val Arg Gly Leu Leu Ser Ala Met Arg 290 295 300 Arg Leu Gly Val Val Gly Glu Phe Ser Leu He Gly Ser Asp Gly Trp 305 310 315 320 Ala Asp Arg Asp Glu Val He Glu Gly Tyr Glu Val Glu Ala Asn Gly 325 330 335 Gly He Thr He Lys Leu Gin Ser Pro Glu Val Arg Ser Phe Asp Asp 340 345 350 Tyr Phe Leu Lys Leu Arg Leu Asp Thr Asn Thr Arg Asn Pro Trp Phe 355 360 365 Pro Glu Phe Trp Gin His Arg Phe Gin Cys Arg Leu Pro Gly His Leu 370 375 380 Leu Glu Asn Pro Asn Phe Lys Lys Val Cys Thr Gly Asn Glu Ser Leu 385 390 395 400 Glu Glu Asn Tyr Val Gin Asp Ser Lys Met Gly Phe Val He Asn Ala 405 410 415 He Tyr Ala Met Ala His Gly Leu Gin Asn Met His His Ala Leu Cys 420 425 430 Pro Gly His Val Gly Leu Cys Asp Ala Met Lys Pro He Asp Gly Arg 435 440 445 Lys Leu Leu Asp Phe Leu He Lys Ser Ser Phe Val Gly Val Ser Gly 450 __-• 455 460 Glu Glu Val Trp Phe Asp Glu Lys Gly Asp Ala Pro Gly Arg Tyr Asp 465 470 475 480 He Met Asn Leu Gin Tyr Thr Glu Ala Asn Arg Tyr Asp Tyr Val His 485 490 495 Val Gly Thr Trp His Glu Gly Val Leu Asn He Asp Asp Tyr Lys He 500 505 510 Gin Met Asn Lys Ser Gly Met Val Arg Ser Val Cys Ser Glu Pro cys 515 520 525 Leu Lys Gly Gin He Lys Val He Arg Lys Gly Glu Val Ser Cys Cys 530 535 540 Trp-Ile cys Thr Ala Cys Lys Glu Asn Glu Phe Val Gin Asp Glu Phe 545 550 555 560 Thr Cys Arg Ala Cys Asp Leu Gly Trp Trp Pro Asn Ala Glu Leu Thr 565 570 575 Gly Cys Glu Pro He Pro Val Arg Tyr Leu Glu Trp Ser Asp He Glu 580 585 590 Ser He He Ala He Ala Phe Ser Cys Leu Gly He Leu Val Thr Leu 595 600 605 Phe Val Thr Leu He Phe Val Leu Tyr Arg Asp Thr Pro Val Val Lys 610 615 620 Ser Ser Ser Arg Glu Leu Cys Tyr He He Leu Ala Gly He Phe Leu 625 630 635 640 -v Gly Tyr Val Cys Pro Phe Thr Leu He Ala Lys Pro Thr Thr Thr Ser 645 650 655 Cys Tyr Leu Gin Arg Leu Leu Val Gly Leu Ser Ser Ala Met Cys Tyr 660 665 670 Ser Ala Leu Val Thr Lys Thr Asn Arg He Ala Arg He Leu Ala Gly 675 680 685 ser Lys Lys Lys He Cys Thr Arg Lys Pro Arg Phe Met Ser Ala Trp 690 695 700 Ala Gin Val He He Ala Ser He Leu He Ser Val Gin Leu Thr Leu 705 710 715 720 Val Val Thr Leu He He Met Glu Pro Pro Met Pro He Leu Ser Tyr 725 730 735 Pro Ser He Lys Glu Val Tyr Leu He cys Asn Thr Ser Asn Leu Gly 740 745 750 Val Val Ser Cys Thr Tyr Tyr Ala Phe Lys Thr Arg Asn Val Pro Ala Asn Phe Asn Glu Ala 770 775 780 Lys Tyr He Ala Phe Thr Met Tyr Thr Thr Cys He He Trp Leu Ala 785 790 795 800 Phe Val Pro He Tyr Phe Gly Ser Asn Tyr Lys He He Thr Thr Cys 805 810 815 Phe Ala Val Ser Leu Ser Val Thr Val Ala Leu Gly Cys Met Phe Thr 820 825 830 Pro Lys Met Tyr He He He Ala Lys Pro Glu Arg Asn Val Arg Ser 835 840 845 91 09422 77 Ala"Phe Thr Thr Ser Asp Val Val Arg Met His Val Gly Asp Gly Lys 850 855 860 Leu Pro Cys Arg Ser Asn Thr Phe Leu Asn He Phe Arg Arg Lys Lys 865 870 875 880 Pro Gly Ala Gly Asn Ala Asn Ser Asn Gly Lys Ser Val Ser Trp Ser 885 890 895 Glu Pro Gly Gly Arg Gin Ala Pro Lys Gly Gin His Val Trp Gin Arg 900 905 910 Leu Ser Val His Val Lys Thr Asn Glu Thr Ala Cys Asn Gin Thr Ala 915 920 925 Val He Lys Pro Leu Thr Lys Ser Tyr Gin Gly Ser Gly Lys Ser Leu 930 935 940 • > Thr Phe Ser Asp Ala Ser Thr Lys Thr Leu Tyr Asn Val Glu Glu Glu 945 950 955 960 Asp Asn Thr Pro Ser Ala His Phe Ser Pro Pro Ser Ser Pro Ser Met 965 970 975 Val Val His Arg Arg Gly Pro Pro Val Ala Thr Thr Pro Pro Leu Pro 980 985 990 Pro His Leu Thr Ala Glu Glu Thr Pro Leu Phe Leu Ala Asp Ser Val 995 1000 1005 He Pro Lys Gly Leu Pro Pro Pro Leu Pro Gin Gin Gin Pro Gin Gin 1010 1015 1020 Pro Pro Pro Gin Gin Pro Pro Gin Gin Pro Lys Ser Leu Met Asp Gin 1025 1030 1035 1040 Leu Gin Gly Val Val Thr Asn Phe Gly Ser Gly He Pro Asp Phe His 1045 1050 1055 Ala Val Leu Ala Gly Pro Gly Thr Pro Gly Asn Ser Leu Arg Ser Leu 1050 1065 1070 Tyr Pro Pro Pro Pro Pro Pro Gin His Leu Gin Met Leu Pro Leu His 1075 1080 1085 Leu Ser Thr Phe Gin Glu Glu Ser He Ser Pro Pro Gly Glu Asp He 1090 1095 1100 Asp Asp Asp Ser Glu Arg Phe Lys Leu Leu Gin Glu Phe Val Tyr Glu 1105 1110 1115 1120 Arg Glu Gly Asn Thr Glu Glu Asp Glu Leu Glu Glu Glu Glu Asp Leu 1125 1130 1135 Pro Thr Ala Ser Lys Leu Thr Pro Glu Asp Ser Pro Ala Leu Thr Pro 1140 1145 1150 ET Pr= Ser Pro Phe Arg Asp Ser Val Ala Ser Gly Ser Ser Val Pro Ser 1155 1160 1165 Ser Pro Val Ser Glu Ser Val Leu Cys Thr Pro Pro Asn Val Thr Tyr 1170 1175 1180 Ala Ser Val He Leu Arg Asp Tyr Lys Gin Ser Ser Ser Thr Leu 1185 * 1190 1195 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 'ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC775 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GCTAGCATAA CCCCTTGGGG CCTCTAAACG GGTCT 35 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC776 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: CTCAAGACCC GTTTAGAGGC CCCAAGGGGT TATGCTAGCT GCA 43 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA SUBSTITUTESHEET 91/09422 79 (vii) IMMEDIATE SOURCE: (B) CLONE: ZC777 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:5: TGAGGGGTTT TTTGCTGAAA GGAGGAACTA TGCGGCCGCA 40 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA 1 (vii) IMMEDIATE SOURCE: (B) CLONE: ZC778 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: AGCTTGCGGC CGCATAGTTC CTCCTTTCAG CAAAAAACCC 40 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC1751 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:7: AATTCTGTGC TCTGTCAAG 19 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA O -_'---83 PCT/US91/09.22 80 -( ii) IMMEDIATE SOURCE: (B) CLONE: ZC1752 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GATCCTTGAC AGAGCACAG 19 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC2063 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GATCCAAACT AGTAAAAGAG CT 22 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC2064 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:10: CTTTTACTAG TTTG 14 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC2938 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GACAGAGCAC AGATTCACTA GTGAGCTCTT TTTTTTTTTT TTT 4 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA *» (vii) IMMEDIATE SOURCE: (B) CLONE: ZC3015 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:12: TTCCATGGCA CCGTCAAGGC T 2 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC3016 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: AGTGATGGCA TGGACTGTGG T 2 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA W ° ' 2 ,0S83 PCT/US91/09422 82 (vii) IMMEDIATE SOURCE: (B) CLONE: ZC3652 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ACATGCACCA TGCTCTGTGT 20 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: ZC3654 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: AGTGATGGCA TGGACTGTGG T 21 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: SN23 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 627..3344 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:16: TAAGAATTTT ATAAATACTC TGGGAATTTT ATTGGTGATG CCTTTGTGTC TACAGGGCAC 60 ACGTTCCAGA GAGCTCTGGT GTGAAGTGAT GGGGGACTTG TGGCTAGAGA AGCTTTTCAA 120 TGGCCTTAAA CTCTGGGTCC TGCTTGAGAG AGGTCTGAGG TTCTCAACAT CAGAGCAGAG 180 CTTCCACCAλ GCTTTCAGAA TGCTAAGCCC CCACTTCTCA ACACTTAGTG CTCTGATCGG 240 83 GGACTCAGCG TCCAGCTCAC CGCCACTAAC GCGCCGCGCA TTGGACACCT GATCCACACA 360 CCTTCGGGCA CCAGTGAAAA ACCGCGACTT GATTTTCTGG AAGAACGCCC CCAGGGTGTG 420 GGAGCGGTCG TGGAGGACCA GCAGGAGGAA GCGGAGGGGA GAGGGGCAGT AGTGGAGGCA 480 GAGAAAGCGT TGAACCAGCT GTGTTGGCCG AAGGCACGAA ACGGCAAAAG GCAGCGGTGA 540 GCATCTGTGT GGTTCCCGCT GGGAACCTGC AGGCAGGACC GGCGTGGGAA CGTGGCTGGC 600 CCGCGGTGGA CCGCGTCTTC GCCACA ATG GTC CGG CTC CTC TTG ATT TTC TTC 653 Met Val Arg Leu Leu Leu He Phe Phe 1 5 CCA ATG ATC TTT TTG GAG ATG TCC ATT TTG CCC AGG ATG CCT GAC AGA 701 Pro Met He Phe Leu Glu Met Ser He Leu Pro Arg Met Pro Asp Arg 10 15 20 25 AAA GTA TTG CTG GCA GGT GCC TCG TCC CAG CGC TCC GTG GCG AGA ATG 749 Lys Val Leu Leu Ala Gly Ala Ser Ser Gin Arg Ser Val Ala Arg Met 30 35 40 GAC GGA GAT GTC ATC ATC GGA GCC CTC TTC TCA GTC CAT CAC CAG CCT 797 Asp Gly Asp Val He He Gly Ala Leu Phe Ser Val His His Gin Pro 45 50 55 CCA GCC GAG AAG GTA CCC GAA AGG AAG TGT GGG GAG ATC AGG GAA CAG 845 Pro Ala Glu Lys Val Pro Glu Arg Lys Cys Gly Glu He Arg Glu Gin 60 65 70 TAT GGT ATC CAG AGG GTG GAG GCC ATG TTC CAC ACG TTG GAT AAG ATT 893 Tyr Gly He Gin Arg Val Glu Ala Met Phe His Thr Leu Asp Lys He 75 80 85 AAC GCG GAC CCG GTG CTC CTG CCC AAC ATC ACT CTG GGC AGT GAG ATC 941 Asn Ala Asp Pro Val Leu Leu Pro Asn He Thr Leu Gly Ser Glu He 90 95 100 105 CGG GAC TCC TGC TGG CAC TCT TCA GTG GCT CTC GAA CAG AGC ATC GAA 989 Arg Asp Ser Cys Trp His Ser Ser Val Ala Leu Glu Gin Ser He Glu *>• 110 115 120 TTC ATC AGA GAC TCC CTG ATT TCC ATC CGA GAT GAG AAG GAT GGG CTG 1037 Phe He Arg Asp Ser Leu He Ser He Arg Asp Glu Lys Asp Gly Leu 125 130 135 AAC CGA TGC CTG CCT GAT GGC CAG ACC CTG CCC CCT GGC AGG ACT AAG 1085 Asn Arg Cys Leu Pro Asp Gly Gin Thr Leu Pro Pro Gly Arg Thr Lys 140 145 150 AAG CCT ATT GCT GGA GTG ATC GGC CCT GGC TCC AGC TCT GTG GCC ATT 1133 Lys Pro He Ala Gly Val He Gly Pro Gly Ser Ser Ser Val Ala He 155 160 165 CAA GTC CAG AAT CTT CTC CAG CTG TTC GAC ATC CCA CAG ATC GCC TAT 1181 Gin Val Gin Asn Leu Leu Gin Leu Phe Asp He Pro Gin He Ala Tyr TCT" GCC ACA AGC ATA GAC CTG AGT GAC AAA ACT TTG TAC AAA TAC TTC 1229 Ser Ala Thr Ser He Asp Leu Ser Asp Lys Thr Leu Tyr Lys Tyr Phe 190 195 200 CTG AGG GTG GTC CCT TCT GAC ACT TTG CAG GCA AGG GCG ATG CTC GAC 1277 Leu Arg Val Val Pro Ser Asp Thr Leu Gin Ala Arg Ala Met Leu Asp 205 210 215 ATA GTC AAG CGT TAC AAC TGG ACC TAT GTC TCA GCA GTC CAC ACA GAA 1325 He Val Lys Arg Tyr Asn Trp Thr Tyr Val Ser Ala Val His Thr Glu 220 225 230 GGG AAT TAC GGC GAG AGT GGA ATG GAT GCT TTC AAA GAA CTG GCT GCC 1373 Gly Asn Tyr Gly Glu Ser Gly Met Asp Ala Phe Lys Glu Leu Ala Ala 235 240 245 CAG GAA GGC CTC TGC ATC GCA CAC TCG GAC AAA ATC TAC AGC AAT GCT 1421 "Sin f.lu Gly Leu Cys He Ala His Ser Asp Lys He Tyr Ser Asn Ala 250 255 260 265 GGC GAG AAG AGC TTT GAC CGG CTC CTG CGT AAA CTC CGG GAG CGG CTT 1469 Gly Glu Lys Ser Phe Asp Arg Leu Leu Arg Lys Leu Arg Glu Arg Leu 270 275 280 CCC AAG GCC AGG GTT GTG GTC TGC TTC TGC GAG GGC ATG ACA GTG CGG 1517 Pro Lys Ala Arg Val Val Val cys Phe cys Glu Gly Met Thr Val Arg 285 290 295 GGC TTA CTG AGT GCC ATG CGC CGC CTG GGC GTC GTG GGC GAG TTC TCA 1565 Gly Leu Leu Ser Ala Met Arg Arg Leu Gly Val Val Gly Glu Phe Ser 300 305 310 CTC ATT GGA AGT GAT GGA TGG GCA GAC AGA GAT GAA GTC ATC GAA GGC 1613 Leu He Gly Ser Asp Gly Trp Ala Asp Arg Asp Glu Val He Glu Gly 315 320 325 TAT GAG GTG GAA GCC AAC GGA GGG ATC ACA ATA AAG CTT CAG TCT CCA 1661 Tyr Glu Val Glu Ala Asn Gly Gly He Thr He Lys Leu Gin Ser Pro 330 335 340 * 345 GAG GTC AGG TC__r-TTT GAT GAC TAC TTC CTG AAG CTG AGG CTG GAC ACC 1709 Glu Val Arg Ser Phe Asp Asp Tyr Phe Leu Lys Leu Arg Leu Asp Thr 350 355 360 AAC ACA AGG AAT CCT TGG TTC CCT GAG TTC TGG CAA CAT CGC TTC CAG 1757 Asn Thr Arg Asn Pro Trp Phe Pro Glu Phe Trp Gin His Arg Phe Gin 365 370 375 TGT CGC CTA CCT GGA CAC CTC TTG GAA AAC CCC AAC TTT AAG AAA GTG 1805 Cys Arg Leu Pro Gly His Leu Leu Glu Asn Pro Asn Phe Lys Lys Val 380 385 390 TGC ACA GGA AAT GAA AGC TTG GAA GAA AAC TAT GTC CAG GAC AGC AAA 1853 Cys Thr Gly Asn Glu Ser Leu Glu Glu Asn Tyr Val Gin Asp Ser Lys 395 400 405 - - -_- T US91/09422 85 Met- Gly Phe Val He Asn Ala He Tyr Ala Met Ala His Gly Leu Gin 410 415 420 425 AAC ATG CAC CAT GCT CTG TGT CCC GGC CAT GTG GGC CTG TGT GAT GCT 1949 Asn Met His His Ala Leu Cys Pro Gly His Val Gly Leu Cys Asp Ala 430 435 440 ATG AAA CCC ATT GAT GGC AGG AAG CTC CTG GAT TTC CTC ATC AAA TCC 1997 Met Lys Pro He Asp Gly Arg Lys Leu Leu Asp Phe Leu He Lys Ser 445 450 455 TCT TTT GTC GGA GTG TCT GGA GAG GAG GTG TGG TTC GAT GAG AAG GGG 2045 Ser Phe Val Gly Val Ser Gly Glu Glu Val Trp Phe Asp Glu Lys Gly 460 465 470 GAT GCT CCC GGA AGG TAT GAC ATT ATG AAT CTG CAG TAC ACA GAA GCT 2093 Asp Ala Pro Gly Arg Tyr Asp He Met Asn Leu Gin Tyr Thr Glu Ala -, Λ75 480 485 AAT CGC TAT GAC TAT GTC CAC GTG GGG ACC TGG CAT GAA GGA GTG CTG 2141 Asn Arg Tyr Asp Tyr Val His Val Gly Thr Trp His Glu Gly Val Leu 490 495 " 500 505 AAT ATT GAT GAT TAC AAA ATC CAG ATG AAC AAA AGC GGA ATG GTA CGA 2189 Asn He Asp Asp Tyr Lys He Gin Met Asn Lys Ser Gly Met Val Arg 510 515 520 TCT GTG TGC AGT GAG CCT TGC TTA AAG GGT CAG ATT AAG GTC ATA CGG 2237 Ser Val Cys Ser Glu Pro Cys Leu Lys Gly Gin He Lys Val He Arg 525 530 535 AAA GGA GAA GTG AGC TGC TGC TGG ATC TGC ACG GCC TGC AAA GAG AAT 2285 Lys Gly Glu Val Ser Cys Cys Trp He Cys Thr Ala Cys Lys Glu Asn 540 545 550 GAG TTT GTG CAG GAC GAG TTC ACC TGC AGA GCC TGT GAC CTG GGG TGG 2333 Glu Phe Val Gin Asp Glu Phe Thr Cys Arg Ala Cys Asp Leu Gly Trp 555 560 565 TGG CCC AAC GCA GAG CTC ACA GGC TGT GAG CCC ATT CCT GTC CGT TAT 2381 Trp Pro Asn Ala ' Glu Leu Thr Gly Cys Glu Pro He Pro Val Arg Tyr 570 575 580 585 CTT GAG TGG AGT GAC ATA GAA TCT ATC ATA GCC ATC GCC TTT TCT TGC 2429 Leu Glu Trp Ser Asp He Glu Ser He He Ala He Ala Phe Ser Cys 590 595 600 CTG GGC ATC CTC GTG ACG CTG TTT GTC ACC CTC ATC TTC GTT CTG TAC 2477 Leu Gly He Leu Val Thr Leu Phe Val Thr Leu He Phe Val Leu Tyr 605 610 615 CGG GAC ACA CCC GTG GTC AAA TCC TCC AGT AGG GAG CTC TGC TAT ATC 2525 Arg Asp Thr Pro Val Val Lys Ser Ser Ser Arg Glu Leu Cys Tyr He 620 625 630 ATT CTG GCT GGT ATT TTC CTC GGC TAT GTG TGC CCT TTC ACC CTC ATC 2573 He Leu Ala Gl He Phe Leu Gl T r Val C s Pro Phe Thr Leu He - 635 640 645 GCC AAA CCT ACT ACC ACA TCC TGC TAC CTC CAG CGC CTC CTA GTT GGC 2621 Ala Lys Pro Thr Thr Thr Ser Cys Tyr Leu Gin Arg Leu Leu Val Gly 650 655 660 665 CTC TCT TCT GCC ATG TGC TAC TCT GCT TTA GTG ACC AAA ACC AAT CGT 2669 Leu Ser Ser Ala Met Cys Tyr Ser Ala Leu Val Thr Lys Thr Asn Arg 670 675 680 ATT GCA CGC ATC CTG GCT GGC AGC AAG AAG AAG ATC TGC ACC CGG AAG 2717 He Ala Arg He Leu Ala Gly Ser Lys Lys Lys He Cys Thr Arg Lys 685 690 695 CCC AGA TTC ATG AGC GCT TGG GCC CAA GTG ATC ATA GCC TCC ATT CTG 2765 Pro Arg Phe Met Ser Ala Trp Ala Gin Val He He Ala Ser He Leu 700 705 710 ATT AGT GTA CAG CTA ACA CTA GTG GTG ACC TTG ATC ATC ATG GAG CCT 2813 He Ser Val Gin Leu Thr Leu Val Val Thr Leu He He Met Glu Pro 715 720 725 CCC ATG CCC ATT TTG TCC TAC CCG AGT ATC AAG GAA GTC TAC CTT ATC 2861 Pro Met Pro He Leu Ser Tyr Pro Ser He Lys Glu Val Tyr Leu He 730 735 740 745 TGC AAT ACC AGC AAC CTG GGT GTA GTG GCC CCT GTG GGT TAC AAT GGA 2909 Cys Asn Thr Ser Asn Leu Gly Val Val Ala Pro Val Gly Tyr Asn Gly 750 755 760 CTC CTC ATC ATG AGC TGT ACC TAC TAT GCC TTC AAG ACC CGC AAC GTG 2957 Leu Leu He Met Ser Cys Thr Tyr Tyr Ala Phe Lys Thr Arg Asn Val 765 770 775 CCG GCC AAC TTC AAT GAG GCT AAA TAC ATC GCC TTC ACC ATG TAC ACT 3005 Pro Ala Asn Phe Asn Glu Ala Lys Tyr He Ala Phe Thr Met Tyr Thr 780 785 790 ACC TGC ATC ATC TGG CTG GCT TTC GTT CCC ATT TAC TTT GGG AGC AAC 3053 Thr Cys He He Trp Leu Ala Phe Val Pro He Tyr Phe Gly Ser Asn 795 _*- 800 805 TAC AAG ATC ATC ACT ACC TGC TTC GCG GTG AGC CTC AGT GTG ACG GTG 3101 Tyr Lys He He Thr Thr Cys Phe Ala Val Ser Leu Ser val Thr Val 810 815 820 825 GCC CTG GGG TGC ATG TTT ACT CCG AAG ATG TAC ATC ATC ATT GCC AAA 3149 Ala Leu Gly Cys Met Phe Thr Pro Lys Met Tyr He He He Ala Lys 830 835 840 CCT GAG AGG AAC GTC CGC AGT GCC TTC ACG ACC TCT GAT GTT GTC CGC 3197 Pro Glu Arg Asn Val Arg Ser Ala Phe Thr Thr Ser Asp Val Val Arg 845 850 855 ATG CAC GTC GGT GAT GGC AAA CTG CCG TGC CGC TCC AAC ACC TTC CTC 3245 Met His Val Gly Asp Gly Lys Leu Pro Cys Arg Ser Asn Thr Phe Leu 87 AAC" ATT TTC CGG AGA AAG AAG CCC GGG GCA GGG AAT GCC AAG AAG AGG 3293 Asn He Phe Arg Arg Lys Lys Pro Gly Ala Gly Asn Ala Lys Lys Arg 875 880 885 CAG CCA GAA TTC TCG CCC AGC AGC CAG TGT CCG TCG GCA CAT GCG CAG 3341 Gin Pro Glu Phe Ser Pro Ser Ser Gin Cys Pro Ser Ala His Ala Gin 890 895 900 905 CTT TGAAAACCCC CACACTGCAG TGAATGTTTC TAACGGCAAG TCTGTGTCAT 3394 Leu GGTCTGAACC AGGTGGAAGA CAGGCGCCCA AGGGACAGCA CGTGTGGCAG CGCCTCTCTG 3454 TGCACGTGAA GACCAACGAG ACGGCCTGTA ACCAAACAGC CGTAATCAAA CCCCTCACTA 3514 AAAGTTACCA AGGCTCTGGC AAGAGCCTGA CCTTTTCAGA TGCCAGCACC AAGACCCTTT 3574 ACAATGTGGA AGAAGAGGAC AATACCCCTT CTGCTCACTT CAGCCCTCCC AGCAGCCCTT 3634 CTATGGTGGT GCACCGACGC GGGCCACCCG TGGCCACCAC ACCACCTCTG CCACCCCATC 3694 TGACCGCAGA AGAGACCCCC CTGTTCCTGG CTGATTCCGT CATCCCCAAG GGCTTGCCTC 3754 CTCCTCTCCC GCAGCAGCAG CCACAGCAGC CGCCCCCTCA GCAGCCCCCG CAGCAGCCCA 3814 AGTCCCTGAT GGACCAGCTG CAAGGCGTAG TCACCAACTT CGGTTCGGGG ATTCCAGATT 3874 TCCATGCGGT GCTGGCAGGC CCGGGGACAC CAGGAAACAG CCTGCGCTCT CTGTACCCGC 3934 CCCCGCCTCC GCCGCAACAC CTGCAGATGC TGCCCCTGCA CCTGAGCACC TTCCAGGAGG 3994 AGTCCATCTC CCCTCCTGGG GAGGACATCG ATGATGACAG TGAGAGATTC AAGCTCCTGC 4054 AGGAGTTCGT GTACGAGCGC GAAGGGAACA CCGAAGAAGA TGAATTGGAA GAGGAGGAGG 4114 ACCTGCCCAC AGCCAGCAAG CTGACCCCTG AGGATTCTCC TGCCCTGACG CCTCCTTCTC 4174 CTTTCCGAGA TTCCGTGGCC TCTGGCAGCT CAGTGCCCAG TTCCCCCGTA TCTGAGTCGG 4234 TCCTCTGCAC CCCTCGAAAT GTAACCTACG CCTCTGTCAT TCTGAGGGAC TACAAGCAAA 4294 GCTCTTCCAC CCTGTAGTGT GTGTGTGTGT GTGGGGGCGG GGGGAGTGCG CATGGAGAAG 4354 CCAGAGATGC CAAGGAGTGT CAACCCTTCC AGAAATGTGT AGAAAGCAGG GTGAGGGATG 4414 GGG TGGAGG ACCACGGTCT GCAGGGAAGA AAAAAAAAAA TGCTGCGGCT GCCTTAAAGA 4474 AGGAGAGGGA CGATGCCAAC TGAACAGTGG TCCTGGCCAG GATTGTGACT CTTGAATTAT 4534 TCAAAAACCT TCTCTAGAAA GAAAGGGAAT TATGACAAAG CACAATTCCA TATGGTATGT 4594 AACTTTTATC GAAAAAAATA ATAAAACGTA AAAATAAAAT CAACAAAAAT AATCTCTTCT 4654 TTTGCTCAAT CGTGCATACA TATATCTGCC CACACTCCCG TGGTAAAACT AGAAGCGAAG 4714 CAGGCCCTGC GATGGTGCCA ACTGAATCCT AAGTTCATCA TCCTAGTGAG CAGATGGAGA 4774 GAGGGCAGGA GGCGAGAGGG CAGGAGGCGG GGGTAGGTTC GGACAACAGC TCCCATCTCA 4834 GACCTTGACT GTGCTGAGTC TTCAGACTCC TGGACTAAGG AAGACCCGGG GACTGACCTT 4894 ATGAGGGTCC CTTTCCACTG CTGTGATCCA TTGCCAGCCT GTAGTCACCC GGGATAAAGG 4954 CACAGTAACC TTTTGCATTC CTGTGATTCC CTGTGTTTAA GGAAAAGGAA AGTATGAGCA 5014 AAGCTATCAC CAAAAAGAGC GCCATTAGAA GTTACGGGGG AGAAAAAAAG AGAAGCAAGA 5074 TGATATATAA GCACAGGGCC TTGAACAAGG TGAGCGTGCT TCACAGATTC CGTATTAATG 5134 TACAGATACT TTTGGAGAGG AGAAAGATAA CAAGGAGTGT CAGGCCGTTT GTGAACTCAC 5194 TTGCACTGTG CCAACCAGGT TCTCCGCTGC CCTTCAGCAA AA 5236 ,2) T.NFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 906 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Val Arg Leu Leu Leu He Phe Phe Pro Met He Phe Leu Glu Met 1 5 10 15 Ser He Leu Pro Arg Met Pro Asp Arg Lys Val Leu Leu Ala Gly Ala 20 25 30 Ser Ser Gin Arg Ser Val Ala Arg Met Asp Gly Asp Val lie lie Gly 35 40 45 Ala Leu Phe Ser Val His His Gin Pro Pro Ala Glu Lys Val Pro Glu 50 55 60 Arg Lys Cys Gly- Glu He Arg Glu Gin Tyr Gly He Gin Arg Val Glu 65 70 75 80 Ala Met Phe His Thr Leu Asp Lys He Asn Ala Asp Pro Val Leu Leu 85 90 95 Pro Asn He Thr Leu Gly Ser Glu He Arg Asp Ser Cys Trp His Ser 100 105 110 Ser Val Ala Leu Glu Gin Ser He Glu Phe He Arg Asp Ser Leu He 115 120 125 Ser He Arg Asp Glu Lys Asp Gly Leu Asn Arg Cys Leu Pro Asp Gly 130 135 140 Gin Thr Leu Pro Pro Gly Arg Thr Lys Lys Pro He Ala Gly Val He Gly-Pro Gly Ser Ser Ser Val Ala He Gin Val Gin Asn Leu Leu Gin 165 170 175 Leu Phe Asp He Pro Gin He Ala Tyr Ser Ala Thr Ser He Asp Leu 180 185 190 Ser Asp Lys Thr Leu Tyr Lys Tyr Phe Leu Arg Val Val Pro Ser Asp 105 200 205 Thr Leu Gin Ala Arg Ala Met Leu Asp He Val Lys Arg Tyr Asn Trp 210 215 220 Thr Tyr Val ser Ala Val His Thr Glu Gly Asn Tyr Gly Glu Ser Gly 225 230 235 240 Met Asp Ala Phe Lys Glu Leu Ala Ala Gin Glu Gly Leu Cys He Ala 245 250 255 His Ser Asp Lys He Tyr Ser Asn Ala Gly Glu Lys Ser Phe Asp Arg 260 265 270 Leu Leu Arg Lys Leu Arg Glu Arg Leu Pro Lys Ala Arg Val Val Val 275 280 285 Cys Phe Cys Glu Gly Met Thr Val Arg Gly Leu Leu Ser Ala Met Arg 290 295 300 Arg Leu Gly Val Val Gly Glu Phe Ser Leu He Gly Ser Asp Gly Trp 305 310 315 320 Ala Asp Arg Asp Glu Val He Glu Gly Tyr Glu Val Glu Ala Asn Gly 325 330 335 Gly He Thr He Lys Leu Gin Ser Pro Glu Val Arg ser Phe Asp Asp 340 345 350 Tyr Phe Leu Lys Leu Arg Leu Asp Thr Asn Thr Arg Asn Pro Trp Phe 355 360 365 Pro Glu Phe Trp Gin His Arg Phe Gin Cys Arg Leu Pro Gly His Leu 370 375 380 Leu Glu Asn Pro Asn Phe Lys Lys Val Cys Thr Gly Asn Glu Ser Leu 385 390 395 400 Glu Glu Asn Tyr Val Gin Asp Ser Lys Met Gly Phe Val He Asn Ala 405 410 415 He Tyr Ala Met Ala His Gly Leu Gin Asn Met His His Ala Leu Cys 420 425 430 Pro Gly His Val Gly Leu Cys Asp Ala Met Lys Pro He Asp Gly Arg 435 440 445 Lys Leu Leu Asp Phe Leu He Lys Ser Ser Phe Val Gly Val Ser Gly 450 455 460 Glu Glu Val Trp Phe Asp Glu Lys Gly Asp Ala Pro Gly Arg Tyr Asp 465 470 475 480 He Met Asn Leu Gin Tyr Thr Glu Ala Asn Arg Tyr Asp Tyr Val His 485 490 495 Val Gly Thr Trp His Glu Gly Val Leu Asn He Asp Asp Tyr Lys He - 500 505 510 Gin Met Asn Lys Ser Gly Met Val Arg Ser Val Cys Ser Glu Pro Cys 515 520 525 Leu Lys Gly Gin He Lys Val He Arg Lys Gly Glu Val Ser Cys Cys 530 535 540 Trp He Cys Thr Ala Cys Lys Glu Asn Glu Phe Val Gin Asp Glu Phe 545 550 555 560 Thr cys Arg Ala Cys Asp Leu Gly Trp Trp Pro Asn Ala Glu Leu Thr 565 570 575 Gly cys Glu Pro He Pro Val Arg Tyr Leu Glu Trp ser Asp He Glu 580 585 590 Ser He He Ala He Ala Phe Ser Cys Leu Gly He Leu Val Thr Leu 595 600 605 Phe Val Thr Leu He Phe Val Leu Tyr Arg Asp Thr Pro Val Val Lys 610 615 620 Ser Ser Ser Arg Glu Leu Cys Tyr He He Leu Ala Gly He Phe Leu 625 630 635 . 640 Gly Tyr Val Cys Pro Phe Thr Leu He Ala Lys Pro Thr Thr Thr Ser 645 650 655 Cys Tyr Leu Gin Arg Leu Leu Val Gly Leu Ser Ser Ala Met Cys Tyr 660 665 670 Ser Ala Leu Val Thr Lys Thr Asn Arg He Ala Arg He Leu Ala Gly 675 _-- 680 685 Ser Lys Lys Lys He Cys Thr Arg Lys Pro Arg Phe Met Ser Ala Trp 690 695 700 Ala Gin Val He He Ala Ser He Leu He Ser Val Gin Leu Thr Leu 705 710 715 720 Val Val Thr Leu He He Met Glu Pro Pro Met Pro He Leu Ser Tyr 725 730 735 Pro Ser He Lys Glu Val Tyr Leu He Cys Asn Thr Ser Asn Leu Gly 740 745 750 Val Val Ala Pro Val Gly Tyr Asn Gly Leu Leu He Met Ser Cys Thr 755 760 765 91 Tyr Tyr Ala Phe Lys Thr Arg Asn Val Pro Ala Asn Phe Asn Glu Ala 770 775 780 Lys Tyr He Ala Phe Thr Met Tyr Thr Thr Cys He He Trp Leu Ala 785 790 795 800 Phe Val Pro He Tyr Phe Gly Ser Asn Tyr Lys He He Thr Thr Cys 805 810 815 Phe Ala Val Ser Leu Ser Val Thr Val Ala Leu Gly Cys Met Phe Thr 820 825 830 Pro Lys Met Tyr He He He Ala Lys Pro Glu Arg Asn Val Arg Ser 835 840 845 Ala Phe Thr Thr Ser Asp Val Val Arg Met His Val Gly Asp Gly Lys 850 855 860 s Leu Pro Cys Arg Ser Asn Thr Phe Leu Asn He Phe Arg Arg Lys Lys 865 870 875 880 Pro Gly Ala Gly Asn Ala Lys Lys Arg Gin Pro Glu Phe Ser Pro Ser 885 890 895 Ser Gin Cys Pro Ser Ala His Ala Gin Leu 900 905 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4095 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (Vii) IMMEDIATE SOURCE: (B) CLONE: SN30 _ * . (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 463..3198 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: CCCGGGCTCC CGGCAGTGCG AGCAGCTAAG GGCTGGCCGC CGCCTCCCTG AGCTCCCCCG 60 GAGCAGCCGA CCCCTGGTCG CGGCGTTCAC CTCGCCGATG CGCGGTTGGT AGGAGTGACC 120 GGAGCCATTC TCTCCTCGTT GATAAGATTC CCTACCAGGA TAGGAGCCTA TCTCCCTTTC 180 ACAGCAGGAC ACAGAAATCT GGCCTTCAGT ACTTTGGGAA AAGGATCTGA GACCTCCTGG 240 AGCTCTGACC ACTGGCTGTC ATCTGTGGCT CTGGCCTGTG TGGGCCACTG AGCTCTACTC 300 92 AAΛCATTAAA GAGGAGGAGG GGAGATCTGT GGAATGGGCC ACCCCGTTGG CCTGCTGCAT 360 TACTGAACCT GCGCTGTCCA CACGTGCCCA GATCATGGGA CCCAGGGCCT GCTAGGGCTA 420 GGAGCGGGGC CCAGTATTCA TGGGTCTCTA GGCCTTTCCG AA ATG TCC GGG AAG 474 Met Ser Gly Lys 1 GGA GGC TGG GCC TGG TGG TGG GCC CGG CTG CCC CTC TGC CTA CTC CTC 522 Gly Gly Trp Ala Trp Trυ Trp Ala Arg Leu Pro Leu Cys Leu Leu Leu 5 10 15 20 AGC CTT TAT GCC CCC TGG GTG CCT TCA TCC TTG GGA AAG CCC AAG GGT 570 Ser Leu Tyr Ala Pro Trp Val Pro Ser Ser Leu Gly Lys Pro Lys Gly 25 30 35 CAC CCC CAC ATG AAC TCT ATC CGA ATT GAC GGG GAC ATC ACA CTG GGA 618 sy.s τo His Met Asn Ser He Arg He Asp Gly Asp He Thr Leu Gly 40 45 50 GGC CTG TTT CCC GTC CAC GGC CGT GGC TCT GAG GGT AAG GCC TGC GGG 666 Gly Leu Phe Pro Val His Gly Arg Gly Ser Glu Gly Lys Ala Cys Gly 55 60 65 GAG CTG AAG AAG GAG AAA GGC ATC CAC CGC CTG GAG GCC ATG .CTG TTT 714 Glu Leu Lys Lys Glu Lys Gly He His Arg Leu Glu Ala Met Leu Phe 70 75 80 GCC CTG GAC CGC ATC AAC AAT GAC CCG GAC CTA CTG CCC AAC ATC ACG 762 Ala Leu Asp Arg He Asn Asn Asp Pro Asp Leu Leu Pro Asn He Thr 85 90 95 100 TTG GGC GCC CGC ATT CTG GAC ACC TGC TCG AGG GAC ACC CAC GCC CTG 810 Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp Thr His Ala Leu 105 110 115 GAG CAG TCA CTG ACC TTT GTG CGG GCG CTC ATC GAG AAG GAC GGC ACG 858 Glu Gin Ser Leu Thr Phe Val Arg Ala Leu He Glu Lys Asp Gly Thr 120 125 130 GAG GTC CGC TGG- GGC AGG CGG GGC CCG CCC ATC ATC ACC AAG CCC GAA 906 Glu Val Arg Cys Gly Arg Arg Gly Pro Pro He He Thr Lys Pro Glu 135 140 145 CGA GTG GTG GGT GTC ATT GGA GCT TCG GGG AGC TCC GTC TCG ATC ATG 954 Arg Val Val Gly Val He Gly Ala Ser Gly Ser Ser Val Ser He Met 150 155 160 GTG GCC AAC ATC CTC CGC CTC TTC AAG ATC CCT CAG ATC AGC TAT GCC 1002 Val Ala Asn He Leu Arg Leu Phe Lys He Pro Gin He Ser Tyr Ala 165 170 175 180 TCC ACG GCC CCT GAC TTG AGT GAC AAC AGC CGC TAT GAC TTC TTC TCC 1050 Ser Thr Ala Pro Asp Leu Ser Asp Asn Ser Arg Tyr Asp Phe Phe Ser 185 190 195 93 Arg Val Val Pro Ser Asp Thr Tyr Gin Ala Gin Ala Met Val Asp He 200 205 210 GTC CGA GCC CTC AAG TGG AAC TAT GTG TCC ACA CTG GCC TCA GAG GGC 114 Val Arg Ala Leu Lys Trp Asn Tyr Val Ser Thr Leu Ala Ser Glu Gly 215 220 225 AGC TAC GGT GAG AGT GGT GTG GAG GCC TTT ATC CAG AAG TCC CGA GAG 119 Ser Tyr Gly Glu Ser Gly Val Glu Ala Phe He Gin Lys Ser Arg Glu 230 235 240 AAC GGA GGT GTG TGC ATT GCC CAG TCG GTG AAG ATT CCA CGG GAA CCC 124 Asn Gly Gly Val Cys He Ala Gin Ser Val Lys He Pro Arg Glu Pro 245 250 255 260 AAG ACG GGG GAG TTC GAC AAG ATC ATC AAA CGC CTA CTG GAA ACA TCC 129 Lys Thr Gly Glu Phe Asp Lys He He Lys Arg Leu Leu Glu Thr Ser ^ 265 270 275 AAT GCC AGG GGT ATC ATC ATC TTT GCC AAC GAG GAT GAC ATC AGG AGG 133 Asn Ala Arg Gly He He He Phe Ala Asn Glu Asp Asp He Arg Arg 280 285 290 GTG TTG GAG GCA GCT CGC AGG GCC AAC CAG ACC GGC CAC TTC TTT TGG 138 Val Leu Glu Ala Ala Arg Arg Ala Asn Gin Thr Gly His Phe Phe Trp 295 300 305 ATG GGT TCT GAT AGC TGG GGC TCC AAG AGT GCC CCT GTG CTG CGC CTT 143 Met Gly Ser Asp Ser Trp Gly Ser Lys Ser Ala Pro Val Leu Arg Leu 310 315 320 GAG GAG GTG GCC GAG GGC GCA GTC ACC ATT CTC CCC AAG AGG ATG TCT 148 Glu Glu Val Ala Glu Gly Ala Val Thr He Leu Pro Lys Arg Met Ser 325 330 335 340 GTT CGA GGG TTC GAC CGA TAC TTC TCC AGC CGC ACG CTG GAC AAC AAC 153 Val Arg Gly Phe Asp Arg Tyr Phe Ser Ser Arg Thr Leu Asp Asn Asn 345 350 355 AGG CGC AAC ATC TGG TTT GCC GAG TTC TGG GAG GAC AAC TTC CAT TGC 157 Arg Arg Asn He- Trp Phe Ala Glu Phe Trp Glu Asp Asn Phe His Cys 360 365 370 AAG TTG AGC CGC CAC GCG CTC AAG AAG GGA AGC CAC ATC AAG AAG TGC 162 Lys Leu Ser Arg His Ala Leu Lys Lys Gly Ser His He Lys Lys Cys 375 380 385 ACC AAC CGA GAG CGC ATC GGG CAG GAC TCG GCC TAT GAG CAG GAG GGG 167 Thr Asn Arg Glu Arg He Gly Gin Asp Ser Ala Tyr Glu Gin Glu Gly 390 395 400 AAG GTG CAG TTC GTG ATT GAC GCT GTG TAC GCC ATG GGC CAC GCG CTG 172 Lys Val Gin Phe Val He Asp Ala Val Tyr Ala Met Gly His Ala Leu 405 410 415 420 CAC GCC ATG CAC CGT GAC CTG TGT CCC GGC CGC GTA GGA CTC TGC CCT 177 His Ala Met His Arg Asp Leu Cys Pro Gly Arg Val Gly Leu Cys Pro 425 430 435 CGC ATG GAC CCC GTG GAT GGC ACC CAG CTG CTT AAG TAC ATC AGG AAC 1818 Arg Met Asp Pro Val Asp Gly Thr Gin Leu Leu Lys Tyr He Arg Asn 440 445 450 GTC AAC TTC TCA GGC ATT GCG GGG AAC CCT GTA ACC TTC AAT GAG AAC 1866 Val Asn PIxe Ser Gly He Ala Gly Asn Pro Val Thr Phe Asn Glu Asn 455 460 465 GGA GAC GCA CCG GGG CGC TAC GAC ATC TAC CAG TAC CAA CTG CGC AAT 1914 Gly Asp Ala Pro Gly Arg Tyr Asp He Tyr Gin Tyr Gin Leu Arg Asn 470 475 480 GGC TCG GCC GAG TAC AAG GTC ATC GGC TCG TGG ACA GAC CAC CTG CAC 1962 Gly Ser Ala Glu Tyr Lys Val He Gly Ser Trp Thr Asp His Leu His 485 490 495 500 CTC AGA ATA GAG CGG ATG CAG TGG CCA GGG AGT GGC CAG CAG CTG CCG 2010 Leu Arg He Glu Arg Met Gin Trp Pro Gly Ser Gly Gin Gin Leu Pro 505 510 515 CGC TCC ATC TGC AGT CTG CCC TGC CAG CCC GGG GAG CGA AAG AAG ACT 2058 Arg Ser He Cys Ser Leu Pro Cys Gin Pro Gly Glu Arg Lys Lys Thr 520 525 530 GTG AAG GGC ATG GCT TGC TGC TGG CAC TGC GAG CCC TGC ACC GGG TAC 2106 Val Lys Gly Met Ala Cys Cys Trp His Cys Glu Pro Cys Thr Gly Tyr 535 540 545 CAG TAC CAA GTG GAC CGC TAC ACC TGT AAG ACC TGC CCC TAC GAC ATG 2154 Gin Tyr Gin Val Asp Arg Tyr Thr Cys Lys Thr Cys Pro Tyr Asp Met 550 555 560 CGG CCC ACA GAG AAC CGC ACG AGC TGC CAG CCC ATC CCC ATC GTC AAG 2202 Arg Pro Thr Glu Asn Arg Thr Ser Cys Gin Pro He Pro He Val Lys 565 570 575 580 TTG GAG TGG GAC TCG CCG TGG GCC GTG CTG CCC CTC TTC CTG GCC GTG 2250 Leu Glu Trp Asp Ser Pro Trp Ala Val Leu Pro Leu Phe Leu Ala Val ~- 585 590 595 GTG GGC ATC GCC GCC ACG CTG TTC GTG GTG GTC ACG TTT GTG CGC TAC 2298 Val Gly He Ala Ala Thr Leu Phe Val Val Val Thr Phe Val Arg Tyr 600 605 610 AAC GAT ACC CCC ATC GTC AAG GCC TCG GGC CGG GAG CTG AGC TAC GTG 2346 Asn Asp Thr Pro He Val Lys Ala Ser Gly Arg Glu Leu Ser Tyr Val 615 620 625 CTG CTG GCG GGC ATC TTT CTG TGC TAC GCC ACT ACC TTC CTC ATG ATC 2394 Leu Leu Ala Gly He Phe Leu Cys Tyr Ala Thr Thr Phe Leu Met He 630 635 640 GCA GAG CCG GAC CTG GGG ACC TGT TCG CTC CGC CGC ATC TTC CTA GGG 2442 Ala Glu Pro Asp Leu Gly Thr Cys Ser Leu Arg Arg He Phe Leu Gly CTC GGC ATG AGC ATC AGC TAC GCG GCC CTG CTG ACC AAG ACC AAC CGC 2490 Leu Gly Met Ser He Ser Tyr Ala Ala Leu Leu Thr Lys Thr Asn Arg 665 670 675 ATT TAC CGC ATC TTT GAG CAG GGC AAA CGG TCG GTC AGT GCC CCG CGT 2538 He Tyr Arg He Phe Glu Gin Gly Lys Arg Ser Val Ser Ala Pro Arg 680 685 690 TTC ATC AGC CCG GCC TCG CAG CTG GCC ATC ACC TTC ATC CTC ATC TCC 2586 Phe He Ser Pro Ala Ser Gin Leu Ala He Thr Phe He Leu He Ser 695 700 705 CTG CAG CTG CTC GGC ATC TGC GTG TGG TTC GTG GTG GAC CCC TCC CAC 2634 Leu Gin Leu Leu Gly He Cys Val Trp Phe Val Val Asp Pro Ser His 710 715 720 TCG GTG GTG GAC TTC CAG GAC CAA CGG ACA CTT GAC CCC CGC TTT GCC 2682 Ser * al Val Asp Phe Gin Asp Gin Arg Thr Leu Asp Pro Arg Phe Ala 725 730 735 740 AGG GGC GTG CTC AAG TGC GAC ATC TCG GAC CTG TCC CTC ATC TGC CTG 2730 Arg Gly Val Leu Lys Cys Asp He Ser Asp Leu Ser Leu He Cys Leu 745 750 755 CTG GGC TAC AGC ATG CTG CTG ATG GTC ACG TGT ACT GTG TAC GCC ATC 2778 Leu Gly Tyr Ser Met Leu Leu Met Val Thr Cys Thr Val Tyr Ala He 760 765 770 AAG ACC CGA GGC GTG CCC GAG ACC TTC AAC GAG GCC AAG CCC ATC GGC 2826 Lys Thr Arg Gly Val Pro Glu Thr Phe Asn Glu Ala Lys Pro He Gly 775 780 785 TTC ACC ATG TAC ACC ACC TGC ATT GTC TGG CTG GCC TTC ATC CCC ATC 2874 Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala Phe He Pro He 790 795 800 TTT TTT GGC ACC TCA CAG TCA GCC GAC AAG CTG TAC ATC CAG ACA ACC 2922 Phe Phe Gly Thr Ser Gin Ser Ala Asp Lys Leu Tyr He Gin Thr Thr 805 810 815 820 ACA CTG ACG GTC TCC GTG AGT CTG AGC GCT TCA GTG TCC CTG GGG ATG 2970 Thr Leu Thr Vai Ser Val Ser Leu Ser Ala Ser Val Ser Leu Gly Met 825 830 835 CTC TAC ATG CCC AAA GTC TAC ATC ATC CTC TTC CAC CCG GAG CAG AAC 3018 Leu Tyr Met Pro Lys Val Tyr He He Leu Phe His Pro Glu Gin Asn 840 845 850 GTG CCC AAG CGC AAG CGC AGT CTC AAA GCC GTG GTC ACC GCC GCC ACC 3066 Val Pro Lys Arg Lys Arg Ser Leu Lys Ala Val Val Thr Ala Ala Thr 855 860 865 ATG TCC AAC AAG TTC ACA CAG AAG GGC AAC TTC AGG CCC AAT GGG GAA 3114 Met Ser Asn Lys Phe Thr Gin Lys Gly Asn Phe Arg Pro Asn Gly Glu 870 875 880 GCC AAA TCA GAG CTG TGT GAG AAC CTG GAG ACC CCA GCG CTG GCT ACC 3162 96 Ala-Lys ser Glu Leu Cys Glu Asn Leu Glu Thr Pro Ala Leu Ala Thr 885 890 895 900 AAA CAG ACC TAC GTC ACC TAC ACC AAC CAT GCC ATC TAGCCGGGCC 3208 Lys Gin Thr Tyr Val Thr Tyr Thr Asn His Ala He 905 910 GCGGAGCCAA-GCAGGCTAAG GAGCCACAAC CTCTGAGGAT GGCACATTGG GCCAGGGCCG 3268 TTCCCGAGGG CCCTGCCGAT GTCTGCCCGC CTCCCGGGCA TCCACGAATG TGGCTTGGTG 3328 CTGAGGACAG TAGAGACCCC GGCCATCACT GCTGGGCAAG CCGTGGTGGG CAACCAGAGG 3388 AGGCCGAGTG GCTGGGGCAG TTCCAGGTTA TGCCACACAC AGGTCTTCCT TCTGGACCAC 3448 TGTTGGCCCA GCCCCAAAGC ACAGGGGCTC GGTCTCCAGA GCCCAGCCCT GGCTTCCTCT 3508 CTT CTCCT GCCΓCCGTCT GTCCTGTGGG TGACCCCGGT TGGTCCCTGC CCCGTCTTTA 3568 CGTTTCTCTT CCGTCTTTGC TCTGCATGTG TTGTCTGTTT GGGCCCTCTG CTTCCATATT 3628 TTTCCATTCT GCTCCTGGCC TTCCCCTGCC ATCTGCCCTG CCCCCTGCCC CTCCTCCCTG 3688 AGCTGCCCCA TCCCCGCCAT CATTTTCTCT TCTGTTCCCC CTCGATCTCA TTTCCTACCA 3748 GCCTTCCCCC TACTTGGCTT CATCCACCAA CTCTTTCACC ACGTTGCAAA AGAGAAAAAA 3808 AAAGGGGGGG GGGAATCACC CCCTACAAAA AAGCCCAAAC AAAAACTAAT CTTGAGTGTG 3868 TTTCGAAGTG CTGCGTCCTC CTGGTGGCCT GTGTGTCCCT GTGCCTGCAG CCTGTCTGCC 3928 CGCCCTACCC GTCTGCCGTG TGTCCTGCCC CCCCCGCCTG CCCGCCTTGC CCTTCCTGCT 3988 AACGACACGG AGTTCAGTGC CTGGGTGTTT GGTGATGGTC TCTGATGTGT AGCATGTCTG 4048 TTTTTATACC GAGAACATTT CTAATAAAGA TAAACACATG GTTTTGC 4095 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 912 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Ser Gly Lys Gly Gly Trp Ala Trp Trp Trp Ala Arg Leu Pro Leu 1 5 10 15 Cys Leu Leu Leu Ser Leu Tyr Ala Pro Trp Val Pro Ser Ser Leu Gly 20 25 30 Lys Pro Lys Gly His Pro His Met Asn Ser He Arg He Asp Gly Asp _- B 97 He..Thr Leu Gly Gly Leu Phe Pro Val His Gly Arg Gly Ser Glu Gly 50 55 60 Lys Ala Cys Gly Glu Leu Lys Lys Glu Lys Gly He His Arg Leu Glu 65 70 75 80 Ala Met Leu Phe Ala Leu Asp Arg He Asn Asn Asp Pro Asp Leu Leu 85 90 95 Pro Asn He Thr Leu Gly Ala Arg He Leu Asp Thr Cys Ser Arg Asp 100 105 110 Thr His Ala Leu Glu Gin Ser Leu Thr Phe Val Arg Ala Leu He Glu 115 120 125 Lys Asp Gly Thr Glu Val Arg Cys Gly Arg Arg Gly Pro Pro He He 130 135 140 Thr Lys Pro Glu Arg Val Val Gly Val He Gly Ala Ser Gly Ser Ser 145 150 155 160 Val Ser He Met Val Ala Asn He Leu Arg Leu Phe Lys He Fro Gin 165 170 175 He Ser Tyr Ala Ser Thr Ala Pro Asp Leu Ser Asp Asn Ser Arg Tyr 180 185 190 Asp Phe Phe Ser Arg Val Val Pro Ser Asp Thr Tyr Gin Ala Gin Ala 195 200 205 Met Val Asp He Val Arg Ala Leu Lys Trp Asn Tyr Val Ser Thr Leu 210 215 220 Ala Ser Glu Gly Ser Tyr Gly Glu Ser Gly Val Glu Ala Phe He Gin 225 230 235 240 Lys Ser Arg Glu Asn Gly Gly Val Cys He Ala Gin Ser Val Lys He 245 250 255 Pro Arg Glu Pro Lys Thr Gly Glu Phe Asp Lys He He Lys Arg Leu 260 265 270 Leu Glu Thr Ser Asn Ala Arg Gly He He He Phe Ala Asn Glu Asp 275 280 285 Asp He Arg Arg Val Leu Glu Ala Ala Arg Arg Ala Asn Gin Thr Gly 290 295 300 His Phe Phe Trp Met Gly Ser Asp Ser Trp Gly Ser Lys Ser Ala Pro 305 310 315 320 Val Leu Arg Leu Glu Glu Val Ala Glu Gly Ala Val Thr He Leu Pro 325 330 335 Lys Arg Met Ser Val Arg Gly Phe Asp Arg Tyr Phe Ser Ser Arg Thr 340 345 350 Leu Asp Asn Asn Arg Arg Asn He Trp Phe Ala Glu Phe Trp Glu Asp 355 360 365 Asn Phe His Cys Lys Leu Ser Arg His Ala Leu Lys Lys Gly Ser His 370 375 380 He Lys Lys Cys Thr Asn Arg Glu Arg He Gly Gin Asp Ser Ala Tyr 385 - 390 395 400 Glu Gin Glu Gly Lys Val Gin Phe Val He Asp Ala Val Tyr Ala Met 405 410 415 Gly His Ala Leu His Ala Met His Arg Asp Leu Cys Pro Gly Arg Val 420 425 430 Gly Leu Cys Pro Arg Met Asp Pro Val Asp Gly Thr Gin Leu Leu Lys 435 440 445 Tyr He Arg Asn Val Asn Phe Ser Gly He Ala Gly Asn Pro Val Thr 450 455 460 Phe Asn Glu Asn Gly Asp Ala Pro Gly Arg Tyr Asp He Tyr Gin Tyr 465 470 475 480 Gin Leu Arg Asn Gly Ser Ala Glu Tyr Lys Val He Gly Ser Trp Thr 485 490 495 Asp His Leu His Leu Arg He Glu Arg Met Gin Trp Pro Gly Ser Gly 500 505 510 Gin Gin Leu Pro Arg Ser He Cys Ser Leu Pro Cys Gin Pro Gly Glu 515 520 525 Arg Lys Lys Thr Val Lys Gly Met Ala Cys Cys Trp His Cys Glu Pro 530 535 540 cys Thr Gly Tyr Gin Tyr Gin Val Asp Arg Tyr Thr Cys Lys Thr Cys 545 550 555 560 Pro Tyr Asp Met Arg Pro Thr Glu Asn Arg Thr Ser Cys Gin Pro He --.565 570 575 Pro He Val Lys Leu Glu Trp Asp Ser Pro Trp Ala Val Leu Pro Leu 580 585 590 Phe Leu Ala Val Val Gly He Ala Ala Thr Leu Phe Val Val Val Thr 595 600 605 Phe Val Arg Tyr Asn Asp Thr Pro He Val Lys Ala Ser Gly Arg Glu 610 615 620 Leu Ser Tyr Val Leu Leu Ala Gly He Phe Leu Cys Tyr Ala Thr Thr 625 630 635 640 Phe Leu Met He Ala Glu Pro Asp Leu Gly Thr Cys Ser Leu Arg Arg 645 650 655 99 I1& Phe Leu Gly Leu Gly Met Ser He Ser Tyr Ala Ala Leu Leu Thr 660 665 670 Lys Thr Asn Arg He Tyr Arg He Phe Glu Gin Gly Lys Arg Ser Val 675 680 685 Ser Ala Pro Arg Phe He Ser Pro Ala Ser Gin Leu Ala He Thr Phe 690 695 700 He Leu He Ser Leu Gin Leu Leu Gly He Cys Val Trp Phe Val Val 705 710 715 720 Asp Pro Ser His Ser Val Val Asp Phe Gin Asp Gin Arg Thr Leu Asp 725 730 735 Pro Arg Phe Ala Arg Gly Val Leu Lys Cys Asp He Ser Asp Leu Ser 740 745 750 Leu He Cys Leu Leu Gly Tyr Ser Met Leu Leu Met val Thr Cys Thr 755 760 765 Val Tyr Ala He Lys Thr Arg Gly Val Pro Glu Thr Phe Asn Glu Ala 770 775 780 Lys Pro He Gly Phe Thr Met Tyr Thr Thr Cys He Val Trp Leu Ala 785 790 795 800 Phe He Pro He Phe Phe Gly Thr Ser Gin Ser Ala Asp Lys Leu Tyr 805 810 815 He Gin Thr Thr Thr Leu Thr Val Ser Val Ser Leu Ser Ala Ser Val 820 825 830 Ser Leu Gly Met Leu Tyr Met Pro Lys Val Tyr He He Leu Phe His 835 840 845 Pro Glu Gin Asn Val Pro Lys Arg Lys Arg Ser Leu Lys Ala Val Val 850 855 860 Thr Ala Ala Thr Met Ser Asn Lys Phe Thr Gin Lys Gly Asn Phe Arg 865 _ 870 875 880 Pro Asn Gly Glu Ala Lys Ser Glu Leu Cys Glu Asn Leu Glu Thr Pro 885 890 895 Ala Leu Ala Thr Lys Gin Thr Tyr Val Thr Tyr Thr Asn His Ala He 900 905 910 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2426 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 100 — (ii) MOLECULE TYPE: CDNA (vii) IMMEDIATE SOURCE: (B) CLONE: SR13 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: CCCAACATCA CGTTGGGCGC CCGCATTCTG GACACCTGCT CGAGGGACAC CCACGCCCTG 60 GAGCAGTCAC TGACCTTTGT GCGGGCGCTC ATCGAGAAGG ACGGCACGGA GGTCCGCTGC 120 GGCAGGCGGG GCCCGCCCAT CATCACCAAG CCCGAACGAG TGGTGGGTGT CATTGGAGCT 180 TCGGGGAGCT CCGTCTCGAT CATGGTGGCC AACATCCTCC GCCTCTTCAA GATCCCTCAG 240 .ATCA CTATG CCTCCACGGC CCCTGACTTG AGTGACAACA GCCGCTATGA CTTCTTCTCC 300 CGGGTGGTGC CCTCAGACAC ATACCAGGCC CAGGCCATGG TGGATATTGT CCGAGCCCTC 360 AAGTGGAACT ATGTGTCCAC ACTGGCCTCA GAGGGCAGCT ACGGTGAGAG TGGTGTGGAG 420 GCCTTTATCC AGAAGTCCCG AGAGAACGGA GGTGTGTGCA TTGCCCAGTC GGTGAAGATT 480 CCACGGGAAC CCAAGACGGG GGAGTTCGAC AAGATCATCA AACGCCTACT GGAAACATCC 540 AATGCCAGGG GTATCATCAT CTTTGCCAAC GAGGATGACA TCAGGAGGGT GTTGGAGGCA 600 GCTCGCAGGG CCAACCAGAC CGGCCACTTC TTTTGGATGG GTTCTGATAG CTGGGGCTCC 660 AAGAGTGCCC CTGTGCTGCG CCTTGAGGAG GTGGCCGAGG GCGCAGTCAC CATTCTCCCC 720 AAGAGGATGT CTGTTCGAGG GTTCGACCGA TACTTCTCCA GCCGCACGCT GGACAACAAC 780 AGGCGCAACA TCTGGTTTGC CGAGTTCTGG GAGGACAACT TCCATTGCAA GTTGAGCCGC 840 CACGCGCTCA AGAAGGGAAG CCACATCAAG AAGTGCACCA ACCGAGAGCG CATCGGGCAG 900 GACTCGGCCT ATGAGCAGGA GGGGAAGGTG CAGTTCGTGA TTGACGCTGT GTACGCCATG 960 GGCCACGCGC TGCACGCCAT GCACCGTGAC CTGTGTCCCG GCCGCGTAGG ACTCTGCCCT 1020 CGCATGGACC CCGTGGATGG CACCCAGCTG CTTAAGTACA TCAGGAACGT CAACTTCTCA 1080 GGCATTGCGG GGAACCCTGT AACCTTCAAT GAGAACGGAG ACGCACCGGG GCGCTACGAC 1140 ATCTACCAGT ACCAACTGCG CAATGGCTCG GCCGAGTACA AGGTCATCGG CTCGTGGACA 1200 GACCACCTGC ACCTCAGAAT AGAGCGGATG CAGTGGCCAG GGAGTGGCCA GCAGCTGCCG 1260 CGCTCCATCT GCAGTCTGCC CTGCCAGCCC GGGGAGCGAA AGAAGACTGT GAAGGGCATG 1320 GCTTGCTGCT GGCACTGCGA GCCCTGCACC GGGTACCAGT ACCAAGTGGA CCGCTACACC 1380 TGTAAGACCT GCCCCTACGA CATGCGGCCC ACAGAGAACC GCACGAGCTG CCAGCCCATC 1440 PCI7US91/09422 101 CCCATCGTCA AGTTGGAGTG GGACTCGCCG TGGGCCGTGC TGCCCCTCTT CCTGGCCGTG 150 GTGGGCATCG CCGCCACGCT GTTCGTGGTG GTCACGTTTG TGCGCTACAA CGATACCCCC 156 ATCGTCAAGG CCTCGGGCCG GGAGCTGAGC TACGTGCTGC TGGCGGGCAT CTTTCTGTGC 162 TACGCCACTA CCTTCCTCAT GATCGCAGAG CCGGACCTGG GGACCTGTTC GCTCCGCCGC 168 ATCTTCCTAG GGCTCGGCAT GAGCATCAGC TACGCGGCCC TGCTGACCAA GACCAACCGC 174 ATTTACCGCA TCTTTGAGCA GGGCAAACGG TCGGTCAGTG CCCCGCGTTT CATCAGCCCG 180 GCCTCGCAGC TGGCCATCAC CTTCATCCTC ATCTCCCTGC AGCTGCTCGG CATCTGCGTG 186 TGGTTCGTGG TGGACCCCTC CCACTCGGTG GTGGACTTCC AGGACCAACG GACACTTGAC 192 CCCCGCTTTG CCAGGGGCGT GCTCAAGTGC GACATCTCGG ACCTGTCCCT CATCTGCCTG 198 CTGGGCTACA GCATGCTGCT GATGGTCACG TGTACTGTGT ACGCCATCAA GACCCGAGGC 204 GTGCCCGAGA CCTTCAACGA GGCCAAGCCC ATCGGCTTCA CCATGTACAC CACCTGCATT 210 GTCTGGCTGG CCTTCATCCC CATCTTTTTT GGCACCTCAC AGTCAGCCGA CAAGCTGTAC 216 ATCCAGACAA CCACACTGAC GGTCTCCGTG AGTCTGAGCG CTTCAGTGTC CCTGGGGATG 222 CTCTACATGC CCAAAGTCTA CATCATCCTC TTCCATATTT TTCCATTCTG CTCCTGGCCT 228 TCCCCTGCCA TCTGCCCTGC CCCCTGCCCC TCCTCCCTGA GCTGCCCCAT CCCCGCCATC 234 ATTTTCTCTT CTGTTCCCCC TCGATCTCAT TTCCTACCAG CCTTCCCCCT ACTTGGCTTC 240 CTCCACCAAC TCTTTCACCA CGTTGC 242 (2) INFORMATION FOR SEQ ID NO: 21 : ( i) SEQUENCE CHARACTERISTICS : (A) LENGTH: 17 amino acids (B) TYPE : amino acid (C) STRANDEDNESS : single (D) TOPOLOGY : linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21 : Arg Asp Ser Leu He Ser He Arg Asp Glu Lys Asp Gly Leu Asn Arg 1 5 10 15 Cys (2) INFORMATION FOR SEQ ID NO:22: 102 (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:22: Asp Arg Leu Leu Arg Lys Leu Arg Glu Arg Leu Pro Lys Ala Arg Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:23: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:23: Glu Glu Val Trp Phe Asp Glu Lys Gly Asp Ala Pro Gly Arg Tyr Asp 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Glu Phe Val Tyr Glu Arg Glu Gly Asn Thr Glu Glu Asp Glu Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single PCT/US91/09422 103 - (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Pro Glu Arg Lys Cys Cys Glu lie Arg Glu Gin Tyr Gly He Gin Arg 1 - 5 10 15 Val (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: He Gly Pro Gly Ser Ser Ser Val Ala He Gin Val Gin Asn Leu Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: He Ala Tyr Ser Ala Thr Ser He Asp Leu Ser Asp Lys Thr Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 104 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Lys Lys Pro Gly Ala Gly Asn Ala Lys Lys Arg Gin Pro Glu Phe Ser 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:29 Pro Glu Phe Ser Pro Ser Ser Gin Cys Pro Ser Ala His Ala Gin Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Asp Lys He He Lys Arg Leu Leu Glu Thr Ser Asn Ala Arg Gly 1 ~- 5 10 15 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:31: 105 Val Asn Phe Ser Gly He Ala Gly Asn Pro Val Thr Phe Asn Glu Asn 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 32 : ( i) SEQUENCE CHARACTERISTICS : ■ "(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Gly Glu Ala Lys Ser Glu Leu Cys Glu Asn Leu Glu Thr Pro Ala Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Pro Ala Arg Leu Ala Leu Pro Ala Asn Asp Thr Glu Phe Ser Ala Trp 1 5 10 15 Val

Claims: WHAT IS CLAIMED IS: 1. An isolated mammalian G protein-coupled glutamate receptor or a fragment thereof. 2. The G protein-coupled glutamate receptor of claim 1, which is substantially pure. 3. The G protein-coupled glutamate receptor of claim 1, which is human or rodent. 4. An antiserum obtained from an animal immunized with the G protein-coupled glutamate receptor of claim 1. 5. A monoclonal antibody which specifically binds to the G protein-coupled glutamate receptor of claim 1. 6. The G protein-coupled glutamate receptor of claim 1, which binds glutamate or quisqualate and thereby activates phospholipase C or stimulates inositol phospholipid metabolism in a vertebrate cell. 7. A recombinantly produced polypeptide having the activity of a mammalian G protein-coupled glutamate receptor. 8. The polypeptide of claim 7, which has the activity of a human or rodent mammalian G protein-coupled glutamate receptor. 9. An isolated and purified polynucleotide molecule which codes for a mammalian G protein-coupled glutamate receptor or a fragment thereof. 10. The polynucleotide of claim 9, which is a genomic DNA sequence, a cDNA sequence, or an RNA antisense sequence. 11. The polynucleotide of claim 9, which codes for human or rodent G protein-coupled glutamate receptor. 12. The polynucleotide of claim 9, which encodes a polypeptide displaying mammalian G protein-coupled glutamate receptor activity. 13. The polynucleotide of claim 9, which is substantially the sequence of Fig. 5, Fig. 7, Fig. 8 or Fig. 9. 14. A probe which comprises an oligonucleotide capable of specifically hybridizing with a gene which encodes a mammalian G protein-coupled glutamate receptor or a fragment thereof. 15. The probe of claim 14, which comprises from about 40 to about 60 nucleotides in length. 16. The probe of claim 15, which is labeled to provide a detectable signal. 17. A DNA construct comprising the following operably linked elements: a transcriptional promoter; a DNA sequence encoding a mammalian G protein-coupled glutamate receptor or a fragment thereof; and a transcriptional terminator. 18. The DNA construct of claim 17, wherein the DNA sequence encodes a human or rodent G protein-coupled glutamate receptor polypeptide. 19. The DNA construct of claim 17, wherein the DNA sequence encoding the mammalian G protein-coupled glutamate receptor is substantially the sequence of Fig. 5, Fig. 7, Fig. 8 or Fig. 9. 20. A cultured eukaryotic cell transformed or transfected with a DNA construct which comprises the following operably linked elements: a transcriptional promoter; a DNA sequence encoding a mammalian G protein-coupled glutamate receptor or a fragment thereof; and a transcriptional terminator. 21. The eukaryotic cell of claim 20, which is a mammalian cell. 22. The eukaryotic cell of claim 20, which does not express endogenous G protein-coupled glutamate receptors. 23. The eukaryotic cell line of claim 20, wherein the DNA sequence encodes a human or rodent G protein-coupled glutamate receptor polypeptide. 24. The eukaryotic cell line of claim 21, wherein the G protein-coupled glutamate receptor polypeptide encoded by the DNA sequence is coupled to G protein in a mammalian cell. 25. The DNA construct of claim 20, wherein the DNA sequence encoding the mammalian G protein-coupled glutamate receptor is substantially the sequence of Fig. 5, Fig. 7, Fig. 8 or Fig. 9. 26. A method for producing a mammalian G protein- coupled glutamate receptor, which comprises: growing eukaryotic cells transformed or transfected with a DNA construct which comprises a DNA sequence coding for the expression of the G protein-coupled glutamate receptor, and isolating the receptor from the cells. 27. The method of claim 26, wherein the cells are cultured mammalian cells. 28. The method of claim 26, wherein the glutamate receptor is human or rodent. 29. The method of claim 26, wherein the glutamate receptor is isolated by immunoaffinity purification. 30. The method of claim 26, wherein the G protein- coupled glutamate receptor is not coupled to protein G in the eukaryotic cells. 31. A method for determining the presence of a mammalian G protein-coupled glutamate receptor in a biological sample, which comprises incubating the sample with a monospecific antibody which specifically binds to the receptor under conditions sufficient for immune complex formation and determining therefrom the presence of the immune complexes. 32. The method of claim 31, wherein the monospecific antibody is a monoclonal antibody or a purified antiserum. 33. The method of claim 32, wherein the monospecific antibody is labeled. 34. A method for identifying a compound which alters G protein-coupled glutamate receptor mediated-metabolism, which comprises incubating the compound with eukaryotic cells which express recombinant mammalian G protein-coupled glutamate receptor and determining therefrom the effect of said compound on receptor-mediated metabolism in the cells. 35. The method of claim 34, wherein the compound is incubated with the receptor and ligand. 36. The method of claim 35, wherein the ligand is glutamate or quisqualate. 37. The method of claim 34, wherein the eukaryotic cell expresses a human or rodent G protein-coupled glutamate receptor. 38. The method of claim 37, wherein inositol phospholipid metabolism in the eukaryotic cell is monitored for alteration by the compound.

Inventors: ALMERS WOLFHARD, HAGEN FREDERICK STAMNER, HOUAMED KHALED M, MULVIHILL EILEEN RANAE, ALMERS, WOLFHARD, HAGEN, FREDERICK, STAMNER, HOUAMED, KHALED, M., MULVIHILL, EILEEN, RANAE
Applicants: UNIV WASHINGTON, ZYMOGENETICS INC, THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGT, ZYMOGENETICS, INC.
Application year: 1991
Main classification: C07H15
IPC codes: A61K35, A61K38, A61K39, A61P43, C07K1, C07K14, C07K16, C07K19, C12N5, C12N15, C12P21, G01N33